#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Real-time fMRI neurofeedback to down-regulate superior temporal gyrus activity in patients with schizophrenia and auditory hallucinations: a proof-of-concept study
#Text=Neurocognitive models and previous neuroimaging work posit that auditory verbal hallucinations (AVH) arise due to increased activity in speech-sensitive regions of the left posterior superior temporal gyrus (STG).
1-1	0-9	Real-time	_	
1-2	10-14	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
1-3	15-28	neurofeedback	_	
1-4	29-31	to	_	
1-5	32-45	down-regulate	_	
1-6	46-54	superior	_	
1-7	55-63	temporal	_	
1-8	64-69	gyrus	_	
1-9	70-78	activity	_	
1-10	79-81	in	_	
1-11	82-90	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-12	91-95	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-13	96-109	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
1-14	110-113	and	_	
1-15	114-122	auditory	_	
1-16	123-137	hallucinations	_	
1-17	137-138	:	_	
1-18	139-140	a	_	
1-19	141-157	proof-of-concept	_	
1-20	158-163	study	_	
1-21	164-178	Neurocognitive	_	
1-22	179-185	models	_	
1-23	186-189	and	_	
1-24	190-198	previous	_	
1-25	199-211	neuroimaging	_	
1-26	212-216	work	_	
1-27	217-222	posit	_	
1-28	223-227	that	_	
1-29	228-236	auditory	_	
1-30	237-243	verbal	_	
1-31	244-258	hallucinations	_	
1-32	259-260	(	_	
1-33	260-263	AVH	_	
1-34	263-264	)	_	
1-35	265-270	arise	_	
1-36	271-274	due	_	
1-37	275-277	to	_	
1-38	278-287	increased	_	
1-39	288-296	activity	_	
1-40	297-299	in	_	
1-41	300-316	speech-sensitive	_	
1-42	317-324	regions	_	
1-43	325-327	of	_	
1-44	328-331	the	_	
1-45	332-336	left	_	
1-46	337-346	posterior	_	
1-47	347-355	superior	_	
1-48	356-364	temporal	_	
1-49	365-370	gyrus	_	
1-50	371-372	(	_	
1-51	372-375	STG	_	
1-52	375-376	)	_	
1-53	376-377	.	_	

#Text=Here, we examined if patients with schizophrenia (SCZ) and AVH could be trained to down-regulate STG activity using real-time functional magnetic resonance imaging neurofeedback (rtfMRI-NF).
2-1	378-382	Here	_	
2-2	382-383	,	_	
2-3	384-386	we	_	
2-4	387-395	examined	_	
2-5	396-398	if	_	
2-6	399-407	patients	_	
2-7	408-412	with	_	
2-8	413-426	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
2-9	427-428	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
2-10	428-431	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
2-11	431-432	)	_	
2-12	433-436	and	_	
2-13	437-440	AVH	_	
2-14	441-446	could	_	
2-15	447-449	be	_	
2-16	450-457	trained	_	
2-17	458-460	to	_	
2-18	461-474	down-regulate	_	
2-19	475-478	STG	_	
2-20	479-487	activity	_	
2-21	488-493	using	_	
2-22	494-503	real-time	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
2-23	504-514	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
2-24	515-523	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
2-25	524-533	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
2-26	534-541	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
2-27	542-555	neurofeedback	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
2-28	556-557	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
2-29	557-566	rtfMRI-NF	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
2-30	566-567	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
2-31	567-568	.	_	

#Text=We also examined the effects of rtfMRI-NF training on functional connectivity between the STG and other speech and language regions.
3-1	569-571	We	_	
3-2	572-576	also	_	
3-3	577-585	examined	_	
3-4	586-589	the	_	
3-5	590-597	effects	_	
3-6	598-600	of	_	
3-7	601-610	rtfMRI-NF	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
3-8	611-619	training	_	
3-9	620-622	on	_	
3-10	623-633	functional	_	
3-11	634-646	connectivity	_	
3-12	647-654	between	_	
3-13	655-658	the	_	
3-14	659-662	STG	_	
3-15	663-666	and	_	
3-16	667-672	other	_	
3-17	673-679	speech	_	
3-18	680-683	and	_	
3-19	684-692	language	_	
3-20	693-700	regions	_	
3-21	700-701	.	_	

#Text=Twelve patients with SCZ and treatment-refractory AVH were recruited to participate in the study and were trained to down-regulate STG activity using rtfMRI-NF, over four MRI scanner visits during a 2-week training period.
4-1	702-708	Twelve	_	
4-2	709-717	patients	_	
4-3	718-722	with	_	
4-4	723-726	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
4-5	727-730	and	_	
4-6	731-751	treatment-refractory	_	
4-7	752-755	AVH	_	
4-8	756-760	were	_	
4-9	761-770	recruited	_	
4-10	771-773	to	_	
4-11	774-785	participate	_	
4-12	786-788	in	_	
4-13	789-792	the	_	
4-14	793-798	study	_	
4-15	799-802	and	_	
4-16	803-807	were	_	
4-17	808-815	trained	_	
4-18	816-818	to	_	
4-19	819-832	down-regulate	_	
4-20	833-836	STG	_	
4-21	837-845	activity	_	
4-22	846-851	using	_	
4-23	852-861	rtfMRI-NF	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
4-24	861-862	,	_	
4-25	863-867	over	_	
4-26	868-872	four	_	
4-27	873-876	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
4-28	877-884	scanner	_	
4-29	885-891	visits	_	
4-30	892-898	during	_	
4-31	899-900	a	_	
4-32	901-902	2	_	
4-33	902-903	-	_	
4-34	903-907	week	_	
4-35	908-916	training	_	
4-36	917-923	period	_	
4-37	923-924	.	_	

#Text=STG activity and functional connectivity were compared pre- and post-training.
5-1	925-928	STG	_	
5-2	929-937	activity	_	
5-3	938-941	and	_	
5-4	942-952	functional	_	
5-5	953-965	connectivity	_	
5-6	966-970	were	_	
5-7	971-979	compared	_	
5-8	980-983	pre	_	
5-9	983-984	-	_	
5-10	985-988	and	_	
5-11	989-1002	post-training	_	
5-12	1002-1003	.	_	

#Text=Patients successfully learnt to down-regulate activity in their left STG over the rtfMRI-NF training.
6-1	1004-1012	Patients	_	
6-2	1013-1025	successfully	_	
6-3	1026-1032	learnt	_	
6-4	1033-1035	to	_	
6-5	1036-1049	down-regulate	_	
6-6	1050-1058	activity	_	
6-7	1059-1061	in	_	
6-8	1062-1067	their	_	
6-9	1068-1072	left	_	
6-10	1073-1076	STG	_	
6-11	1077-1081	over	_	
6-12	1082-1085	the	_	
6-13	1086-1095	rtfMRI-NF	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
6-14	1096-1104	training	_	
6-15	1104-1105	.	_	

#Text=Post- training, patients showed increased functional connectivity between the left STG, the left inferior prefrontal gyrus (IFG) and the inferior parietal gyrus.
7-1	1106-1110	Post	_	
7-2	1110-1111	-	_	
7-3	1112-1120	training	_	
7-4	1120-1121	,	_	
7-5	1122-1130	patients	_	
7-6	1131-1137	showed	_	
7-7	1138-1147	increased	_	
7-8	1148-1158	functional	_	
7-9	1159-1171	connectivity	_	
7-10	1172-1179	between	_	
7-11	1180-1183	the	_	
7-12	1184-1188	left	_	
7-13	1189-1192	STG	_	
7-14	1192-1193	,	_	
7-15	1194-1197	the	_	
7-16	1198-1202	left	_	
7-17	1203-1211	inferior	_	
7-18	1212-1222	prefrontal	_	
7-19	1223-1228	gyrus	_	
7-20	1229-1230	(	_	
7-21	1230-1233	IFG	_	
7-22	1233-1234	)	_	
7-23	1235-1238	and	_	
7-24	1239-1242	the	_	
7-25	1243-1251	inferior	_	
7-26	1252-1260	parietal	_	
7-27	1261-1266	gyrus	_	
7-28	1266-1267	.	_	

#Text=The post-training increase in functional connectivity between the left STG and IFG was associated with a reduction in AVH symptoms over the training period.
8-1	1268-1271	The	_	
8-2	1272-1285	post-training	_	
8-3	1286-1294	increase	_	
8-4	1295-1297	in	_	
8-5	1298-1308	functional	_	
8-6	1309-1321	connectivity	_	
8-7	1322-1329	between	_	
8-8	1330-1333	the	_	
8-9	1334-1338	left	_	
8-10	1339-1342	STG	_	
8-11	1343-1346	and	_	
8-12	1347-1350	IFG	_	
8-13	1351-1354	was	_	
8-14	1355-1365	associated	_	
8-15	1366-1370	with	_	
8-16	1371-1372	a	_	
8-17	1373-1382	reduction	_	
8-18	1383-1385	in	_	
8-19	1386-1389	AVH	_	
8-20	1390-1398	symptoms	_	
8-21	1399-1403	over	_	
8-22	1404-1407	the	_	
8-23	1408-1416	training	_	
8-24	1417-1423	period	_	
8-25	1423-1424	.	_	

#Text=The speech-sensitive region of the left STG is a suitable target region for rtfMRI-NF in patients with SCZ and treatment-refractory AVH.
9-1	1425-1428	The	_	
9-2	1429-1445	speech-sensitive	_	
9-3	1446-1452	region	_	
9-4	1453-1455	of	_	
9-5	1456-1459	the	_	
9-6	1460-1464	left	_	
9-7	1465-1468	STG	_	
9-8	1469-1471	is	_	
9-9	1472-1473	a	_	
9-10	1474-1482	suitable	_	
9-11	1483-1489	target	_	
9-12	1490-1496	region	_	
9-13	1497-1500	for	_	
9-14	1501-1510	rtfMRI-NF	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
9-15	1511-1513	in	_	
9-16	1514-1522	patients	_	
9-17	1523-1527	with	_	
9-18	1528-1531	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
9-19	1532-1535	and	_	
9-20	1536-1556	treatment-refractory	_	
9-21	1557-1560	AVH	_	
9-22	1560-1561	.	_	

#Text=Successful down-regulation of left STG activity can increase functional connectivity between speech motor and perception regions.
10-1	1562-1572	Successful	_	
10-2	1573-1588	down-regulation	_	
10-3	1589-1591	of	_	
10-4	1592-1596	left	_	
10-5	1597-1600	STG	_	
10-6	1601-1609	activity	_	
10-7	1610-1613	can	_	
10-8	1614-1622	increase	_	
10-9	1623-1633	functional	_	
10-10	1634-1646	connectivity	_	
10-11	1647-1654	between	_	
10-12	1655-1661	speech	_	
10-13	1662-1667	motor	_	
10-14	1668-1671	and	_	
10-15	1672-1682	perception	_	
10-16	1683-1690	regions	_	
10-17	1690-1691	.	_	

#Text=These findings suggest that patients with AVH have the ability to alter activity and connectivity in speech and language regions, and raise the possibility that rtfMRI-NF training could present a novel therapeutic intervention in SCZ.
11-1	1692-1697	These	_	
11-2	1698-1706	findings	_	
11-3	1707-1714	suggest	_	
11-4	1715-1719	that	_	
11-5	1720-1728	patients	_	
11-6	1729-1733	with	_	
11-7	1734-1737	AVH	_	
11-8	1738-1742	have	_	
11-9	1743-1746	the	_	
11-10	1747-1754	ability	_	
11-11	1755-1757	to	_	
11-12	1758-1763	alter	_	
11-13	1764-1772	activity	_	
11-14	1773-1776	and	_	
11-15	1777-1789	connectivity	_	
11-16	1790-1792	in	_	
11-17	1793-1799	speech	_	
11-18	1800-1803	and	_	
11-19	1804-1812	language	_	
11-20	1813-1820	regions	_	
11-21	1820-1821	,	_	
11-22	1822-1825	and	_	
11-23	1826-1831	raise	_	
11-24	1832-1835	the	_	
11-25	1836-1847	possibility	_	
11-26	1848-1852	that	_	
11-27	1853-1862	rtfMRI-NF	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
11-28	1863-1871	training	_	
11-29	1872-1877	could	_	
11-30	1878-1885	present	_	
11-31	1886-1887	a	_	
11-32	1888-1893	novel	_	
11-33	1894-1905	therapeutic	_	
11-34	1906-1918	intervention	_	
11-35	1919-1921	in	_	
11-36	1922-1925	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
11-37	1925-1926	.	_	

#Text=Introduction
#Text=Auditory verbal hallucinations (AVH) are a cardinal feature of schizophrenia (SCZ), occurring in around 70% of patients with the illness.
12-1	1927-1939	Introduction	_	
12-2	1940-1948	Auditory	_	
12-3	1949-1955	verbal	_	
12-4	1956-1970	hallucinations	_	
12-5	1971-1972	(	_	
12-6	1972-1975	AVH	_	
12-7	1975-1976	)	_	
12-8	1977-1980	are	_	
12-9	1981-1982	a	_	
12-10	1983-1991	cardinal	_	
12-11	1992-1999	feature	_	
12-12	2000-2002	of	_	
12-13	2003-2016	schizophrenia	_	
12-14	2017-2018	(	_	
12-15	2018-2021	SCZ	_	
12-16	2021-2022	)	_	
12-17	2022-2023	,	_	
12-18	2024-2033	occurring	_	
12-19	2034-2036	in	_	
12-20	2037-2043	around	_	
12-21	2044-2047	70%	_	
12-22	2048-2050	of	_	
12-23	2051-2059	patients	_	
12-24	2060-2064	with	_	
12-25	2065-2068	the	_	
12-26	2069-2076	illness	_	
12-27	2076-2077	.	_	

#Text=They are associated with high levels of distress as well as functional and occupational disability.
13-1	2078-2082	They	_	
13-2	2083-2086	are	_	
13-3	2087-2097	associated	_	
13-4	2098-2102	with	_	
13-5	2103-2107	high	_	
13-6	2108-2114	levels	_	
13-7	2115-2117	of	_	
13-8	2118-2126	distress	_	
13-9	2127-2129	as	_	
13-10	2130-2134	well	_	
13-11	2135-2137	as	_	
13-12	2138-2148	functional	_	
13-13	2149-2152	and	_	
13-14	2153-2165	occupational	_	
13-15	2166-2176	disability	_	
13-16	2176-2177	.	_	

#Text=In 30% of patients with AVH, traditional antipsychotic drugs have little or no effect.
14-1	2178-2180	In	_	
14-2	2181-2184	30%	_	
14-3	2185-2187	of	_	
14-4	2188-2196	patients	_	
14-5	2197-2201	with	_	
14-6	2202-2205	AVH	_	
14-7	2205-2206	,	_	
14-8	2207-2218	traditional	_	
14-9	2219-2232	antipsychotic	_	
14-10	2233-2238	drugs	_	
14-11	2239-2243	have	_	
14-12	2244-2250	little	_	
14-13	2251-2253	or	_	
14-14	2254-2256	no	_	
14-15	2257-2263	effect	_	
14-16	2263-2264	.	_	

#Text=Thus, there is a clear need for an enhanced understanding of the neural systems that underlie AVH and how function within these systems can be altered.
15-1	2265-2269	Thus	_	
15-2	2269-2270	,	_	
15-3	2271-2276	there	_	
15-4	2277-2279	is	_	
15-5	2280-2281	a	_	
15-6	2282-2287	clear	_	
15-7	2288-2292	need	_	
15-8	2293-2296	for	_	
15-9	2297-2299	an	_	
15-10	2300-2308	enhanced	_	
15-11	2309-2322	understanding	_	
15-12	2323-2325	of	_	
15-13	2326-2329	the	_	
15-14	2330-2336	neural	_	
15-15	2337-2344	systems	_	
15-16	2345-2349	that	_	
15-17	2350-2358	underlie	_	
15-18	2359-2362	AVH	_	
15-19	2363-2366	and	_	
15-20	2367-2370	how	_	
15-21	2371-2379	function	_	
15-22	2380-2386	within	_	
15-23	2387-2392	these	_	
15-24	2393-2400	systems	_	
15-25	2401-2404	can	_	
15-26	2405-2407	be	_	
15-27	2408-2415	altered	_	
15-28	2415-2416	.	_	

#Text=The neural basis of AVH in patients with SCZ is not fully understood.
16-1	2417-2420	The	_	
16-2	2421-2427	neural	_	
16-3	2428-2433	basis	_	
16-4	2434-2436	of	_	
16-5	2437-2440	AVH	_	
16-6	2441-2443	in	_	
16-7	2444-2452	patients	_	
16-8	2453-2457	with	_	
16-9	2458-2461	SCZ	_	
16-10	2462-2464	is	_	
16-11	2465-2468	not	_	
16-12	2469-2474	fully	_	
16-13	2475-2485	understood	_	
16-14	2485-2486	.	_	

#Text=However, over the last few decades, neuroimaging techniques have allowed researchers to identify brain regions associated with AVH.
17-1	2487-2494	However	_	
17-2	2494-2495	,	_	
17-3	2496-2500	over	_	
17-4	2501-2504	the	_	
17-5	2505-2509	last	_	
17-6	2510-2513	few	_	
17-7	2514-2521	decades	_	
17-8	2521-2522	,	_	
17-9	2523-2535	neuroimaging	_	
17-10	2536-2546	techniques	_	
17-11	2547-2551	have	_	
17-12	2552-2559	allowed	_	
17-13	2560-2571	researchers	_	
17-14	2572-2574	to	_	
17-15	2575-2583	identify	_	
17-16	2584-2589	brain	_	
17-17	2590-2597	regions	_	
17-18	2598-2608	associated	_	
17-19	2609-2613	with	_	
17-20	2614-2617	AVH	_	
17-21	2617-2618	.	_	

#Text=There is now consensus that AVH are associated with a functional network of brain areas including auditory and language regions in the superior temporal gyrus (STG) and inferior parietal gyrus (IPG), and speech motor regions in the inferior prefrontal cortex/gyrus (IFG), as well as cortical midline region around the cingulate cortex and paracingulate sulcus.
18-1	2619-2624	There	_	
18-2	2625-2627	is	_	
18-3	2628-2631	now	_	
18-4	2632-2641	consensus	_	
18-5	2642-2646	that	_	
18-6	2647-2650	AVH	_	
18-7	2651-2654	are	_	
18-8	2655-2665	associated	_	
18-9	2666-2670	with	_	
18-10	2671-2672	a	_	
18-11	2673-2683	functional	_	
18-12	2684-2691	network	_	
18-13	2692-2694	of	_	
18-14	2695-2700	brain	_	
18-15	2701-2706	areas	_	
18-16	2707-2716	including	_	
18-17	2717-2725	auditory	_	
18-18	2726-2729	and	_	
18-19	2730-2738	language	_	
18-20	2739-2746	regions	_	
18-21	2747-2749	in	_	
18-22	2750-2753	the	_	
18-23	2754-2762	superior	_	
18-24	2763-2771	temporal	_	
18-25	2772-2777	gyrus	_	
18-26	2778-2779	(	_	
18-27	2779-2782	STG	_	
18-28	2782-2783	)	_	
18-29	2784-2787	and	_	
18-30	2788-2796	inferior	_	
18-31	2797-2805	parietal	_	
18-32	2806-2811	gyrus	_	
18-33	2812-2813	(	_	
18-34	2813-2816	IPG	_	
18-35	2816-2817	)	_	
18-36	2817-2818	,	_	
18-37	2819-2822	and	_	
18-38	2823-2829	speech	_	
18-39	2830-2835	motor	_	
18-40	2836-2843	regions	_	
18-41	2844-2846	in	_	
18-42	2847-2850	the	_	
18-43	2851-2859	inferior	_	
18-44	2860-2870	prefrontal	_	
18-45	2871-2877	cortex	_	
18-46	2877-2878	/	_	
18-47	2878-2883	gyrus	_	
18-48	2884-2885	(	_	
18-49	2885-2888	IFG	_	
18-50	2888-2889	)	_	
18-51	2889-2890	,	_	
18-52	2891-2893	as	_	
18-53	2894-2898	well	_	
18-54	2899-2901	as	_	
18-55	2902-2910	cortical	_	
18-56	2911-2918	midline	_	
18-57	2919-2925	region	_	
18-58	2926-2932	around	_	
18-59	2933-2936	the	_	
18-60	2937-2946	cingulate	_	
18-61	2947-2953	cortex	_	
18-62	2954-2957	and	_	
18-63	2958-2971	paracingulate	_	
18-64	2972-2978	sulcus	_	
18-65	2978-2979	.	_	

#Text=Hyperactivity in the posterior STG, a region sensitive to speech and human voices, is a particularly robust neuroimaging finding in patients with SCZ and AVH.
19-1	2980-2993	Hyperactivity	_	
19-2	2994-2996	in	_	
19-3	2997-3000	the	_	
19-4	3001-3010	posterior	_	
19-5	3011-3014	STG	_	
19-6	3014-3015	,	_	
19-7	3016-3017	a	_	
19-8	3018-3024	region	_	
19-9	3025-3034	sensitive	_	
19-10	3035-3037	to	_	
19-11	3038-3044	speech	_	
19-12	3045-3048	and	_	
19-13	3049-3054	human	_	
19-14	3055-3061	voices	_	
19-15	3061-3062	,	_	
19-16	3063-3065	is	_	
19-17	3066-3067	a	_	
19-18	3068-3080	particularly	_	
19-19	3081-3087	robust	_	
19-20	3088-3100	neuroimaging	_	
19-21	3101-3108	finding	_	
19-22	3109-3111	in	_	
19-23	3112-3120	patients	_	
19-24	3121-3125	with	_	
19-25	3126-3129	SCZ	_	
19-26	3130-3133	and	_	
19-27	3134-3137	AVH	_	
19-28	3137-3138	.	_	

#Text=The posterior STG has been shown to spontaneously activate during silence and increased resting activity  and cerebral perfusion in this sensory region have also been reported in people with AVH.
20-1	3139-3142	The	_	
20-2	3143-3152	posterior	_	
20-3	3153-3156	STG	_	
20-4	3157-3160	has	_	
20-5	3161-3165	been	_	
20-6	3166-3171	shown	_	
20-7	3172-3174	to	_	
20-8	3175-3188	spontaneously	_	
20-9	3189-3197	activate	_	
20-10	3198-3204	during	_	
20-11	3205-3212	silence	_	
20-12	3213-3216	and	_	
20-13	3217-3226	increased	_	
20-14	3227-3234	resting	_	
20-15	3235-3243	activity	_	
20-16	3245-3248	and	_	
20-17	3249-3257	cerebral	_	
20-18	3258-3267	perfusion	_	
20-19	3268-3270	in	_	
20-20	3271-3275	this	_	
20-21	3276-3283	sensory	_	
20-22	3284-3290	region	_	
20-23	3291-3295	have	_	
20-24	3296-3300	also	_	
20-25	3301-3305	been	_	
20-26	3306-3314	reported	_	
20-27	3315-3317	in	_	
20-28	3318-3324	people	_	
20-29	3325-3329	with	_	
20-30	3330-3333	AVH	_	
20-31	3333-3334	.	_	

#Text=These findings are consistent with neuroimaging studies employing a “symptom-capture design” that show increased activity in the STG and temporo-parietal language regions when patients with SCZ are actively experiencing AVH.
21-1	3335-3340	These	_	
21-2	3341-3349	findings	_	
21-3	3350-3353	are	_	
21-4	3354-3364	consistent	_	
21-5	3365-3369	with	_	
21-6	3370-3382	neuroimaging	_	
21-7	3383-3390	studies	_	
21-8	3391-3400	employing	_	
21-9	3401-3402	a	_	
21-10	3403-3404	“	_	
21-11	3404-3419	symptom-capture	_	
21-12	3420-3426	design	_	
21-13	3426-3427	”	_	
21-14	3428-3432	that	_	
21-15	3433-3437	show	_	
21-16	3438-3447	increased	_	
21-17	3448-3456	activity	_	
21-18	3457-3459	in	_	
21-19	3460-3463	the	_	
21-20	3464-3467	STG	_	
21-21	3468-3471	and	_	
21-22	3472-3488	temporo-parietal	_	
21-23	3489-3497	language	_	
21-24	3498-3505	regions	_	
21-25	3506-3510	when	_	
21-26	3511-3519	patients	_	
21-27	3520-3524	with	_	
21-28	3525-3528	SCZ	_	
21-29	3529-3532	are	_	
21-30	3533-3541	actively	_	
21-31	3542-3554	experiencing	_	
21-32	3555-3558	AVH	_	
21-33	3558-3559	.	_	

#Text=Moreover, altered neuronal connectivity between STG and speech motor areas in the inferior frontal gyrus (IFG) has also been reported.
22-1	3560-3568	Moreover	_	
22-2	3568-3569	,	_	
22-3	3570-3577	altered	_	
22-4	3578-3586	neuronal	_	
22-5	3587-3599	connectivity	_	
22-6	3600-3607	between	_	
22-7	3608-3611	STG	_	
22-8	3612-3615	and	_	
22-9	3616-3622	speech	_	
22-10	3623-3628	motor	_	
22-11	3629-3634	areas	_	
22-12	3635-3637	in	_	
22-13	3638-3641	the	_	
22-14	3642-3650	inferior	_	
22-15	3651-3658	frontal	_	
22-16	3659-3664	gyrus	_	
22-17	3665-3666	(	_	
22-18	3666-3669	IFG	_	
22-19	3669-3670	)	_	
22-20	3671-3674	has	_	
22-21	3675-3679	also	_	
22-22	3680-3684	been	_	
22-23	3685-3693	reported	_	
22-24	3693-3694	.	_	

#Text=Dysconnectivity between STG and speech motor regions in the IFG may impair the ability of the motor system to convey information about the sensory consequences of self-generated actions, such as inner speech, to sensory regions.
23-1	3695-3710	Dysconnectivity	_	
23-2	3711-3718	between	_	
23-3	3719-3722	STG	_	
23-4	3723-3726	and	_	
23-5	3727-3733	speech	_	
23-6	3734-3739	motor	_	
23-7	3740-3747	regions	_	
23-8	3748-3750	in	_	
23-9	3751-3754	the	_	
23-10	3755-3758	IFG	_	
23-11	3759-3762	may	_	
23-12	3763-3769	impair	_	
23-13	3770-3773	the	_	
23-14	3774-3781	ability	_	
23-15	3782-3784	of	_	
23-16	3785-3788	the	_	
23-17	3789-3794	motor	_	
23-18	3795-3801	system	_	
23-19	3802-3804	to	_	
23-20	3805-3811	convey	_	
23-21	3812-3823	information	_	
23-22	3824-3829	about	_	
23-23	3830-3833	the	_	
23-24	3834-3841	sensory	_	
23-25	3842-3854	consequences	_	
23-26	3855-3857	of	_	
23-27	3858-3872	self-generated	_	
23-28	3873-3880	actions	_	
23-29	3880-3881	,	_	
23-30	3882-3886	such	_	
23-31	3887-3889	as	_	
23-32	3890-3895	inner	_	
23-33	3896-3902	speech	_	
23-34	3902-3903	,	_	
23-35	3904-3906	to	_	
23-36	3907-3914	sensory	_	
23-37	3915-3922	regions	_	
23-38	3922-3923	.	_	

#Text=Such a defective prediction mechanism may result in the failure of the normal attenuation of sensory response in the speech-sensitive STG to self-generated speech.
24-1	3924-3928	Such	_	
24-2	3929-3930	a	_	
24-3	3931-3940	defective	_	
24-4	3941-3951	prediction	_	
24-5	3952-3961	mechanism	_	
24-6	3962-3965	may	_	
24-7	3966-3972	result	_	
24-8	3973-3975	in	_	
24-9	3976-3979	the	_	
24-10	3980-3987	failure	_	
24-11	3988-3990	of	_	
24-12	3991-3994	the	_	
24-13	3995-4001	normal	_	
24-14	4002-4013	attenuation	_	
24-15	4014-4016	of	_	
24-16	4017-4024	sensory	_	
24-17	4025-4033	response	_	
24-18	4034-4036	in	_	
24-19	4037-4040	the	_	
24-20	4041-4057	speech-sensitive	_	
24-21	4058-4061	STG	_	
24-22	4062-4064	to	_	
24-23	4065-4079	self-generated	_	
24-24	4080-4086	speech	_	
24-25	4086-4087	.	_	

#Text=Building on these neuroimaging findings, transcranial magnetic stimulation (TMS) studies have shown that a reduction in the cortical excitability of temporo-parietal sensory regions can reduce AVH severity.
25-1	4088-4096	Building	_	
25-2	4097-4099	on	_	
25-3	4100-4105	these	_	
25-4	4106-4118	neuroimaging	_	
25-5	4119-4127	findings	_	
25-6	4127-4128	,	_	
25-7	4129-4141	transcranial	_	
25-8	4142-4150	magnetic	_	
25-9	4151-4162	stimulation	_	
25-10	4163-4164	(	_	
25-11	4164-4167	TMS	_	
25-12	4167-4168	)	_	
25-13	4169-4176	studies	_	
25-14	4177-4181	have	_	
25-15	4182-4187	shown	_	
25-16	4188-4192	that	_	
25-17	4193-4194	a	_	
25-18	4195-4204	reduction	_	
25-19	4205-4207	in	_	
25-20	4208-4211	the	_	
25-21	4212-4220	cortical	_	
25-22	4221-4233	excitability	_	
25-23	4234-4236	of	_	
25-24	4237-4253	temporo-parietal	_	
25-25	4254-4261	sensory	_	
25-26	4262-4269	regions	_	
25-27	4270-4273	can	_	
25-28	4274-4280	reduce	_	
25-29	4281-4284	AVH	_	
25-30	4285-4293	severity	_	
25-31	4293-4294	.	_	

#Text=Whilst this approach has the advantage of establishing causal links between these regions and AVH, it is often unattractive to patients as it involves the application of a strong magnetic pulse.
26-1	4295-4301	Whilst	_	
26-2	4302-4306	this	_	
26-3	4307-4315	approach	_	
26-4	4316-4319	has	_	
26-5	4320-4323	the	_	
26-6	4324-4333	advantage	_	
26-7	4334-4336	of	_	
26-8	4337-4349	establishing	_	
26-9	4350-4356	causal	_	
26-10	4357-4362	links	_	
26-11	4363-4370	between	_	
26-12	4371-4376	these	_	
26-13	4377-4384	regions	_	
26-14	4385-4388	and	_	
26-15	4389-4392	AVH	_	
26-16	4392-4393	,	_	
26-17	4394-4396	it	_	
26-18	4397-4399	is	_	
26-19	4400-4405	often	_	
26-20	4406-4418	unattractive	_	
26-21	4419-4421	to	_	
26-22	4422-4430	patients	_	
26-23	4431-4433	as	_	
26-24	4434-4436	it	_	
26-25	4437-4445	involves	_	
26-26	4446-4449	the	_	
26-27	4450-4461	application	_	
26-28	4462-4464	of	_	
26-29	4465-4466	a	_	
26-30	4467-4473	strong	_	
26-31	4474-4482	magnetic	_	
26-32	4483-4488	pulse	_	
26-33	4488-4489	.	_	

#Text=Furthermore, changes in network dynamics cannot be readily investigated using TMS in isolation.
27-1	4490-4501	Furthermore	_	
27-2	4501-4502	,	_	
27-3	4503-4510	changes	_	
27-4	4511-4513	in	_	
27-5	4514-4521	network	_	
27-6	4522-4530	dynamics	_	
27-7	4531-4537	cannot	_	
27-8	4538-4540	be	_	
27-9	4541-4548	readily	_	
27-10	4549-4561	investigated	_	
27-11	4562-4567	using	_	
27-12	4568-4571	TMS	_	
27-13	4572-4574	in	_	
27-14	4575-4584	isolation	_	
27-15	4584-4585	.	_	

#Text=Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-NF) offers an alternative approach, as it can be better targeted than TMS, and it allows individuals to monitor and self-regulate their own brain activity.
28-1	4586-4595	Real-time	_	
28-2	4596-4606	functional	_	
28-3	4607-4615	magnetic	_	
28-4	4616-4625	resonance	_	
28-5	4626-4633	imaging	_	
28-6	4634-4647	neurofeedback	_	
28-7	4648-4649	(	_	
28-8	4649-4658	rtfMRI-NF	_	
28-9	4658-4659	)	_	
28-10	4660-4666	offers	_	
28-11	4667-4669	an	_	
28-12	4670-4681	alternative	_	
28-13	4682-4690	approach	_	
28-14	4690-4691	,	_	
28-15	4692-4694	as	_	
28-16	4695-4697	it	_	
28-17	4698-4701	can	_	
28-18	4702-4704	be	_	
28-19	4705-4711	better	_	
28-20	4712-4720	targeted	_	
28-21	4721-4725	than	_	
28-22	4726-4729	TMS	_	
28-23	4729-4730	,	_	
28-24	4731-4734	and	_	
28-25	4735-4737	it	_	
28-26	4738-4744	allows	_	
28-27	4745-4756	individuals	_	
28-28	4757-4759	to	_	
28-29	4760-4767	monitor	_	
28-30	4768-4771	and	_	
28-31	4772-4785	self-regulate	_	
28-32	4786-4791	their	_	
28-33	4792-4795	own	_	
28-34	4796-4801	brain	_	
28-35	4802-4810	activity	_	
28-36	4810-4811	.	_	

#Text=During rtfMRI-NF, brain activity is measured in real time and fed back to participants so that they can progressively achieve voluntary control over their own neural activity.
29-1	4812-4818	During	_	
29-2	4819-4828	rtfMRI-NF	_	
29-3	4828-4829	,	_	
29-4	4830-4835	brain	_	
29-5	4836-4844	activity	_	
29-6	4845-4847	is	_	
29-7	4848-4856	measured	_	
29-8	4857-4859	in	_	
29-9	4860-4864	real	_	
29-10	4865-4869	time	_	
29-11	4870-4873	and	_	
29-12	4874-4877	fed	_	
29-13	4878-4882	back	_	
29-14	4883-4885	to	_	
29-15	4886-4898	participants	_	
29-16	4899-4901	so	_	
29-17	4902-4906	that	_	
29-18	4907-4911	they	_	
29-19	4912-4915	can	_	
29-20	4916-4929	progressively	_	
29-21	4930-4937	achieve	_	
29-22	4938-4947	voluntary	_	
29-23	4948-4955	control	_	
29-24	4956-4960	over	_	
29-25	4961-4966	their	_	
29-26	4967-4970	own	_	
29-27	4971-4977	neural	_	
29-28	4978-4986	activity	_	
29-29	4986-4987	.	_	

#Text=Precisely defining the target brain area or network is important for rtfMRI-NF protocols and the vastly superior spatial resolution of MRI, as compared to alternative neurofeedback protocols using electroencephalography, allows the feedback signal to be better localized. rtfMRI-NF studies in patients with SCZ are limited, but a recent case report shows subjective improvements in some aspects of three patients’ AVH when rtfMRI-NF was applied to the anterior cingulate cortex. rtfMRI-NF experiments could make a major contribution to our understanding of the brain regions and networks involved in AVH and, crucially, could enable us to test if people with SCZ can be trained to alter activity and connectivity in these networks.
30-1	4988-4997	Precisely	_	
30-2	4998-5006	defining	_	
30-3	5007-5010	the	_	
30-4	5011-5017	target	_	
30-5	5018-5023	brain	_	
30-6	5024-5028	area	_	
30-7	5029-5031	or	_	
30-8	5032-5039	network	_	
30-9	5040-5042	is	_	
30-10	5043-5052	important	_	
30-11	5053-5056	for	_	
30-12	5057-5066	rtfMRI-NF	_	
30-13	5067-5076	protocols	_	
30-14	5077-5080	and	_	
30-15	5081-5084	the	_	
30-16	5085-5091	vastly	_	
30-17	5092-5100	superior	_	
30-18	5101-5108	spatial	_	
30-19	5109-5119	resolution	_	
30-20	5120-5122	of	_	
30-21	5123-5126	MRI	_	
30-22	5126-5127	,	_	
30-23	5128-5130	as	_	
30-24	5131-5139	compared	_	
30-25	5140-5142	to	_	
30-26	5143-5154	alternative	_	
30-27	5155-5168	neurofeedback	_	
30-28	5169-5178	protocols	_	
30-29	5179-5184	using	_	
30-30	5185-5207	electroencephalography	_	
30-31	5207-5208	,	_	
30-32	5209-5215	allows	_	
30-33	5216-5219	the	_	
30-34	5220-5228	feedback	_	
30-35	5229-5235	signal	_	
30-36	5236-5238	to	_	
30-37	5239-5241	be	_	
30-38	5242-5248	better	_	
30-39	5249-5258	localized	_	
30-40	5258-5259	.	_	
30-41	5260-5269	rtfMRI-NF	_	
30-42	5270-5277	studies	_	
30-43	5278-5280	in	_	
30-44	5281-5289	patients	_	
30-45	5290-5294	with	_	
30-46	5295-5298	SCZ	_	
30-47	5299-5302	are	_	
30-48	5303-5310	limited	_	
30-49	5310-5311	,	_	
30-50	5312-5315	but	_	
30-51	5316-5317	a	_	
30-52	5318-5324	recent	_	
30-53	5325-5329	case	_	
30-54	5330-5336	report	_	
30-55	5337-5342	shows	_	
30-56	5343-5353	subjective	_	
30-57	5354-5366	improvements	_	
30-58	5367-5369	in	_	
30-59	5370-5374	some	_	
30-60	5375-5382	aspects	_	
30-61	5383-5385	of	_	
30-62	5386-5391	three	_	
30-63	5392-5400	patients	_	
30-64	5400-5401	’	_	
30-65	5402-5405	AVH	_	
30-66	5406-5410	when	_	
30-67	5411-5420	rtfMRI-NF	_	
30-68	5421-5424	was	_	
30-69	5425-5432	applied	_	
30-70	5433-5435	to	_	
30-71	5436-5439	the	_	
30-72	5440-5448	anterior	_	
30-73	5449-5458	cingulate	_	
30-74	5459-5465	cortex	_	
30-75	5465-5466	.	_	
30-76	5467-5476	rtfMRI-NF	_	
30-77	5477-5488	experiments	_	
30-78	5489-5494	could	_	
30-79	5495-5499	make	_	
30-80	5500-5501	a	_	
30-81	5502-5507	major	_	
30-82	5508-5520	contribution	_	
30-83	5521-5523	to	_	
30-84	5524-5527	our	_	
30-85	5528-5541	understanding	_	
30-86	5542-5544	of	_	
30-87	5545-5548	the	_	
30-88	5549-5554	brain	_	
30-89	5555-5562	regions	_	
30-90	5563-5566	and	_	
30-91	5567-5575	networks	_	
30-92	5576-5584	involved	_	
30-93	5585-5587	in	_	
30-94	5588-5591	AVH	_	
30-95	5592-5595	and	_	
30-96	5595-5596	,	_	
30-97	5597-5606	crucially	_	
30-98	5606-5607	,	_	
30-99	5608-5613	could	_	
30-100	5614-5620	enable	_	
30-101	5621-5623	us	_	
30-102	5624-5626	to	_	
30-103	5627-5631	test	_	
30-104	5632-5634	if	_	
30-105	5635-5641	people	_	
30-106	5642-5646	with	_	
30-107	5647-5650	SCZ	_	
30-108	5651-5654	can	_	
30-109	5655-5657	be	_	
30-110	5658-5665	trained	_	
30-111	5666-5668	to	_	
30-112	5669-5674	alter	_	
30-113	5675-5683	activity	_	
30-114	5684-5687	and	_	
30-115	5688-5700	connectivity	_	
30-116	5701-5703	in	_	
30-117	5704-5709	these	_	
30-118	5710-5718	networks	_	
30-119	5718-5719	.	_	

#Text=The aim of the current study was to investigate, for the first time, whether patients with SCZ and AVH could learn to down-regulate left STG activity using an rtfMRI-NF training protocol.
31-1	5720-5723	The	_	
31-2	5724-5727	aim	_	
31-3	5728-5730	of	_	
31-4	5731-5734	the	_	
31-5	5735-5742	current	_	
31-6	5743-5748	study	_	
31-7	5749-5752	was	_	
31-8	5753-5755	to	_	
31-9	5756-5767	investigate	_	
31-10	5767-5768	,	_	
31-11	5769-5772	for	_	
31-12	5773-5776	the	_	
31-13	5777-5782	first	_	
31-14	5783-5787	time	_	
31-15	5787-5788	,	_	
31-16	5789-5796	whether	_	
31-17	5797-5805	patients	_	
31-18	5806-5810	with	_	
31-19	5811-5814	SCZ	_	
31-20	5815-5818	and	_	
31-21	5819-5822	AVH	_	
31-22	5823-5828	could	_	
31-23	5829-5834	learn	_	
31-24	5835-5837	to	_	
31-25	5838-5851	down-regulate	_	
31-26	5852-5856	left	_	
31-27	5857-5860	STG	_	
31-28	5861-5869	activity	_	
31-29	5870-5875	using	_	
31-30	5876-5878	an	_	
31-31	5879-5888	rtfMRI-NF	_	
31-32	5889-5897	training	_	
31-33	5898-5906	protocol	_	
31-34	5906-5907	.	_	

#Text=We also examined if left STG down-regulation would lead to network connectivity changes in speech motor and sensory regions.
32-1	5908-5910	We	_	
32-2	5911-5915	also	_	
32-3	5916-5924	examined	_	
32-4	5925-5927	if	_	
32-5	5928-5932	left	_	
32-6	5933-5936	STG	_	
32-7	5937-5952	down-regulation	_	
32-8	5953-5958	would	_	
32-9	5959-5963	lead	_	
32-10	5964-5966	to	_	
32-11	5967-5974	network	_	
32-12	5975-5987	connectivity	_	
32-13	5988-5995	changes	_	
32-14	5996-5998	in	_	
32-15	5999-6005	speech	_	
32-16	6006-6011	motor	_	
32-17	6012-6015	and	_	
32-18	6016-6023	sensory	_	
32-19	6024-6031	regions	_	
32-20	6031-6032	.	_	

#Text=We chose to use the speech-sensitive region in the posterior STG as our rtfMRI-NF target region as it has been shown to be activated during AVH, to be tonically hyperactive in patients with AVH, can be functionally localized, and can be effectively down-regulated by rtfMRI-NF training.
33-1	6033-6035	We	_	
33-2	6036-6041	chose	_	
33-3	6042-6044	to	_	
33-4	6045-6048	use	_	
33-5	6049-6052	the	_	
33-6	6053-6069	speech-sensitive	_	
33-7	6070-6076	region	_	
33-8	6077-6079	in	_	
33-9	6080-6083	the	_	
33-10	6084-6093	posterior	_	
33-11	6094-6097	STG	_	
33-12	6098-6100	as	_	
33-13	6101-6104	our	_	
33-14	6105-6114	rtfMRI-NF	_	
33-15	6115-6121	target	_	
33-16	6122-6128	region	_	
33-17	6129-6131	as	_	
33-18	6132-6134	it	_	
33-19	6135-6138	has	_	
33-20	6139-6143	been	_	
33-21	6144-6149	shown	_	
33-22	6150-6152	to	_	
33-23	6153-6155	be	_	
33-24	6156-6165	activated	_	
33-25	6166-6172	during	_	
33-26	6173-6176	AVH	_	
33-27	6176-6177	,	_	
33-28	6178-6180	to	_	
33-29	6181-6183	be	_	
33-30	6184-6193	tonically	_	
33-31	6194-6205	hyperactive	_	
33-32	6206-6208	in	_	
33-33	6209-6217	patients	_	
33-34	6218-6222	with	_	
33-35	6223-6226	AVH	_	
33-36	6226-6227	,	_	
33-37	6228-6231	can	_	
33-38	6232-6234	be	_	
33-39	6235-6247	functionally	_	
33-40	6248-6257	localized	_	
33-41	6257-6258	,	_	
33-42	6259-6262	and	_	
33-43	6263-6266	can	_	
33-44	6267-6269	be	_	
33-45	6270-6281	effectively	_	
33-46	6282-6296	down-regulated	_	
33-47	6297-6299	by	_	
33-48	6300-6309	rtfMRI-NF	_	
33-49	6310-6318	training	_	
33-50	6318-6319	.	_	

#Text=Changes in STG activity have also been shown to alter connections with other brain regions in healthy volunteers.
34-1	6320-6327	Changes	_	
34-2	6328-6330	in	_	
34-3	6331-6334	STG	_	
34-4	6335-6343	activity	_	
34-5	6344-6348	have	_	
34-6	6349-6353	also	_	
34-7	6354-6358	been	_	
34-8	6359-6364	shown	_	
34-9	6365-6367	to	_	
34-10	6368-6373	alter	_	
34-11	6374-6385	connections	_	
34-12	6386-6390	with	_	
34-13	6391-6396	other	_	
34-14	6397-6402	brain	_	
34-15	6403-6410	regions	_	
34-16	6411-6413	in	_	
34-17	6414-6421	healthy	_	
34-18	6422-6432	volunteers	_	
34-19	6432-6433	.	_	

#Text=Specifically, we predicted that rtfMRI-NF training, targeting the voice-sensitive region of the STG, would reduce activity in this region, and enhance functional connectivity between left STG and other fronto-temporal speech and language regions.
35-1	6434-6446	Specifically	_	
35-2	6446-6447	,	_	
35-3	6448-6450	we	_	
35-4	6451-6460	predicted	_	
35-5	6461-6465	that	_	
35-6	6466-6475	rtfMRI-NF	_	
35-7	6476-6484	training	_	
35-8	6484-6485	,	_	
35-9	6486-6495	targeting	_	
35-10	6496-6499	the	_	
35-11	6500-6515	voice-sensitive	_	
35-12	6516-6522	region	_	
35-13	6523-6525	of	_	
35-14	6526-6529	the	_	
35-15	6530-6533	STG	_	
35-16	6533-6534	,	_	
35-17	6535-6540	would	_	
35-18	6541-6547	reduce	_	
35-19	6548-6556	activity	_	
35-20	6557-6559	in	_	
35-21	6560-6564	this	_	
35-22	6565-6571	region	_	
35-23	6571-6572	,	_	
35-24	6573-6576	and	_	
35-25	6577-6584	enhance	_	
35-26	6585-6595	functional	_	
35-27	6596-6608	connectivity	_	
35-28	6609-6616	between	_	
35-29	6617-6621	left	_	
35-30	6622-6625	STG	_	
35-31	6626-6629	and	_	
35-32	6630-6635	other	_	
35-33	6636-6651	fronto-temporal	_	
35-34	6652-6658	speech	_	
35-35	6659-6662	and	_	
35-36	6663-6671	language	_	
35-37	6672-6679	regions	_	
35-38	6679-6680	.	_	

#Text=Exploratory analyzes of clinical data examined if changes in AVH symptom severity were related to neurofunctional changes.
36-1	6681-6692	Exploratory	_	
36-2	6693-6701	analyzes	_	
36-3	6702-6704	of	_	
36-4	6705-6713	clinical	_	
36-5	6714-6718	data	_	
36-6	6719-6727	examined	_	
36-7	6728-6730	if	_	
36-8	6731-6738	changes	_	
36-9	6739-6741	in	_	
36-10	6742-6745	AVH	_	
36-11	6746-6753	symptom	_	
36-12	6754-6762	severity	_	
36-13	6763-6767	were	_	
36-14	6768-6775	related	_	
36-15	6776-6778	to	_	
36-16	6779-6794	neurofunctional	_	
36-17	6795-6802	changes	_	
36-18	6802-6803	.	_	

#Text=Methods
#Text=Participants
#Text=Twelve right-handed participants with a Diagnostic and Statistical Manual of Mental Disorders 5th Edition diagnosis of SCZ or schizoaffective disorder were recruited to the study from the South London and Maudsely NHS Trust in London, UK.
37-1	6804-6811	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
37-2	6812-6824	Participants	_	
37-3	6825-6831	Twelve	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-4	6832-6844	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-5	6845-6857	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-6	6858-6862	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-7	6863-6864	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-8	6865-6875	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-9	6876-6879	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-10	6880-6891	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-11	6892-6898	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-12	6899-6901	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-13	6902-6908	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-14	6909-6918	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-15	6919-6922	5th	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-16	6923-6930	Edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-17	6931-6940	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-18	6941-6943	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-19	6944-6947	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
37-20	6948-6950	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-21	6951-6966	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[8]	
37-22	6967-6975	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[8]	
37-23	6976-6980	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-24	6981-6990	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-25	6991-6993	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-26	6994-6997	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-27	6998-7003	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-28	7004-7008	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-29	7009-7012	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-30	7013-7018	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-31	7019-7025	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-32	7026-7029	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-33	7030-7038	Maudsely	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-34	7039-7042	NHS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-35	7043-7048	Trust	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-36	7049-7051	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-37	7052-7058	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-38	7058-7059	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-39	7060-7062	UK	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
37-40	7062-7063	.	_	

#Text=Patients were required to provide written informed consent and to be treated with stable doses of antipsychotic medication for the 3 months prior to study enrollment.
38-1	7064-7072	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-2	7073-7077	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-3	7078-7086	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-4	7087-7089	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-5	7090-7097	provide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-6	7098-7105	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-7	7106-7114	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-8	7115-7122	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-9	7123-7126	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-10	7127-7129	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-11	7130-7132	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-12	7133-7140	treated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-13	7141-7145	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-14	7146-7152	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-15	7153-7158	doses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-16	7159-7161	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-17	7162-7175	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-18	7176-7186	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-19	7187-7190	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-20	7191-7194	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-21	7195-7196	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-22	7197-7203	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-23	7204-7209	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-24	7210-7212	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-25	7213-7218	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-26	7219-7229	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
38-27	7229-7230	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Participants who met the criteria for alcohol or substance dependence in the previous 6 months were excluded.
39-1	7231-7243	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-2	7244-7247	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-3	7248-7251	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-4	7252-7255	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-5	7256-7264	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-6	7265-7268	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-7	7269-7276	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-8	7277-7279	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-9	7280-7289	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-10	7290-7300	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-11	7301-7303	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-12	7304-7307	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-13	7308-7316	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-14	7317-7318	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-15	7319-7325	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-16	7326-7330	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-17	7331-7339	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-18	7339-7340	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=The inclusion criteria required a score of ≥3 on the hallucinatory behavior (P3) item of the Positive and Negative Syndrome Scale (PANSS),.
40-1	7341-7344	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-2	7345-7354	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-3	7355-7363	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-4	7364-7372	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-5	7373-7374	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-6	7375-7380	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-7	7381-7383	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-8	7384-7385	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-9	7385-7386	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-10	7387-7389	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-11	7390-7393	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-12	7394-7407	hallucinatory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-13	7408-7416	behavior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-14	7417-7418	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-15	7418-7420	P3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-16	7420-7421	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-17	7422-7426	item	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-18	7427-7429	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-19	7430-7433	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-20	7434-7442	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
40-21	7443-7446	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
40-22	7447-7455	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
40-23	7456-7464	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
40-24	7465-7470	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
40-25	7471-7472	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
40-26	7472-7477	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
40-27	7477-7478	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
40-28	7478-7479	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-29	7479-7480	.	_	

#Text=The study was approved by the Stanmore National Research Ethics Committee (REC number 15/LO/1007); all study procedures have been conducted in accordance with the Declaration of Helsinki.
41-1	7481-7484	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-2	7485-7490	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-3	7491-7494	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-4	7495-7503	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-5	7504-7506	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-6	7507-7510	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-7	7511-7519	Stanmore	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-8	7520-7528	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-9	7529-7537	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-10	7538-7544	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-11	7545-7554	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-12	7555-7556	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-13	7556-7559	REC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-14	7560-7566	number	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-15	7567-7569	15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-16	7569-7570	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-17	7570-7572	LO	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-18	7572-7573	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-19	7573-7577	1007	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-20	7577-7578	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-21	7578-7579	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-22	7580-7583	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-23	7584-7589	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-24	7590-7600	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-25	7601-7605	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-26	7606-7610	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-27	7611-7620	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-28	7621-7623	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-29	7624-7634	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-30	7635-7639	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-31	7640-7643	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-32	7644-7655	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-33	7656-7658	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-34	7659-7667	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-35	7667-7668	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Study design.
42-1	7669-7674	Study	_	
42-2	7675-7681	design	_	
42-3	7681-7682	.	_	

#Text=Participants attended five study visits.
43-1	7683-7695	Participants	_	
43-2	7696-7704	attended	_	
43-3	7705-7709	five	_	
43-4	7710-7715	study	_	
43-5	7716-7722	visits	_	
43-6	7722-7723	.	_	

#Text=During the baseline visit participants were assessed on the inclusion/exclusion criteria, and clinical and socio-demographic information was collected.
44-1	7724-7730	During	_	
44-2	7731-7734	the	_	
44-3	7735-7743	baseline	_	
44-4	7744-7749	visit	_	
44-5	7750-7762	participants	_	
44-6	7763-7767	were	_	
44-7	7768-7776	assessed	_	
44-8	7777-7779	on	_	
44-9	7780-7783	the	_	
44-10	7784-7793	inclusion	_	
44-11	7793-7794	/	_	
44-12	7794-7803	exclusion	_	
44-13	7804-7812	criteria	_	
44-14	7812-7813	,	_	
44-15	7814-7817	and	_	
44-16	7818-7826	clinical	_	
44-17	7827-7830	and	_	
44-18	7831-7848	socio-demographic	_	
44-19	7849-7860	information	_	
44-20	7861-7864	was	_	
44-21	7865-7874	collected	_	
44-22	7874-7875	.	_	

#Text=During the first scanning visit a mask of the speech-sensitive left STG was created for each participant using the functional localizer task: inc/exc inclusion/exclusion, WASI Wechsler Abbreviate Scale of Intelligence, PsyRats Psychotic Symptom Rating Scale, PANSS Positive and Negative Syndrome Scale, rtfMRI-NF real-time functional magnetic resonance imaging neurofeedback
#Text=Participants were required to attend the study on five separate visits (Fig. 1).
45-1	7876-7882	During	_	
45-2	7883-7886	the	_	
45-3	7887-7892	first	_	
45-4	7893-7901	scanning	_	
45-5	7902-7907	visit	_	
45-6	7908-7909	a	_	
45-7	7910-7914	mask	_	
45-8	7915-7917	of	_	
45-9	7918-7921	the	_	
45-10	7922-7938	speech-sensitive	_	
45-11	7939-7943	left	_	
45-12	7944-7947	STG	_	
45-13	7948-7951	was	_	
45-14	7952-7959	created	_	
45-15	7960-7963	for	_	
45-16	7964-7968	each	_	
45-17	7969-7980	participant	_	
45-18	7981-7986	using	_	
45-19	7987-7990	the	_	
45-20	7991-8001	functional	_	
45-21	8002-8011	localizer	_	
45-22	8012-8016	task	_	
45-23	8016-8017	:	_	
45-24	8018-8021	inc	_	
45-25	8021-8022	/	_	
45-26	8022-8025	exc	_	
45-27	8026-8035	inclusion	_	
45-28	8035-8036	/	_	
45-29	8036-8045	exclusion	_	
45-30	8045-8046	,	_	
45-31	8047-8051	WASI	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[14]	
45-32	8052-8060	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[14]	
45-33	8061-8071	Abbreviate	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[14]	
45-34	8072-8077	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[14]	
45-35	8078-8080	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[14]	
45-36	8081-8093	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[14]	
45-37	8093-8094	,	_	
45-38	8095-8102	PsyRats	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[15]	
45-39	8103-8112	Psychotic	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[15]	
45-40	8113-8120	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[15]	
45-41	8121-8127	Rating	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[15]	
45-42	8128-8133	Scale	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[15]	
45-43	8133-8134	,	_	
45-44	8135-8140	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-45	8141-8149	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-46	8150-8153	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-47	8154-8162	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-48	8163-8171	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-49	8172-8177	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-50	8177-8178	,	_	
45-51	8179-8188	rtfMRI-NF	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[17]	
45-52	8189-8198	real-time	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[17]	
45-53	8199-8209	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[17]	
45-54	8210-8218	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[17]	
45-55	8219-8228	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[17]	
45-56	8229-8236	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[17]	
45-57	8237-8250	neurofeedback	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[17]	
45-58	8251-8263	Participants	_	
45-59	8264-8268	were	_	
45-60	8269-8277	required	_	
45-61	8278-8280	to	_	
45-62	8281-8287	attend	_	
45-63	8288-8291	the	_	
45-64	8292-8297	study	_	
45-65	8298-8300	on	_	
45-66	8301-8305	five	_	
45-67	8306-8314	separate	_	
45-68	8315-8321	visits	_	
45-69	8322-8323	(	_	
45-70	8323-8326	Fig	_	
45-71	8326-8327	.	_	
45-72	8328-8329	1	_	
45-73	8329-8330	)	_	
45-74	8330-8331	.	_	

#Text=Baseline clinical assessments were conducted on the first day.
46-1	8332-8340	Baseline	_	
46-2	8341-8349	clinical	_	
46-3	8350-8361	assessments	_	
46-4	8362-8366	were	_	
46-5	8367-8376	conducted	_	
46-6	8377-8379	on	_	
46-7	8380-8383	the	_	
46-8	8384-8389	first	_	
46-9	8390-8393	day	_	
46-10	8393-8394	.	_	

#Text=The four subsequent visits for MRI scans were completed over a 2-week period.
47-1	8395-8398	The	_	
47-2	8399-8403	four	_	
47-3	8404-8414	subsequent	_	
47-4	8415-8421	visits	_	
47-5	8422-8425	for	_	
47-6	8426-8429	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
47-7	8430-8435	scans	_	
47-8	8436-8440	were	_	
47-9	8441-8450	completed	_	
47-10	8451-8455	over	_	
47-11	8456-8457	a	_	
47-12	8458-8459	2	_	
47-13	8459-8460	-	_	
47-14	8460-8464	week	_	
47-15	8465-8471	period	_	
47-16	8471-8472	.	_	

#Text=Clinical assessments were also completed during these visits.
48-1	8473-8481	Clinical	_	
48-2	8482-8493	assessments	_	
48-3	8494-8498	were	_	
48-4	8499-8503	also	_	
48-5	8504-8513	completed	_	
48-6	8514-8520	during	_	
48-7	8521-8526	these	_	
48-8	8527-8533	visits	_	
48-9	8533-8534	.	_	

#Text=Assessment included the PANSS at baseline and after the last fMRI visit, and the Psychotic Rating Symptom Scale (PsyRats) hallucination subscale at baseline, after each rtfMRI-NF scan (visits 2–4), and 1 week post fMRI.
49-1	8535-8545	Assessment	_	
49-2	8546-8554	included	_	
49-3	8555-8558	the	_	
49-4	8559-8564	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
49-5	8565-8567	at	_	
49-6	8568-8576	baseline	_	
49-7	8577-8580	and	_	
49-8	8581-8586	after	_	
49-9	8587-8590	the	_	
49-10	8591-8595	last	_	
49-11	8596-8600	fMRI	_	
49-12	8601-8606	visit	_	
49-13	8606-8607	,	_	
49-14	8608-8611	and	_	
49-15	8612-8615	the	_	
49-16	8616-8625	Psychotic	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[18]	
49-17	8626-8632	Rating	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[18]	
49-18	8633-8640	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[18]	
49-19	8641-8646	Scale	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[18]	
49-20	8647-8648	(	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[18]	
49-21	8648-8655	PsyRats	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[18]	
49-22	8655-8656	)	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale[18]	
49-23	8657-8670	hallucination	_	
49-24	8671-8679	subscale	_	
49-25	8680-8682	at	_	
49-26	8683-8691	baseline	_	
49-27	8691-8692	,	_	
49-28	8693-8698	after	_	
49-29	8699-8703	each	_	
49-30	8704-8713	rtfMRI-NF	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
49-31	8714-8718	scan	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
49-32	8719-8720	(	_	
49-33	8720-8726	visits	_	
49-34	8727-8728	2	_	
49-35	8728-8729	–	_	
49-36	8729-8730	4	_	
49-37	8730-8731	)	_	
49-38	8731-8732	,	_	
49-39	8733-8736	and	_	
49-40	8737-8738	1	_	
49-41	8739-8743	week	_	
49-42	8744-8748	post	_	
49-43	8749-8753	fMRI	_	
49-44	8753-8754	.	_	

#Text=Intelligence quotient (IQ) was assessed using subsets (Matrix reasoning, and vocabulary) of the Wechsler Abbreviated Scale of Intelligence.
50-1	8755-8767	Intelligence	_	
50-2	8768-8776	quotient	_	
50-3	8777-8778	(	_	
50-4	8778-8780	IQ	_	
50-5	8780-8781	)	_	
50-6	8782-8785	was	_	
50-7	8786-8794	assessed	_	
50-8	8795-8800	using	_	
50-9	8801-8808	subsets	_	
50-10	8809-8810	(	_	
50-11	8810-8816	Matrix	_	
50-12	8817-8826	reasoning	_	
50-13	8826-8827	,	_	
50-14	8828-8831	and	_	
50-15	8832-8842	vocabulary	_	
50-16	8842-8843	)	_	
50-17	8844-8846	of	_	
50-18	8847-8850	the	_	
50-19	8851-8859	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[20]	
50-20	8860-8871	Abbreviated	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[20]	
50-21	8872-8877	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[20]	
50-22	8878-8880	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[20]	
50-23	8881-8893	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[20]	
50-24	8893-8894	.	_	

#Text=The PANSS and PsyRats instruments were administered by an independent researcher (MS), who was blind to the study protocol and objectives.
51-1	8895-8898	The	_	
51-2	8899-8904	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
51-3	8905-8908	and	_	
51-4	8909-8916	PsyRats	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale	
51-5	8917-8928	instruments	_	
51-6	8929-8933	were	_	
51-7	8934-8946	administered	_	
51-8	8947-8949	by	_	
51-9	8950-8952	an	_	
51-10	8953-8964	independent	_	
51-11	8965-8975	researcher	_	
51-12	8976-8977	(	_	
51-13	8977-8979	MS	_	
51-14	8979-8980	)	_	
51-15	8980-8981	,	_	
51-16	8982-8985	who	_	
51-17	8986-8989	was	_	
51-18	8990-8995	blind	_	
51-19	8996-8998	to	_	
51-20	8999-9002	the	_	
51-21	9003-9008	study	_	
51-22	9009-9017	protocol	_	
51-23	9018-9021	and	_	
51-24	9022-9032	objectives	_	
51-25	9032-9033	.	_	

#Text=Imaging data acquisition
#Text=Functional images were acquired on a General Electric MR750 3.0 T MR scanner at the Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London (London, UK).
52-1	9034-9041	Imaging	_	
52-2	9042-9046	data	_	
52-3	9047-9058	acquisition	_	
52-4	9059-9069	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[21]	
52-5	9070-9076	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[21]	
52-6	9077-9081	were	_	
52-7	9082-9090	acquired	_	
52-8	9091-9093	on	_	
52-9	9094-9095	a	_	
52-10	9096-9103	General	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[22]	
52-11	9104-9112	Electric	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[22]	
52-12	9113-9118	MR750	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[22]	
52-13	9119-9122	3.0	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[22]	
52-14	9123-9124	T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[22]	
52-15	9125-9127	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[22]	
52-16	9128-9135	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[22]	
52-17	9136-9138	at	_	
52-18	9139-9142	the	_	
52-19	9143-9153	Department	_	
52-20	9154-9156	of	_	
52-21	9157-9169	Neuroimaging	_	
52-22	9169-9170	,	_	
52-23	9171-9180	Institute	_	
52-24	9181-9183	of	_	
52-25	9184-9194	Psychiatry	_	
52-26	9194-9195	,	_	
52-27	9196-9206	Psychology	_	
52-28	9207-9210	and	_	
52-29	9211-9223	Neuroscience	_	
52-30	9223-9224	,	_	
52-31	9225-9229	King	_	
52-32	9229-9230	’	_	
52-33	9230-9231	s	_	
52-34	9232-9239	College	_	
52-35	9240-9246	London	_	
52-36	9247-9248	(	_	
52-37	9248-9254	London	_	
52-38	9254-9255	,	_	
52-39	9256-9258	UK	_	
52-40	9258-9259	)	_	
52-41	9259-9260	.	_	

#Text=A 12-channel head coil was used for radio frequency transmission and reception.
53-1	9261-9262	A	_	
53-2	9263-9265	12	_	
53-3	9265-9266	-	_	
53-4	9266-9273	channel	_	
53-5	9274-9278	head	_	
53-6	9279-9283	coil	_	
53-7	9284-9287	was	_	
53-8	9288-9292	used	_	
53-9	9293-9296	for	_	
53-10	9297-9302	radio	_	
53-11	9303-9312	frequency	_	
53-12	9313-9325	transmission	_	
53-13	9326-9329	and	_	
53-14	9330-9339	reception	_	
53-15	9339-9340	.	_	

#Text=A single-shot gradient recalled echo planar imaging sequence was used for fMRI acquisition (64 × 64 matrix over a 21.1 × 21.1 cm2 field of view (FOV), giving an in-plane voxel size of 3.3 mm; slice thickness 3 mm with a 0.3 mm slice gap; repetition time (TR) = 2000ms; echo time (TE) = 30ms, flip angle = 75°).
54-1	9341-9342	A	_	
54-2	9343-9354	single-shot	_	
54-3	9355-9363	gradient	_	
54-4	9364-9372	recalled	_	
54-5	9373-9377	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
54-6	9378-9384	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
54-7	9385-9392	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
54-8	9393-9401	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
54-9	9402-9405	was	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
54-10	9406-9410	used	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
54-11	9411-9414	for	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
54-12	9415-9419	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
54-13	9420-9431	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
54-14	9432-9433	(	_	
54-15	9433-9435	64	_	
54-16	9436-9437	×	_	
54-17	9438-9440	64	_	
54-18	9441-9447	matrix	_	
54-19	9448-9452	over	_	
54-20	9453-9454	a	_	
54-21	9455-9459	21.1	_	
54-22	9460-9461	×	_	
54-23	9462-9466	21.1	_	
54-24	9467-9470	cm2	_	
54-25	9471-9476	field	_	
54-26	9477-9479	of	_	
54-27	9480-9484	view	_	
54-28	9485-9486	(	_	
54-29	9486-9489	FOV	_	
54-30	9489-9490	)	_	
54-31	9490-9491	,	_	
54-32	9492-9498	giving	_	
54-33	9499-9501	an	_	
54-34	9502-9510	in-plane	_	
54-35	9511-9516	voxel	_	
54-36	9517-9521	size	_	
54-37	9522-9524	of	_	
54-38	9525-9528	3.3	_	
54-39	9529-9531	mm	_	
54-40	9531-9532	;	_	
54-41	9533-9538	slice	_	
54-42	9539-9548	thickness	_	
54-43	9549-9550	3	_	
54-44	9551-9553	mm	_	
54-45	9554-9558	with	_	
54-46	9559-9560	a	_	
54-47	9561-9564	0.3	_	
54-48	9565-9567	mm	_	
54-49	9568-9573	slice	_	
54-50	9574-9577	gap	_	
54-51	9577-9578	;	_	
54-52	9579-9589	repetition	_	
54-53	9590-9594	time	_	
54-54	9595-9596	(	_	
54-55	9596-9598	TR	_	
54-56	9598-9599	)	_	
54-57	9600-9601	=	_	
54-58	9602-9608	2000ms	_	
54-59	9608-9609	;	_	
54-60	9610-9614	echo	_	
54-61	9615-9619	time	_	
54-62	9620-9621	(	_	
54-63	9621-9623	TE	_	
54-64	9623-9624	)	_	
54-65	9625-9626	=	_	
54-66	9627-9631	30ms	_	
54-67	9631-9632	,	_	
54-68	9633-9637	flip	_	
54-69	9638-9643	angle	_	
54-70	9644-9645	=	_	
54-71	9646-9648	75	_	
54-72	9648-9649	°	_	
54-73	9649-9650	)	_	
54-74	9650-9651	.	_	

#Text=A high-resolution three-dimensional (3D) T1-weighted enhanced gradient echo (256 × 256 matrix over a 27 × 27 cm2 FOV, giving an in-plane voxel size of 1.05 mm; slice thickness 1.2 mm; TR = 7.312 ms, TE = 3.015 ms, flip angle = 11°) scan was acquired for image normalization.
55-1	9652-9653	A	_	
55-2	9654-9669	high-resolution	_	
55-3	9670-9687	three-dimensional	_	
55-4	9688-9689	(	_	
55-5	9689-9691	3D	_	
55-6	9691-9692	)	_	
55-7	9693-9695	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
55-8	9695-9696	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
55-9	9696-9704	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
55-10	9705-9713	enhanced	_	
55-11	9714-9722	gradient	_	
55-12	9723-9727	echo	_	
55-13	9728-9729	(	_	
55-14	9729-9732	256	_	
55-15	9733-9734	×	_	
55-16	9735-9738	256	_	
55-17	9739-9745	matrix	_	
55-18	9746-9750	over	_	
55-19	9751-9752	a	_	
55-20	9753-9755	27	_	
55-21	9756-9757	×	_	
55-22	9758-9760	27	_	
55-23	9761-9764	cm2	_	
55-24	9765-9768	FOV	_	
55-25	9768-9769	,	_	
55-26	9770-9776	giving	_	
55-27	9777-9779	an	_	
55-28	9780-9788	in-plane	_	
55-29	9789-9794	voxel	_	
55-30	9795-9799	size	_	
55-31	9800-9802	of	_	
55-32	9803-9807	1.05	_	
55-33	9808-9810	mm	_	
55-34	9810-9811	;	_	
55-35	9812-9817	slice	_	
55-36	9818-9827	thickness	_	
55-37	9828-9831	1.2	_	
55-38	9832-9834	mm	_	
55-39	9834-9835	;	_	
55-40	9836-9838	TR	_	
55-41	9839-9840	=	_	
55-42	9841-9846	7.312	_	
55-43	9847-9849	ms	_	
55-44	9849-9850	,	_	
55-45	9851-9853	TE	_	
55-46	9854-9855	=	_	
55-47	9856-9861	3.015	_	
55-48	9862-9864	ms	_	
55-49	9864-9865	,	_	
55-50	9866-9870	flip	_	
55-51	9871-9876	angle	_	
55-52	9877-9878	=	_	
55-53	9879-9881	11	_	
55-54	9881-9882	°	_	
55-55	9882-9883	)	_	
55-56	9884-9888	scan	_	
55-57	9889-9892	was	_	
55-58	9893-9901	acquired	_	
55-59	9902-9905	for	_	
55-60	9906-9911	image	_	
55-61	9912-9925	normalization	_	
55-62	9925-9926	.	_	

#Text=The first four volumes of each rtfMRI-NF run were discarded to allow steady-state magnetization to be established.
56-1	9927-9930	The	_	
56-2	9931-9936	first	_	
56-3	9937-9941	four	_	
56-4	9942-9949	volumes	_	
56-5	9950-9952	of	_	
56-6	9953-9957	each	_	
56-7	9958-9967	rtfMRI-NF	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
56-8	9968-9971	run	_	
56-9	9972-9976	were	_	
56-10	9977-9986	discarded	_	
56-11	9987-9989	to	_	
56-12	9990-9995	allow	_	
56-13	9996-10008	steady-state	_	
56-14	10009-10022	magnetization	_	
56-15	10023-10025	to	_	
56-16	10026-10028	be	_	
56-17	10029-10040	established	_	
56-18	10040-10041	.	_	

#Text=Localizer scan
#Text=During the first visit participants underwent a localizer scan to identify voice-sensitive regions in their left STG.
57-1	10042-10051	Localizer	_	
57-2	10052-10056	scan	_	
57-3	10057-10063	During	_	
57-4	10064-10067	the	_	
57-5	10068-10073	first	_	
57-6	10074-10079	visit	_	
57-7	10080-10092	participants	_	
57-8	10093-10102	underwent	_	
57-9	10103-10104	a	_	
57-10	10105-10114	localizer	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-11	10115-10119	scan	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-12	10120-10122	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-13	10123-10131	identify	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-14	10132-10147	voice-sensitive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-15	10148-10155	regions	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
57-16	10156-10158	in	_	
57-17	10159-10164	their	_	
57-18	10165-10169	left	_	
57-19	10170-10173	STG	_	
57-20	10173-10174	.	_	

#Text=This consisted of a voice perception task comprising blocks of vocal and non-vocal stimuli.
58-1	10175-10179	This	_	
58-2	10180-10189	consisted	_	
58-3	10190-10192	of	_	
58-4	10193-10194	a	_	
58-5	10195-10200	voice	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
58-6	10201-10211	perception	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
58-7	10212-10216	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
58-8	10217-10227	comprising	_	
58-9	10228-10234	blocks	_	
58-10	10235-10237	of	_	
58-11	10238-10243	vocal	_	
58-12	10244-10247	and	_	
58-13	10248-10257	non-vocal	_	
58-14	10258-10265	stimuli	_	
58-15	10265-10266	.	_	

#Text=Vocal stimuli were words for everyday objects neutral in semantic and prosodic content, whereas the non-vocal stimuli were based on non-speech digitalized sounds with amplitude and energy matched with control sounds.
59-1	10267-10272	Vocal	_	
59-2	10273-10280	stimuli	_	
59-3	10281-10285	were	_	
59-4	10286-10291	words	_	
59-5	10292-10295	for	_	
59-6	10296-10304	everyday	_	
59-7	10305-10312	objects	_	
59-8	10313-10320	neutral	_	
59-9	10321-10323	in	_	
59-10	10324-10332	semantic	_	
59-11	10333-10336	and	_	
59-12	10337-10345	prosodic	_	
59-13	10346-10353	content	_	
59-14	10353-10354	,	_	
59-15	10355-10362	whereas	_	
59-16	10363-10366	the	_	
59-17	10367-10376	non-vocal	_	
59-18	10377-10384	stimuli	_	
59-19	10385-10389	were	_	
59-20	10390-10395	based	_	
59-21	10396-10398	on	_	
59-22	10399-10409	non-speech	_	
59-23	10410-10421	digitalized	_	
59-24	10422-10428	sounds	_	
59-25	10429-10433	with	_	
59-26	10434-10443	amplitude	_	
59-27	10444-10447	and	_	
59-28	10448-10454	energy	_	
59-29	10455-10462	matched	_	
59-30	10463-10467	with	_	
59-31	10468-10475	control	_	
59-32	10476-10482	sounds	_	
59-33	10482-10483	.	_	

#Text=The presentation was alternated, with a total of eight 20 s blocks of vocal and seven 20 s blocks of non-vocal stimuli, lasting approximately 5 min in total.
60-1	10484-10487	The	_	
60-2	10488-10500	presentation	_	
60-3	10501-10504	was	_	
60-4	10505-10515	alternated	_	
60-5	10515-10516	,	_	
60-6	10517-10521	with	_	
60-7	10522-10523	a	_	
60-8	10524-10529	total	_	
60-9	10530-10532	of	_	
60-10	10533-10538	eight	_	
60-11	10539-10541	20	_	
60-12	10542-10543	s	_	
60-13	10544-10550	blocks	_	
60-14	10551-10553	of	_	
60-15	10554-10559	vocal	_	
60-16	10560-10563	and	_	
60-17	10564-10569	seven	_	
60-18	10570-10572	20	_	
60-19	10573-10574	s	_	
60-20	10575-10581	blocks	_	
60-21	10582-10584	of	_	
60-22	10585-10594	non-vocal	_	
60-23	10595-10602	stimuli	_	
60-24	10602-10603	,	_	
60-25	10604-10611	lasting	_	
60-26	10612-10625	approximately	_	
60-27	10626-10627	5	_	
60-28	10628-10631	min	_	
60-29	10632-10634	in	_	
60-30	10635-10640	total	_	
60-31	10640-10641	.	_	

#Text=Stimuli loudness was adjusted individually, to ensure that participants could hear the stimuli clearly above the scanner noise.
61-1	10642-10649	Stimuli	_	
61-2	10650-10658	loudness	_	
61-3	10659-10662	was	_	
61-4	10663-10671	adjusted	_	
61-5	10672-10684	individually	_	
61-6	10684-10685	,	_	
61-7	10686-10688	to	_	
61-8	10689-10695	ensure	_	
61-9	10696-10700	that	_	
61-10	10701-10713	participants	_	
61-11	10714-10719	could	_	
61-12	10720-10724	hear	_	
61-13	10725-10728	the	_	
61-14	10729-10736	stimuli	_	
61-15	10737-10744	clearly	_	
61-16	10745-10750	above	_	
61-17	10751-10754	the	_	
61-18	10755-10762	scanner	_	
61-19	10763-10768	noise	_	
61-20	10768-10769	.	_	

#Text=To create a functional mask from which to derive the rtfMRI-NF signal, we calculated the effective signal change in areas activated by the functional localizer task using conventional univariate fMRI analysis techniques.
62-1	10770-10772	To	_	
62-2	10773-10779	create	_	
62-3	10780-10781	a	_	
62-4	10782-10792	functional	_	
62-5	10793-10797	mask	_	
62-6	10798-10802	from	_	
62-7	10803-10808	which	_	
62-8	10809-10811	to	_	
62-9	10812-10818	derive	_	
62-10	10819-10822	the	_	
62-11	10823-10832	rtfMRI-NF	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
62-12	10833-10839	signal	_	
62-13	10839-10840	,	_	
62-14	10841-10843	we	_	
62-15	10844-10854	calculated	_	
62-16	10855-10858	the	_	
62-17	10859-10868	effective	_	
62-18	10869-10875	signal	_	
62-19	10876-10882	change	_	
62-20	10883-10885	in	_	
62-21	10886-10891	areas	_	
62-22	10892-10901	activated	_	
62-23	10902-10904	by	_	
62-24	10905-10908	the	_	
62-25	10909-10919	functional	_	
62-26	10920-10929	localizer	_	
62-27	10930-10934	task	_	
62-28	10935-10940	using	_	
62-29	10941-10953	conventional	_	
62-30	10954-10964	univariate	_	
62-31	10965-10969	fMRI	_	
62-32	10970-10978	analysis	_	
62-33	10979-10989	techniques	_	
62-34	10989-10990	.	_	

#Text=This was based on the task contrast of the average BOLD signal between the activation block (vocal stimuli) and the baseline block (non-vocal stimuli).
63-1	10991-10995	This	_	
63-2	10996-10999	was	_	
63-3	11000-11005	based	_	
63-4	11006-11008	on	_	
63-5	11009-11012	the	_	
63-6	11013-11017	task	_	
63-7	11018-11026	contrast	_	
63-8	11027-11029	of	_	
63-9	11030-11033	the	_	
63-10	11034-11041	average	_	
63-11	11042-11046	BOLD	_	
63-12	11047-11053	signal	_	
63-13	11054-11061	between	_	
63-14	11062-11065	the	_	
63-15	11066-11076	activation	_	
63-16	11077-11082	block	_	
63-17	11083-11084	(	_	
63-18	11084-11089	vocal	_	
63-19	11090-11097	stimuli	_	
63-20	11097-11098	)	_	
63-21	11099-11102	and	_	
63-22	11103-11106	the	_	
63-23	11107-11115	baseline	_	
63-24	11116-11121	block	_	
63-25	11122-11123	(	_	
63-26	11123-11132	non-vocal	_	
63-27	11133-11140	stimuli	_	
63-28	11140-11141	)	_	
63-29	11141-11142	.	_	

#Text=Online pre-processing and analysis were conducted using AFNI software (https://afni.nimh.nih.gov/) and using local scripts written and developed by the author V.G.
64-1	11143-11149	Online	_	
64-2	11150-11164	pre-processing	_	
64-3	11165-11168	and	_	
64-4	11169-11177	analysis	_	
64-5	11178-11182	were	_	
64-6	11183-11192	conducted	_	
64-7	11193-11198	using	_	
64-8	11199-11203	AFNI	_	
64-9	11204-11212	software	_	
64-10	11213-11214	(	_	
64-11	11214-11219	https	_	
64-12	11219-11220	:	_	
64-13	11220-11221	/	_	
64-14	11221-11222	/	_	
64-15	11222-11239	afni.nimh.nih.gov	_	
64-16	11239-11240	/	_	
64-17	11240-11241	)	_	
64-18	11242-11245	and	_	
64-19	11246-11251	using	_	
64-20	11252-11257	local	_	
64-21	11258-11265	scripts	_	
64-22	11266-11273	written	_	
64-23	11274-11277	and	_	
64-24	11278-11287	developed	_	
64-25	11288-11290	by	_	
64-26	11291-11294	the	_	
64-27	11295-11301	author	_	
64-28	11302-11305	V.G	_	
64-29	11305-11306	.	_	

#Text=In short, the data were smoothed and corrected for head motion.
65-1	11307-11309	In	_	
65-2	11310-11315	short	_	
65-3	11315-11316	,	_	
65-4	11317-11320	the	_	
65-5	11321-11325	data	_	
65-6	11326-11330	were	_	
65-7	11331-11339	smoothed	_	
65-8	11340-11343	and	_	
65-9	11344-11353	corrected	_	
65-10	11354-11357	for	_	
65-11	11358-11362	head	_	
65-12	11363-11369	motion	_	
65-13	11369-11370	.	_	

#Text=The contrast vocal > non-vocal was chosen and faces touching clusters with the highest t-statistic were displayed (https://afni.nimh.nih.gov/pub/dist/doc/program_help/3dclust.html).
66-1	11371-11374	The	_	
66-2	11375-11383	contrast	_	
66-3	11384-11389	vocal	_	
66-4	11390-11391	>	_	
66-5	11392-11401	non-vocal	_	
66-6	11402-11405	was	_	
66-7	11406-11412	chosen	_	
66-8	11413-11416	and	_	
66-9	11417-11422	faces	_	
66-10	11423-11431	touching	_	
66-11	11432-11440	clusters	_	
66-12	11441-11445	with	_	
66-13	11446-11449	the	_	
66-14	11450-11457	highest	_	
66-15	11458-11469	t-statistic	_	
66-16	11470-11474	were	_	
66-17	11475-11484	displayed	_	
66-18	11485-11486	(	_	
66-19	11486-11491	https	_	
66-20	11491-11492	:	_	
66-21	11492-11493	/	_	
66-22	11493-11494	/	_	
66-23	11494-11511	afni.nimh.nih.gov	_	
66-24	11511-11512	/	_	
66-25	11512-11515	pub	_	
66-26	11515-11516	/	_	
66-27	11516-11520	dist	_	
66-28	11520-11521	/	_	
66-29	11521-11524	doc	_	
66-30	11524-11525	/	_	
66-31	11525-11537	program_help	_	
66-32	11537-11538	/	_	
66-33	11538-11550	3dclust.html	_	
66-34	11550-11551	)	_	
66-35	11551-11552	.	_	

#Text=The individual functional masks were created based on the maximally activated cluster in the left posterior STG by manually thresholding the target cluster until the required size/shape was present in the left posterior STG (ROISTG).
67-1	11553-11556	The	_	
67-2	11557-11567	individual	_	
67-3	11568-11578	functional	_	
67-4	11579-11584	masks	_	
67-5	11585-11589	were	_	
67-6	11590-11597	created	_	
67-7	11598-11603	based	_	
67-8	11604-11606	on	_	
67-9	11607-11610	the	_	
67-10	11611-11620	maximally	_	
67-11	11621-11630	activated	_	
67-12	11631-11638	cluster	_	
67-13	11639-11641	in	_	
67-14	11642-11645	the	_	
67-15	11646-11650	left	_	
67-16	11651-11660	posterior	_	
67-17	11661-11664	STG	_	
67-18	11665-11667	by	_	
67-19	11668-11676	manually	_	
67-20	11677-11689	thresholding	_	
67-21	11690-11693	the	_	
67-22	11694-11700	target	_	
67-23	11701-11708	cluster	_	
67-24	11709-11714	until	_	
67-25	11715-11718	the	_	
67-26	11719-11727	required	_	
67-27	11728-11732	size	_	
67-28	11732-11733	/	_	
67-29	11733-11738	shape	_	
67-30	11739-11742	was	_	
67-31	11743-11750	present	_	
67-32	11751-11753	in	_	
67-33	11754-11757	the	_	
67-34	11758-11762	left	_	
67-35	11763-11772	posterior	_	
67-36	11773-11776	STG	_	
67-37	11777-11778	(	_	
67-38	11778-11784	ROISTG	_	
67-39	11784-11785	)	_	
67-40	11785-11786	.	_	

#Text=The left STG was chosen because this region is typically active during AVH.
68-1	11787-11790	The	_	
68-2	11791-11795	left	_	
68-3	11796-11799	STG	_	
68-4	11800-11803	was	_	
68-5	11804-11810	chosen	_	
68-6	11811-11818	because	_	
68-7	11819-11823	this	_	
68-8	11824-11830	region	_	
68-9	11831-11833	is	_	
68-10	11834-11843	typically	_	
68-11	11844-11850	active	_	
68-12	11851-11857	during	_	
68-13	11858-11861	AVH	_	
68-14	11861-11862	.	_	

#Text=We used white matter as a reference region to cancel out non-specific global brain effects (ROIREF): a white matter mask was created by segmenting the T1-weighted structural image in AFNI, eroding to limit partial volume effects, and mapping it onto the functional localizer mask by reversing the normalization process.
#Text=rtfMRI-NF data acquisition and processing
#Text=A custom rtfMRI-NF interface system and AFNI software were used for real-time transfer and analysis of fMRI data.
69-1	11863-11865	We	_	
69-2	11866-11870	used	_	
69-3	11871-11876	white	_	
69-4	11877-11883	matter	_	
69-5	11884-11886	as	_	
69-6	11887-11888	a	_	
69-7	11889-11898	reference	_	
69-8	11899-11905	region	_	
69-9	11906-11908	to	_	
69-10	11909-11915	cancel	_	
69-11	11916-11919	out	_	
69-12	11920-11932	non-specific	_	
69-13	11933-11939	global	_	
69-14	11940-11945	brain	_	
69-15	11946-11953	effects	_	
69-16	11954-11955	(	_	
69-17	11955-11961	ROIREF	_	
69-18	11961-11962	)	_	
69-19	11962-11963	:	_	
69-20	11964-11965	a	_	
69-21	11966-11971	white	_	
69-22	11972-11978	matter	_	
69-23	11979-11983	mask	_	
69-24	11984-11987	was	_	
69-25	11988-11995	created	_	
69-26	11996-11998	by	_	
69-27	11999-12009	segmenting	_	
69-28	12010-12013	the	_	
69-29	12014-12016	T1	_	
69-30	12016-12017	-	_	
69-31	12017-12025	weighted	_	
69-32	12026-12036	structural	_	
69-33	12037-12042	image	_	
69-34	12043-12045	in	_	
69-35	12046-12050	AFNI	_	
69-36	12050-12051	,	_	
69-37	12052-12059	eroding	_	
69-38	12060-12062	to	_	
69-39	12063-12068	limit	_	
69-40	12069-12076	partial	_	
69-41	12077-12083	volume	_	
69-42	12084-12091	effects	_	
69-43	12091-12092	,	_	
69-44	12093-12096	and	_	
69-45	12097-12104	mapping	_	
69-46	12105-12107	it	_	
69-47	12108-12112	onto	_	
69-48	12113-12116	the	_	
69-49	12117-12127	functional	_	
69-50	12128-12137	localizer	_	
69-51	12138-12142	mask	_	
69-52	12143-12145	by	_	
69-53	12146-12155	reversing	_	
69-54	12156-12159	the	_	
69-55	12160-12173	normalization	_	
69-56	12174-12181	process	_	
69-57	12181-12182	.	_	
69-58	12183-12192	rtfMRI-NF	_	
69-59	12193-12197	data	_	
69-60	12198-12209	acquisition	_	
69-61	12210-12213	and	_	
69-62	12214-12224	processing	_	
69-63	12225-12226	A	_	
69-64	12227-12233	custom	_	
69-65	12234-12243	rtfMRI-NF	_	
69-66	12244-12253	interface	_	
69-67	12254-12260	system	_	
69-68	12261-12264	and	_	
69-69	12265-12269	AFNI	_	
69-70	12270-12278	software	_	
69-71	12279-12283	were	_	
69-72	12284-12288	used	_	
69-73	12289-12292	for	_	
69-74	12293-12302	real-time	_	
69-75	12303-12311	transfer	_	
69-76	12312-12315	and	_	
69-77	12316-12324	analysis	_	
69-78	12325-12327	of	_	
69-79	12328-12332	fMRI	_	
69-80	12333-12337	data	_	
69-81	12337-12338	.	_	

#Text=The rtfMRI-NF interface system ran on the scanner hardware to access the fMRI scans as they were reconstructed.
70-1	12339-12342	The	_	
70-2	12343-12352	rtfMRI-NF	_	
70-3	12353-12362	interface	_	
70-4	12363-12369	system	_	
70-5	12370-12373	ran	_	
70-6	12374-12376	on	_	
70-7	12377-12380	the	_	
70-8	12381-12388	scanner	_	
70-9	12389-12397	hardware	_	
70-10	12398-12400	to	_	
70-11	12401-12407	access	_	
70-12	12408-12411	the	_	
70-13	12412-12416	fMRI	_	
70-14	12417-12422	scans	_	
70-15	12423-12425	as	_	
70-16	12426-12430	they	_	
70-17	12431-12435	were	_	
70-18	12436-12449	reconstructed	_	
70-19	12449-12450	.	_	

#Text=The images were then transferred to a Linux workstation where they were pre-processed using AFNI’s built in real-time capabilities.
71-1	12451-12454	The	_	
71-2	12455-12461	images	_	
71-3	12462-12466	were	_	
71-4	12467-12471	then	_	
71-5	12472-12483	transferred	_	
71-6	12484-12486	to	_	
71-7	12487-12488	a	_	
71-8	12489-12494	Linux	_	
71-9	12495-12506	workstation	_	
71-10	12507-12512	where	_	
71-11	12513-12517	they	_	
71-12	12518-12522	were	_	
71-13	12523-12536	pre-processed	_	
71-14	12537-12542	using	_	
71-15	12543-12547	AFNI	_	
71-16	12547-12548	’	_	
71-17	12548-12549	s	_	
71-18	12550-12555	built	_	
71-19	12556-12558	in	_	
71-20	12559-12568	real-time	_	
71-21	12569-12581	capabilities	_	
71-22	12581-12582	.	_	

#Text=Once the target in the STG ROI (ROISTG) had been identified using the functional localizer described above, the neurofeedback signal was calculated using the formula: ((ROISTG−ROIREF)−(ROI STG Previous−ROIREF Previous)), where the previous ROIs are the average activation of the left STG and references regions in the previous rest block.
72-1	12583-12587	Once	_	
72-2	12588-12591	the	_	
72-3	12592-12598	target	_	
72-4	12599-12601	in	_	
72-5	12602-12605	the	_	
72-6	12606-12609	STG	_	
72-7	12610-12613	ROI	_	
72-8	12614-12615	(	_	
72-9	12615-12621	ROISTG	_	
72-10	12621-12622	)	_	
72-11	12623-12626	had	_	
72-12	12627-12631	been	_	
72-13	12632-12642	identified	_	
72-14	12643-12648	using	_	
72-15	12649-12652	the	_	
72-16	12653-12663	functional	_	
72-17	12664-12673	localizer	_	
72-18	12674-12683	described	_	
72-19	12684-12689	above	_	
72-20	12689-12690	,	_	
72-21	12691-12694	the	_	
72-22	12695-12708	neurofeedback	_	
72-23	12709-12715	signal	_	
72-24	12716-12719	was	_	
72-25	12720-12730	calculated	_	
72-26	12731-12736	using	_	
72-27	12737-12740	the	_	
72-28	12741-12748	formula	_	
72-29	12748-12749	:	_	
72-30	12750-12751	(	_	
72-31	12751-12752	(	_	
72-32	12752-12758	ROISTG	_	
72-33	12758-12759	−	_	
72-34	12759-12765	ROIREF	_	
72-35	12765-12766	)	_	
72-36	12766-12767	−	_	
72-37	12767-12768	(	_	
72-38	12768-12771	ROI	_	
72-39	12772-12775	STG	_	
72-40	12776-12784	Previous	_	
72-41	12784-12785	−	_	
72-42	12785-12791	ROIREF	_	
72-43	12792-12800	Previous	_	
72-44	12800-12801	)	_	
72-45	12801-12802	)	_	
72-46	12802-12803	,	_	
72-47	12804-12809	where	_	
72-48	12810-12813	the	_	
72-49	12814-12822	previous	_	
72-50	12823-12827	ROIs	_	
72-51	12828-12831	are	_	
72-52	12832-12835	the	_	
72-53	12836-12843	average	_	
72-54	12844-12854	activation	_	
72-55	12855-12857	of	_	
72-56	12858-12861	the	_	
72-57	12862-12866	left	_	
72-58	12867-12870	STG	_	
72-59	12871-12874	and	_	
72-60	12875-12885	references	_	
72-61	12886-12893	regions	_	
72-62	12894-12896	in	_	
72-63	12897-12900	the	_	
72-64	12901-12909	previous	_	
72-65	12910-12914	rest	_	
72-66	12915-12920	block	_	
72-67	12920-12921	.	_	

#Text=Thus, the NF signal was a function of the difference of the current ROISTG activity (averaged over 3 TR periods in order to reduce jitter) to the average of the previous rest block, with all values being measured relative to the corresponding white matter signal (changes which represent global signal variations of no interest).
#Text=rtfMRI-NF training
#Text=Each rtfMRI-NF training run comprised a block design similar to that used in previous studies.
73-1	12922-12926	Thus	_	
73-2	12926-12927	,	_	
73-3	12928-12931	the	_	
73-4	12932-12934	NF	_	
73-5	12935-12941	signal	_	
73-6	12942-12945	was	_	
73-7	12946-12947	a	_	
73-8	12948-12956	function	_	
73-9	12957-12959	of	_	
73-10	12960-12963	the	_	
73-11	12964-12974	difference	_	
73-12	12975-12977	of	_	
73-13	12978-12981	the	_	
73-14	12982-12989	current	_	
73-15	12990-12996	ROISTG	_	
73-16	12997-13005	activity	_	
73-17	13006-13007	(	_	
73-18	13007-13015	averaged	_	
73-19	13016-13020	over	_	
73-20	13021-13022	3	_	
73-21	13023-13025	TR	_	
73-22	13026-13033	periods	_	
73-23	13034-13036	in	_	
73-24	13037-13042	order	_	
73-25	13043-13045	to	_	
73-26	13046-13052	reduce	_	
73-27	13053-13059	jitter	_	
73-28	13059-13060	)	_	
73-29	13061-13063	to	_	
73-30	13064-13067	the	_	
73-31	13068-13075	average	_	
73-32	13076-13078	of	_	
73-33	13079-13082	the	_	
73-34	13083-13091	previous	_	
73-35	13092-13096	rest	_	
73-36	13097-13102	block	_	
73-37	13102-13103	,	_	
73-38	13104-13108	with	_	
73-39	13109-13112	all	_	
73-40	13113-13119	values	_	
73-41	13120-13125	being	_	
73-42	13126-13134	measured	_	
73-43	13135-13143	relative	_	
73-44	13144-13146	to	_	
73-45	13147-13150	the	_	
73-46	13151-13164	corresponding	_	
73-47	13165-13170	white	_	
73-48	13171-13177	matter	_	
73-49	13178-13184	signal	_	
73-50	13185-13186	(	_	
73-51	13186-13193	changes	_	
73-52	13194-13199	which	_	
73-53	13200-13209	represent	_	
73-54	13210-13216	global	_	
73-55	13217-13223	signal	_	
73-56	13224-13234	variations	_	
73-57	13235-13237	of	_	
73-58	13238-13240	no	_	
73-59	13241-13249	interest	_	
73-60	13249-13250	)	_	
73-61	13250-13251	.	_	
73-62	13252-13261	rtfMRI-NF	_	
73-63	13262-13270	training	_	
73-64	13271-13275	Each	_	
73-65	13276-13285	rtfMRI-NF	_	
73-66	13286-13294	training	_	
73-67	13295-13298	run	_	
73-68	13299-13308	comprised	_	
73-69	13309-13310	a	_	
73-70	13311-13316	block	_	
73-71	13317-13323	design	_	
73-72	13324-13331	similar	_	
73-73	13332-13334	to	_	
73-74	13335-13339	that	_	
73-75	13340-13344	used	_	
73-76	13345-13347	in	_	
73-77	13348-13356	previous	_	
73-78	13357-13364	studies	_	
73-79	13364-13365	.	_	

#Text=Each rtfMRI-NF training run alternated between no-regulation “rest” blocks (7 blocks of 30 s) and down-regulation blocks (6 blocks of 50 s), lasting around 9 min per run.
74-1	13366-13370	Each	_	
74-2	13371-13380	rtfMRI-NF	_	
74-3	13381-13389	training	_	
74-4	13390-13393	run	_	
74-5	13394-13404	alternated	_	
74-6	13405-13412	between	_	
74-7	13413-13426	no-regulation	_	
74-8	13427-13428	“	_	
74-9	13428-13432	rest	_	
74-10	13432-13433	”	_	
74-11	13434-13440	blocks	_	
74-12	13441-13442	(	_	
74-13	13442-13443	7	_	
74-14	13444-13450	blocks	_	
74-15	13451-13453	of	_	
74-16	13454-13456	30	_	
74-17	13457-13458	s	_	
74-18	13458-13459	)	_	
74-19	13460-13463	and	_	
74-20	13464-13479	down-regulation	_	
74-21	13480-13486	blocks	_	
74-22	13487-13488	(	_	
74-23	13488-13489	6	_	
74-24	13490-13496	blocks	_	
74-25	13497-13499	of	_	
74-26	13500-13502	50	_	
74-27	13503-13504	s	_	
74-28	13504-13505	)	_	
74-29	13505-13506	,	_	
74-30	13507-13514	lasting	_	
74-31	13515-13521	around	_	
74-32	13522-13523	9	_	
74-33	13524-13527	min	_	
74-34	13528-13531	per	_	
74-35	13532-13535	run	_	
74-36	13535-13536	.	_	

#Text=To motivate participants during training runs, and to provide a more visually engaging task, we used a visual feedback interface depicting a “vertically orientated space rocket”.
75-1	13537-13539	To	_	
75-2	13540-13548	motivate	_	
75-3	13549-13561	participants	_	
75-4	13562-13568	during	_	
75-5	13569-13577	training	_	
75-6	13578-13582	runs	_	
75-7	13582-13583	,	_	
75-8	13584-13587	and	_	
75-9	13588-13590	to	_	
75-10	13591-13598	provide	_	
75-11	13599-13600	a	_	
75-12	13601-13605	more	_	
75-13	13606-13614	visually	_	
75-14	13615-13623	engaging	_	
75-15	13624-13628	task	_	
75-16	13628-13629	,	_	
75-17	13630-13632	we	_	
75-18	13633-13637	used	_	
75-19	13638-13639	a	_	
75-20	13640-13646	visual	_	
75-21	13647-13655	feedback	_	
75-22	13656-13665	interface	_	
75-23	13666-13675	depicting	_	
75-24	13676-13677	a	_	
75-25	13678-13679	“	_	
75-26	13679-13689	vertically	_	
75-27	13690-13700	orientated	_	
75-28	13701-13706	space	_	
75-29	13707-13713	rocket	_	
75-30	13713-13714	”	_	
75-31	13714-13715	.	_	

#Text=Participants were instructed to land the rocket by bringing it down to Earth.
76-1	13716-13728	Participants	_	
76-2	13729-13733	were	_	
76-3	13734-13744	instructed	_	
76-4	13745-13747	to	_	
76-5	13748-13752	land	_	
76-6	13753-13756	the	_	
76-7	13757-13763	rocket	_	
76-8	13764-13766	by	_	
76-9	13767-13775	bringing	_	
76-10	13776-13778	it	_	
76-11	13779-13783	down	_	
76-12	13784-13786	to	_	
76-13	13787-13792	Earth	_	
76-14	13792-13793	.	_	

#Text=Visual feedback was provided during the training blocks, and during the rest block participants observed a fixation cross.
77-1	13794-13800	Visual	_	
77-2	13801-13809	feedback	_	
77-3	13810-13813	was	_	
77-4	13814-13822	provided	_	
77-5	13823-13829	during	_	
77-6	13830-13833	the	_	
77-7	13834-13842	training	_	
77-8	13843-13849	blocks	_	
77-9	13849-13850	,	_	
77-10	13851-13854	and	_	
77-11	13855-13861	during	_	
77-12	13862-13865	the	_	
77-13	13866-13870	rest	_	
77-14	13871-13876	block	_	
77-15	13877-13889	participants	_	
77-16	13890-13898	observed	_	
77-17	13899-13900	a	_	
77-18	13901-13909	fixation	_	
77-19	13910-13915	cross	_	
77-20	13915-13916	.	_	

#Text=After each visit participants reported the strategy that they used to down-regulate their left STG activity.
78-1	13917-13922	After	_	
78-2	13923-13927	each	_	
78-3	13928-13933	visit	_	
78-4	13934-13946	participants	_	
78-5	13947-13955	reported	_	
78-6	13956-13959	the	_	
78-7	13960-13968	strategy	_	
78-8	13969-13973	that	_	
78-9	13974-13978	they	_	
78-10	13979-13983	used	_	
78-11	13984-13986	to	_	
78-12	13987-14000	down-regulate	_	
78-13	14001-14006	their	_	
78-14	14007-14011	left	_	
78-15	14012-14015	STG	_	
78-16	14016-14024	activity	_	
78-17	14024-14025	.	_	

#Text=Participants were informed about the inherent delay in feedback due to the hemodynamic response (approx. 6 s).
79-1	14026-14038	Participants	_	
79-2	14039-14043	were	_	
79-3	14044-14052	informed	_	
79-4	14053-14058	about	_	
79-5	14059-14062	the	_	
79-6	14063-14071	inherent	_	
79-7	14072-14077	delay	_	
79-8	14078-14080	in	_	
79-9	14081-14089	feedback	_	
79-10	14090-14093	due	_	
79-11	14094-14096	to	_	
79-12	14097-14100	the	_	
79-13	14101-14112	hemodynamic	_	
79-14	14113-14121	response	_	
79-15	14122-14123	(	_	
79-16	14123-14129	approx	_	
79-17	14129-14130	.	_	
79-18	14131-14132	6	_	
79-19	14133-14134	s	_	
79-20	14134-14135	)	_	
79-21	14135-14136	.	_	

#Text=To enhance motivation and the likelihood of successful left STG signal down-regulations, we did not provide any overt instructions or suggest any strategies; participants were asked to devise their own strategy to down-regulate their left STG signal (Supplementary material).
80-1	14137-14139	To	_	
80-2	14140-14147	enhance	_	
80-3	14148-14158	motivation	_	
80-4	14159-14162	and	_	
80-5	14163-14166	the	_	
80-6	14167-14177	likelihood	_	
80-7	14178-14180	of	_	
80-8	14181-14191	successful	_	
80-9	14192-14196	left	_	
80-10	14197-14200	STG	_	
80-11	14201-14207	signal	_	
80-12	14208-14224	down-regulations	_	
80-13	14224-14225	,	_	
80-14	14226-14228	we	_	
80-15	14229-14232	did	_	
80-16	14233-14236	not	_	
80-17	14237-14244	provide	_	
80-18	14245-14248	any	_	
80-19	14249-14254	overt	_	
80-20	14255-14267	instructions	_	
80-21	14268-14270	or	_	
80-22	14271-14278	suggest	_	
80-23	14279-14282	any	_	
80-24	14283-14293	strategies	_	
80-25	14293-14294	;	_	
80-26	14295-14307	participants	_	
80-27	14308-14312	were	_	
80-28	14313-14318	asked	_	
80-29	14319-14321	to	_	
80-30	14322-14328	devise	_	
80-31	14329-14334	their	_	
80-32	14335-14338	own	_	
80-33	14339-14347	strategy	_	
80-34	14348-14350	to	_	
80-35	14351-14364	down-regulate	_	
80-36	14365-14370	their	_	
80-37	14371-14375	left	_	
80-38	14376-14379	STG	_	
80-39	14380-14386	signal	_	
80-40	14387-14388	(	_	
80-41	14388-14401	Supplementary	_	
80-42	14402-14410	material	_	
80-43	14410-14411	)	_	
80-44	14411-14412	.	_	

#Text=All participants attended four 1-h visits for MRI.
81-1	14413-14416	All	_	
81-2	14417-14429	participants	_	
81-3	14430-14438	attended	_	
81-4	14439-14443	four	_	
81-5	14444-14445	1	_	
81-6	14445-14446	-	_	
81-7	14446-14447	h	_	
81-8	14448-14454	visits	_	
81-9	14455-14458	for	_	
81-10	14459-14462	MRI	_	
81-11	14462-14463	.	_	

#Text=The functional localizer task was completed during the first scanner visit.
82-1	14464-14467	The	_	
82-2	14468-14478	functional	_	
82-3	14479-14488	localizer	_	
82-4	14489-14493	task	_	
82-5	14494-14497	was	_	
82-6	14498-14507	completed	_	
82-7	14508-14514	during	_	
82-8	14515-14518	the	_	
82-9	14519-14524	first	_	
82-10	14525-14532	scanner	_	
82-11	14533-14538	visit	_	
82-12	14538-14539	.	_	

#Text=During visits 2, 3, and 4, participants completed between 2 and 6 rtfMRI-NF training runs depending on the time available (mean number of runs per scanner v2 = 4.8, v3 = 4.5, v4 = 3.6).
83-1	14540-14546	During	_	
83-2	14547-14553	visits	_	
83-3	14554-14555	2	_	
83-4	14555-14556	,	_	
83-5	14557-14558	3	_	
83-6	14558-14559	,	_	
83-7	14560-14563	and	_	
83-8	14564-14565	4	_	
83-9	14565-14566	,	_	
83-10	14567-14579	participants	_	
83-11	14580-14589	completed	_	
83-12	14590-14597	between	_	
83-13	14598-14599	2	_	
83-14	14600-14603	and	_	
83-15	14604-14605	6	_	
83-16	14606-14615	rtfMRI-NF	_	
83-17	14616-14624	training	_	
83-18	14625-14629	runs	_	
83-19	14630-14639	depending	_	
83-20	14640-14642	on	_	
83-21	14643-14646	the	_	
83-22	14647-14651	time	_	
83-23	14652-14661	available	_	
83-24	14662-14663	(	_	
83-25	14663-14667	mean	_	
83-26	14668-14674	number	_	
83-27	14675-14677	of	_	
83-28	14678-14682	runs	_	
83-29	14683-14686	per	_	
83-30	14687-14694	scanner	_	
83-31	14695-14697	v2	_	
83-32	14698-14699	=	_	
83-33	14700-14703	4.8	_	
83-34	14703-14704	,	_	
83-35	14705-14707	v3	_	
83-36	14708-14709	=	_	
83-37	14710-14713	4.5	_	
83-38	14713-14714	,	_	
83-39	14715-14717	v4	_	
83-40	14718-14719	=	_	
83-41	14720-14723	3.6	_	
83-42	14723-14724	)	_	
83-43	14724-14725	.	_	

#Text=During the fourth (final) visit, participants also undertook a “transfer” run.
84-1	14726-14732	During	_	
84-2	14733-14736	the	_	
84-3	14737-14743	fourth	_	
84-4	14744-14745	(	_	
84-5	14745-14750	final	_	
84-6	14750-14751	)	_	
84-7	14752-14757	visit	_	
84-8	14757-14758	,	_	
84-9	14759-14771	participants	_	
84-10	14772-14776	also	_	
84-11	14777-14786	undertook	_	
84-12	14787-14788	a	_	
84-13	14789-14790	“	_	
84-14	14790-14798	transfer	_	
84-15	14798-14799	”	_	
84-16	14800-14803	run	_	
84-17	14803-14804	.	_	

#Text=The transfer run was identical to the training runs except that no visual feedback (static picture) was given.
85-1	14805-14808	The	_	
85-2	14809-14817	transfer	_	
85-3	14818-14821	run	_	
85-4	14822-14825	was	_	
85-5	14826-14835	identical	_	
85-6	14836-14838	to	_	
85-7	14839-14842	the	_	
85-8	14843-14851	training	_	
85-9	14852-14856	runs	_	
85-10	14857-14863	except	_	
85-11	14864-14868	that	_	
85-12	14869-14871	no	_	
85-13	14872-14878	visual	_	
85-14	14879-14887	feedback	_	
85-15	14888-14889	(	_	
85-16	14889-14895	static	_	
85-17	14896-14903	picture	_	
85-18	14903-14904	)	_	
85-19	14905-14908	was	_	
85-20	14909-14914	given	_	
85-21	14914-14915	.	_	

#Text=This allowed the overall success of the training to be assessed (i.e., participants’ ability to down-regulate their STG signal in the absence of direct feedback).
86-1	14916-14920	This	_	
86-2	14921-14928	allowed	_	
86-3	14929-14932	the	_	
86-4	14933-14940	overall	_	
86-5	14941-14948	success	_	
86-6	14949-14951	of	_	
86-7	14952-14955	the	_	
86-8	14956-14964	training	_	
86-9	14965-14967	to	_	
86-10	14968-14970	be	_	
86-11	14971-14979	assessed	_	
86-12	14980-14981	(	_	
86-13	14981-14984	i.e	_	
86-14	14984-14985	.	_	
86-15	14985-14986	,	_	
86-16	14987-14999	participants	_	
86-17	14999-15000	’	_	
86-18	15001-15008	ability	_	
86-19	15009-15011	to	_	
86-20	15012-15025	down-regulate	_	
86-21	15026-15031	their	_	
86-22	15032-15035	STG	_	
86-23	15036-15042	signal	_	
86-24	15043-15045	in	_	
86-25	15046-15049	the	_	
86-26	15050-15057	absence	_	
86-27	15058-15060	of	_	
86-28	15061-15067	direct	_	
86-29	15068-15076	feedback	_	
86-30	15076-15077	)	_	
86-31	15077-15078	.	_	

#Text=Participants were informed that the picture would remain static, and were asked to employ the same strategies they used during the rtfMRI-NF training.
87-1	15079-15091	Participants	_	
87-2	15092-15096	were	_	
87-3	15097-15105	informed	_	
87-4	15106-15110	that	_	
87-5	15111-15114	the	_	
87-6	15115-15122	picture	_	
87-7	15123-15128	would	_	
87-8	15129-15135	remain	_	
87-9	15136-15142	static	_	
87-10	15142-15143	,	_	
87-11	15144-15147	and	_	
87-12	15148-15152	were	_	
87-13	15153-15158	asked	_	
87-14	15159-15161	to	_	
87-15	15162-15168	employ	_	
87-16	15169-15172	the	_	
87-17	15173-15177	same	_	
87-18	15178-15188	strategies	_	
87-19	15189-15193	they	_	
87-20	15194-15198	used	_	
87-21	15199-15205	during	_	
87-22	15206-15209	the	_	
87-23	15210-15219	rtfMRI-NF	_	
87-24	15220-15228	training	_	
87-25	15228-15229	.	_	

#Text=Transfer runs measure retention of learning and are considered a proximal measure of successful transfer of training strategies to everyday life.
88-1	15230-15238	Transfer	_	
88-2	15239-15243	runs	_	
88-3	15244-15251	measure	_	
88-4	15252-15261	retention	_	
88-5	15262-15264	of	_	
88-6	15265-15273	learning	_	
88-7	15274-15277	and	_	
88-8	15278-15281	are	_	
88-9	15282-15292	considered	_	
88-10	15293-15294	a	_	
88-11	15295-15303	proximal	_	
88-12	15304-15311	measure	_	
88-13	15312-15314	of	_	
88-14	15315-15325	successful	_	
88-15	15326-15334	transfer	_	
88-16	15335-15337	of	_	
88-17	15338-15346	training	_	
88-18	15347-15357	strategies	_	
88-19	15358-15360	to	_	
88-20	15361-15369	everyday	_	
88-21	15370-15374	life	_	
88-22	15374-15375	.	_	

#Text=Data analysis
#Text=Clinical data
#Text=To assess overall clinical change, and any adverse effect of the study procedures on clinical presentation, we conducted a paired t test for PANSS scores pre and post rtfMRI-NF training.
89-1	15376-15380	Data	_	
89-2	15381-15389	analysis	_	
89-3	15390-15398	Clinical	_	
89-4	15399-15403	data	_	
89-5	15404-15406	To	_	
89-6	15407-15413	assess	_	
89-7	15414-15421	overall	_	
89-8	15422-15430	clinical	_	
89-9	15431-15437	change	_	
89-10	15437-15438	,	_	
89-11	15439-15442	and	_	
89-12	15443-15446	any	_	
89-13	15447-15454	adverse	_	
89-14	15455-15461	effect	_	
89-15	15462-15464	of	_	
89-16	15465-15468	the	_	
89-17	15469-15474	study	_	
89-18	15475-15485	procedures	_	
89-19	15486-15488	on	_	
89-20	15489-15497	clinical	_	
89-21	15498-15510	presentation	_	
89-22	15510-15511	,	_	
89-23	15512-15514	we	_	
89-24	15515-15524	conducted	_	
89-25	15525-15526	a	_	
89-26	15527-15533	paired	_	
89-27	15534-15535	t	_	
89-28	15536-15540	test	_	
89-29	15541-15544	for	_	
89-30	15545-15550	PANSS	_	
89-31	15551-15557	scores	_	
89-32	15558-15561	pre	_	
89-33	15562-15565	and	_	
89-34	15566-15570	post	_	
89-35	15571-15580	rtfMRI-NF	_	
89-36	15581-15589	training	_	
89-37	15589-15590	.	_	

#Text=To investigate the specific change in AVH symptoms over the rtfMRI-NF training period, we analyzed the total PsyRats AVH symptoms score by specifying a full maximum-likelihood random-effect multilevel model (MLREM).
90-1	15591-15593	To	_	
90-2	15594-15605	investigate	_	
90-3	15606-15609	the	_	
90-4	15610-15618	specific	_	
90-5	15619-15625	change	_	
90-6	15626-15628	in	_	
90-7	15629-15632	AVH	_	
90-8	15633-15641	symptoms	_	
90-9	15642-15646	over	_	
90-10	15647-15650	the	_	
90-11	15651-15660	rtfMRI-NF	_	
90-12	15661-15669	training	_	
90-13	15670-15676	period	_	
90-14	15676-15677	,	_	
90-15	15678-15680	we	_	
90-16	15681-15689	analyzed	_	
90-17	15690-15693	the	_	
90-18	15694-15699	total	_	
90-19	15700-15707	PsyRats	_	
90-20	15708-15711	AVH	_	
90-21	15712-15720	symptoms	_	
90-22	15721-15726	score	_	
90-23	15727-15729	by	_	
90-24	15730-15740	specifying	_	
90-25	15741-15742	a	_	
90-26	15743-15747	full	_	
90-27	15748-15766	maximum-likelihood	_	
90-28	15767-15780	random-effect	_	
90-29	15781-15791	multilevel	_	
90-30	15792-15797	model	_	
90-31	15798-15799	(	_	
90-32	15799-15804	MLREM	_	
90-33	15804-15805	)	_	
90-34	15805-15806	.	_	

#Text=Post hoc exploratory analyses examined changes over the rtfMRI-NF training period in individual PsyRats items using one-sided, paired-sample t tests.
91-1	15807-15811	Post	_	
91-2	15812-15815	hoc	_	
91-3	15816-15827	exploratory	_	
91-4	15828-15836	analyses	_	
91-5	15837-15845	examined	_	
91-6	15846-15853	changes	_	
91-7	15854-15858	over	_	
91-8	15859-15862	the	_	
91-9	15863-15872	rtfMRI-NF	_	
91-10	15873-15881	training	_	
91-11	15882-15888	period	_	
91-12	15889-15891	in	_	
91-13	15892-15902	individual	_	
91-14	15903-15910	PsyRats	_	
91-15	15911-15916	items	_	
91-16	15917-15922	using	_	
91-17	15923-15932	one-sided	_	
91-18	15932-15933	,	_	
91-19	15934-15947	paired-sample	_	
91-20	15948-15949	t	_	
91-21	15950-15955	tests	_	
91-22	15955-15956	.	_	

#Text=These results are reported at an uncorrected threshold of p < 0.05, but no tests survived correction for multiple testing (p = 0.05/11).
92-1	15957-15962	These	_	
92-2	15963-15970	results	_	
92-3	15971-15974	are	_	
92-4	15975-15983	reported	_	
92-5	15984-15986	at	_	
92-6	15987-15989	an	_	
92-7	15990-16001	uncorrected	_	
92-8	16002-16011	threshold	_	
92-9	16012-16014	of	_	
92-10	16015-16016	p	_	
92-11	16017-16018	<	_	
92-12	16019-16023	0.05	_	
92-13	16023-16024	,	_	
92-14	16025-16028	but	_	
92-15	16029-16031	no	_	
92-16	16032-16037	tests	_	
92-17	16038-16046	survived	_	
92-18	16047-16057	correction	_	
92-19	16058-16061	for	_	
92-20	16062-16070	multiple	_	
92-21	16071-16078	testing	_	
92-22	16079-16080	(	_	
92-23	16080-16081	p	_	
92-24	16082-16083	=	_	
92-25	16084-16088	0.05	_	
92-26	16088-16089	/	_	
92-27	16089-16091	11	_	
92-28	16091-16092	)	_	
92-29	16092-16093	.	_	

#Text=Data distribution checks and statistical analyses were carried out using STATA 12.1.
#Text=fMRI data analysis
#Text=All offline data were pre-processed and analyzed using Statistical Parametric Mapping 12 (SPM12).
93-1	16094-16098	Data	_	
93-2	16099-16111	distribution	_	
93-3	16112-16118	checks	_	
93-4	16119-16122	and	_	
93-5	16123-16134	statistical	_	
93-6	16135-16143	analyses	_	
93-7	16144-16148	were	_	
93-8	16149-16156	carried	_	
93-9	16157-16160	out	_	
93-10	16161-16166	using	_	
93-11	16167-16172	STATA	_	
93-12	16173-16177	12.1	_	
93-13	16177-16178	.	_	
93-14	16179-16183	fMRI	_	
93-15	16184-16188	data	_	
93-16	16189-16197	analysis	_	
93-17	16198-16201	All	_	
93-18	16202-16209	offline	_	
93-19	16210-16214	data	_	
93-20	16215-16219	were	_	
93-21	16220-16233	pre-processed	_	
93-22	16234-16237	and	_	
93-23	16238-16246	analyzed	_	
93-24	16247-16252	using	_	
93-25	16253-16264	Statistical	_	
93-26	16265-16275	Parametric	_	
93-27	16276-16283	Mapping	_	
93-28	16284-16286	12	_	
93-29	16287-16288	(	_	
93-30	16288-16293	SPM12	_	
93-31	16293-16294	)	_	
93-32	16294-16295	.	_	

#Text=All functional data were slice-timed corrected and realigned, to correct for volume-to-volume head motion.
94-1	16296-16299	All	_	
94-2	16300-16310	functional	_	
94-3	16311-16315	data	_	
94-4	16316-16320	were	_	
94-5	16321-16332	slice-timed	_	
94-6	16333-16342	corrected	_	
94-7	16343-16346	and	_	
94-8	16347-16356	realigned	_	
94-9	16356-16357	,	_	
94-10	16358-16360	to	_	
94-11	16361-16368	correct	_	
94-12	16369-16372	for	_	
94-13	16373-16389	volume-to-volume	_	
94-14	16390-16394	head	_	
94-15	16395-16401	motion	_	
94-16	16401-16402	.	_	

#Text=Following this, the time series was co-registered to the high-resolution T1-weighted image, and normalized into the Montreal Neurological Institute (MNI) template using parameters generated by unified segmentation of the T1-weighted structural image.
95-1	16403-16412	Following	_	
95-2	16413-16417	this	_	
95-3	16417-16418	,	_	
95-4	16419-16422	the	_	
95-5	16423-16427	time	_	
95-6	16428-16434	series	_	
95-7	16435-16438	was	_	
95-8	16439-16452	co-registered	_	
95-9	16453-16455	to	_	
95-10	16456-16459	the	_	
95-11	16460-16475	high-resolution	_	
95-12	16476-16478	T1	_	
95-13	16478-16479	-	_	
95-14	16479-16487	weighted	_	
95-15	16488-16493	image	_	
95-16	16493-16494	,	_	
95-17	16495-16498	and	_	
95-18	16499-16509	normalized	_	
95-19	16510-16514	into	_	
95-20	16515-16518	the	_	
95-21	16519-16527	Montreal	_	
95-22	16528-16540	Neurological	_	
95-23	16541-16550	Institute	_	
95-24	16551-16552	(	_	
95-25	16552-16555	MNI	_	
95-26	16555-16556	)	_	
95-27	16557-16565	template	_	
95-28	16566-16571	using	_	
95-29	16572-16582	parameters	_	
95-30	16583-16592	generated	_	
95-31	16593-16595	by	_	
95-32	16596-16603	unified	_	
95-33	16604-16616	segmentation	_	
95-34	16617-16619	of	_	
95-35	16620-16623	the	_	
95-36	16624-16626	T1	_	
95-37	16626-16627	-	_	
95-38	16627-16635	weighted	_	
95-39	16636-16646	structural	_	
95-40	16647-16652	image	_	
95-41	16652-16653	.	_	

#Text=The transformed data were smoothed using an 8 mm full-width at half-maximum isotropic Gaussian kernel.
96-1	16654-16657	The	_	
96-2	16658-16669	transformed	_	
96-3	16670-16674	data	_	
96-4	16675-16679	were	_	
96-5	16680-16688	smoothed	_	
96-6	16689-16694	using	_	
96-7	16695-16697	an	_	
96-8	16698-16699	8	_	
96-9	16700-16702	mm	_	
96-10	16703-16713	full-width	_	
96-11	16714-16716	at	_	
96-12	16717-16729	half-maximum	_	
96-13	16730-16739	isotropic	_	
96-14	16740-16748	Gaussian	_	
96-15	16749-16755	kernel	_	
96-16	16755-16756	.	_	

#Text=For the localizer task subject-specific fixed models were constructed with regressors encoding the predicted blood oxygenation level-dependent (BOLD) response for vocal stimuli and non-vocal stimuli blocks.
97-1	16757-16760	For	_	
97-2	16761-16764	the	_	
97-3	16765-16774	localizer	_	
97-4	16775-16779	task	_	
97-5	16780-16796	subject-specific	_	
97-6	16797-16802	fixed	_	
97-7	16803-16809	models	_	
97-8	16810-16814	were	_	
97-9	16815-16826	constructed	_	
97-10	16827-16831	with	_	
97-11	16832-16842	regressors	_	
97-12	16843-16851	encoding	_	
97-13	16852-16855	the	_	
97-14	16856-16865	predicted	_	
97-15	16866-16871	blood	_	
97-16	16872-16883	oxygenation	_	
97-17	16884-16899	level-dependent	_	
97-18	16900-16901	(	_	
97-19	16901-16905	BOLD	_	
97-20	16905-16906	)	_	
97-21	16907-16915	response	_	
97-22	16916-16919	for	_	
97-23	16920-16925	vocal	_	
97-24	16926-16933	stimuli	_	
97-25	16934-16937	and	_	
97-26	16938-16947	non-vocal	_	
97-27	16948-16955	stimuli	_	
97-28	16956-16962	blocks	_	
97-29	16962-16963	.	_	

#Text=For the rtfMRI-NF runs, subject-specific fixed-effects models were constructed with regressors encoding the predicted BOLD response for each of the rtfMRI-NF runs (ranging from 9 to 16 across subjects), with baseline (rest) blocks serving as the baseline.
98-1	16964-16967	For	_	
98-2	16968-16971	the	_	
98-3	16972-16981	rtfMRI-NF	_	
98-4	16982-16986	runs	_	
98-5	16986-16987	,	_	
98-6	16988-17004	subject-specific	_	
98-7	17005-17018	fixed-effects	_	
98-8	17019-17025	models	_	
98-9	17026-17030	were	_	
98-10	17031-17042	constructed	_	
98-11	17043-17047	with	_	
98-12	17048-17058	regressors	_	
98-13	17059-17067	encoding	_	
98-14	17068-17071	the	_	
98-15	17072-17081	predicted	_	
98-16	17082-17086	BOLD	_	
98-17	17087-17095	response	_	
98-18	17096-17099	for	_	
98-19	17100-17104	each	_	
98-20	17105-17107	of	_	
98-21	17108-17111	the	_	
98-22	17112-17121	rtfMRI-NF	_	
98-23	17122-17126	runs	_	
98-24	17127-17128	(	_	
98-25	17128-17135	ranging	_	
98-26	17136-17140	from	_	
98-27	17141-17142	9	_	
98-28	17143-17145	to	_	
98-29	17146-17148	16	_	
98-30	17149-17155	across	_	
98-31	17156-17164	subjects	_	
98-32	17164-17165	)	_	
98-33	17165-17166	,	_	
98-34	17167-17171	with	_	
98-35	17172-17180	baseline	_	
98-36	17181-17182	(	_	
98-37	17182-17186	rest	_	
98-38	17186-17187	)	_	
98-39	17188-17194	blocks	_	
98-40	17195-17202	serving	_	
98-41	17203-17205	as	_	
98-42	17206-17209	the	_	
98-43	17210-17218	baseline	_	
98-44	17218-17219	.	_	

#Text=For both the localizer task and the rtfMRI-NF runs, the six motion parameters for each run, generated during realignment, were included as nuisance regressors.
99-1	17220-17223	For	_	
99-2	17224-17228	both	_	
99-3	17229-17232	the	_	
99-4	17233-17242	localizer	_	
99-5	17243-17247	task	_	
99-6	17248-17251	and	_	
99-7	17252-17255	the	_	
99-8	17256-17265	rtfMRI-NF	_	
99-9	17266-17270	runs	_	
99-10	17270-17271	,	_	
99-11	17272-17275	the	_	
99-12	17276-17279	six	_	
99-13	17280-17286	motion	_	
99-14	17287-17297	parameters	_	
99-15	17298-17301	for	_	
99-16	17302-17306	each	_	
99-17	17307-17310	run	_	
99-18	17310-17311	,	_	
99-19	17312-17321	generated	_	
99-20	17322-17328	during	_	
99-21	17329-17340	realignment	_	
99-22	17340-17341	,	_	
99-23	17342-17346	were	_	
99-24	17347-17355	included	_	
99-25	17356-17358	as	_	
99-26	17359-17367	nuisance	_	
99-27	17368-17378	regressors	_	
99-28	17378-17379	.	_	

#Text=For all first-level models voxelwise parameter estimates for these regressors were obtained by restricted maximum-likelihood estimation using a temporal high-pass filter (cutoff = 128 s) to remove low-frequency drifts, and modeling temporal autocorrelation across scans with an AR(1) process.
100-1	17380-17383	For	_	
100-2	17384-17387	all	_	
100-3	17388-17399	first-level	_	
100-4	17400-17406	models	_	
100-5	17407-17416	voxelwise	_	
100-6	17417-17426	parameter	_	
100-7	17427-17436	estimates	_	
100-8	17437-17440	for	_	
100-9	17441-17446	these	_	
100-10	17447-17457	regressors	_	
100-11	17458-17462	were	_	
100-12	17463-17471	obtained	_	
100-13	17472-17474	by	_	
100-14	17475-17485	restricted	_	
100-15	17486-17504	maximum-likelihood	_	
100-16	17505-17515	estimation	_	
100-17	17516-17521	using	_	
100-18	17522-17523	a	_	
100-19	17524-17532	temporal	_	
100-20	17533-17542	high-pass	_	
100-21	17543-17549	filter	_	
100-22	17550-17551	(	_	
100-23	17551-17557	cutoff	_	
100-24	17558-17559	=	_	
100-25	17560-17563	128	_	
100-26	17564-17565	s	_	
100-27	17565-17566	)	_	
100-28	17567-17569	to	_	
100-29	17570-17576	remove	_	
100-30	17577-17590	low-frequency	_	
100-31	17591-17597	drifts	_	
100-32	17597-17598	,	_	
100-33	17599-17602	and	_	
100-34	17603-17611	modeling	_	
100-35	17612-17620	temporal	_	
100-36	17621-17636	autocorrelation	_	
100-37	17637-17643	across	_	
100-38	17644-17649	scans	_	
100-39	17650-17654	with	_	
100-40	17655-17657	an	_	
100-41	17658-17660	AR	_	
100-42	17660-17661	(	_	
100-43	17661-17662	1	_	
100-44	17662-17663	)	_	
100-45	17664-17671	process	_	
100-46	17671-17672	.	_	

#Text=Following parameter estimation, contrasts of beta coefficients for the primary contrasts of interest were generated.
101-1	17673-17682	Following	_	
101-2	17683-17692	parameter	_	
101-3	17693-17703	estimation	_	
101-4	17703-17704	,	_	
101-5	17705-17714	contrasts	_	
101-6	17715-17717	of	_	
101-7	17718-17722	beta	_	
101-8	17723-17735	coefficients	_	
101-9	17736-17739	for	_	
101-10	17740-17743	the	_	
101-11	17744-17751	primary	_	
101-12	17752-17761	contrasts	_	
101-13	17762-17764	of	_	
101-14	17765-17773	interest	_	
101-15	17774-17778	were	_	
101-16	17779-17788	generated	_	
101-17	17788-17789	.	_	

#Text=For the localizer task the contrast was vocal stimuli > non-vocal stimuli.
102-1	17790-17793	For	_	
102-2	17794-17797	the	_	
102-3	17798-17807	localizer	_	
102-4	17808-17812	task	_	
102-5	17813-17816	the	_	
102-6	17817-17825	contrast	_	
102-7	17826-17829	was	_	
102-8	17830-17835	vocal	_	
102-9	17836-17843	stimuli	_	
102-10	17844-17845	>	_	
102-11	17846-17855	non-vocal	_	
102-12	17856-17863	stimuli	_	
102-13	17863-17864	.	_	

#Text=As the number of rtfMRI-NF runs differed between participants (9–16; mean = 14; median = 14), the second-level model comprised contrasts for the first vs. last rtfMRI-NF run acquired during the second, third, and fourth scanner visits, entered into a repeated-measures analysis of variance (ANOVA) (i.e., 6 contrasts).
103-1	17865-17867	As	_	
103-2	17868-17871	the	_	
103-3	17872-17878	number	_	
103-4	17879-17881	of	_	
103-5	17882-17891	rtfMRI-NF	_	
103-6	17892-17896	runs	_	
103-7	17897-17905	differed	_	
103-8	17906-17913	between	_	
103-9	17914-17926	participants	_	
103-10	17927-17928	(	_	
103-11	17928-17929	9	_	
103-12	17929-17930	–	_	
103-13	17930-17932	16	_	
103-14	17932-17933	;	_	
103-15	17934-17938	mean	_	
103-16	17939-17940	=	_	
103-17	17941-17943	14	_	
103-18	17943-17944	;	_	
103-19	17945-17951	median	_	
103-20	17952-17953	=	_	
103-21	17954-17956	14	_	
103-22	17956-17957	)	_	
103-23	17957-17958	,	_	
103-24	17959-17962	the	_	
103-25	17963-17975	second-level	_	
103-26	17976-17981	model	_	
103-27	17982-17991	comprised	_	
103-28	17992-18001	contrasts	_	
103-29	18002-18005	for	_	
103-30	18006-18009	the	_	
103-31	18010-18015	first	_	
103-32	18016-18018	vs	_	
103-33	18018-18019	.	_	
103-34	18020-18024	last	_	
103-35	18025-18034	rtfMRI-NF	_	
103-36	18035-18038	run	_	
103-37	18039-18047	acquired	_	
103-38	18048-18054	during	_	
103-39	18055-18058	the	_	
103-40	18059-18065	second	_	
103-41	18065-18066	,	_	
103-42	18067-18072	third	_	
103-43	18072-18073	,	_	
103-44	18074-18077	and	_	
103-45	18078-18084	fourth	_	
103-46	18085-18092	scanner	_	
103-47	18093-18099	visits	_	
103-48	18099-18100	,	_	
103-49	18101-18108	entered	_	
103-50	18109-18113	into	_	
103-51	18114-18115	a	_	
103-52	18116-18133	repeated-measures	_	
103-53	18134-18142	analysis	_	
103-54	18143-18145	of	_	
103-55	18146-18154	variance	_	
103-56	18155-18156	(	_	
103-57	18156-18161	ANOVA	_	
103-58	18161-18162	)	_	
103-59	18163-18164	(	_	
103-60	18164-18167	i.e	_	
103-61	18167-18168	.	_	
103-62	18168-18169	,	_	
103-63	18170-18171	6	_	
103-64	18172-18181	contrasts	_	
103-65	18181-18182	)	_	
103-66	18182-18183	.	_	

#Text=Finally, to check that down-regulation effects in the left STG were not due to repeated exposure to the rtfMRI-NF task (i.e., habituation) over runs within a single visit, we examined the main effect of “visit” as this would be less prone to habituation confounds, that is, patients would be unlikely to show habituation in the left STG from visit to visit.
104-1	18184-18191	Finally	_	
104-2	18191-18192	,	_	
104-3	18193-18195	to	_	
104-4	18196-18201	check	_	
104-5	18202-18206	that	_	
104-6	18207-18222	down-regulation	_	
104-7	18223-18230	effects	_	
104-8	18231-18233	in	_	
104-9	18234-18237	the	_	
104-10	18238-18242	left	_	
104-11	18243-18246	STG	_	
104-12	18247-18251	were	_	
104-13	18252-18255	not	_	
104-14	18256-18259	due	_	
104-15	18260-18262	to	_	
104-16	18263-18271	repeated	_	
104-17	18272-18280	exposure	_	
104-18	18281-18283	to	_	
104-19	18284-18287	the	_	
104-20	18288-18297	rtfMRI-NF	_	
104-21	18298-18302	task	_	
104-22	18303-18304	(	_	
104-23	18304-18307	i.e	_	
104-24	18307-18308	.	_	
104-25	18308-18309	,	_	
104-26	18310-18321	habituation	_	
104-27	18321-18322	)	_	
104-28	18323-18327	over	_	
104-29	18328-18332	runs	_	
104-30	18333-18339	within	_	
104-31	18340-18341	a	_	
104-32	18342-18348	single	_	
104-33	18349-18354	visit	_	
104-34	18354-18355	,	_	
104-35	18356-18358	we	_	
104-36	18359-18367	examined	_	
104-37	18368-18371	the	_	
104-38	18372-18376	main	_	
104-39	18377-18383	effect	_	
104-40	18384-18386	of	_	
104-41	18387-18388	“	_	
104-42	18388-18393	visit	_	
104-43	18393-18394	”	_	
104-44	18395-18397	as	_	
104-45	18398-18402	this	_	
104-46	18403-18408	would	_	
104-47	18409-18411	be	_	
104-48	18412-18416	less	_	
104-49	18417-18422	prone	_	
104-50	18423-18425	to	_	
104-51	18426-18437	habituation	_	
104-52	18438-18447	confounds	_	
104-53	18447-18448	,	_	
104-54	18449-18453	that	_	
104-55	18454-18456	is	_	
104-56	18456-18457	,	_	
104-57	18458-18466	patients	_	
104-58	18467-18472	would	_	
104-59	18473-18475	be	_	
104-60	18476-18484	unlikely	_	
104-61	18485-18487	to	_	
104-62	18488-18492	show	_	
104-63	18493-18504	habituation	_	
104-64	18505-18507	in	_	
104-65	18508-18511	the	_	
104-66	18512-18516	left	_	
104-67	18517-18520	STG	_	
104-68	18521-18525	from	_	
104-69	18526-18531	visit	_	
104-70	18532-18534	to	_	
104-71	18535-18540	visit	_	
104-72	18540-18541	.	_	

#Text=Transfer task
#Text=Using a separate model, subject-specific first-level models were created using a regressor encoding the predicted response for the first rtfMRI-NF run vs. the transfer run.
105-1	18542-18550	Transfer	_	
105-2	18551-18555	task	_	
105-3	18556-18561	Using	_	
105-4	18562-18563	a	_	
105-5	18564-18572	separate	_	
105-6	18573-18578	model	_	
105-7	18578-18579	,	_	
105-8	18580-18596	subject-specific	_	
105-9	18597-18608	first-level	_	
105-10	18609-18615	models	_	
105-11	18616-18620	were	_	
105-12	18621-18628	created	_	
105-13	18629-18634	using	_	
105-14	18635-18636	a	_	
105-15	18637-18646	regressor	_	
105-16	18647-18655	encoding	_	
105-17	18656-18659	the	_	
105-18	18660-18669	predicted	_	
105-19	18670-18678	response	_	
105-20	18679-18682	for	_	
105-21	18683-18686	the	_	
105-22	18687-18692	first	_	
105-23	18693-18702	rtfMRI-NF	_	
105-24	18703-18706	run	_	
105-25	18707-18709	vs	_	
105-26	18709-18710	.	_	
105-27	18711-18714	the	_	
105-28	18715-18723	transfer	_	
105-29	18724-18727	run	_	
105-30	18727-18728	.	_	

#Text=Motion parameters generated during the realignment for both runs were also included.
106-1	18729-18735	Motion	_	
106-2	18736-18746	parameters	_	
106-3	18747-18756	generated	_	
106-4	18757-18763	during	_	
106-5	18764-18767	the	_	
106-6	18768-18779	realignment	_	
106-7	18780-18783	for	_	
106-8	18784-18788	both	_	
106-9	18789-18793	runs	_	
106-10	18794-18798	were	_	
106-11	18799-18803	also	_	
106-12	18804-18812	included	_	
106-13	18812-18813	.	_	

#Text=A second-level paired t test was used to test for effects in the left STG.
107-1	18814-18815	A	_	
107-2	18816-18828	second-level	_	
107-3	18829-18835	paired	_	
107-4	18836-18837	t	_	
107-5	18838-18842	test	_	
107-6	18843-18846	was	_	
107-7	18847-18851	used	_	
107-8	18852-18854	to	_	
107-9	18855-18859	test	_	
107-10	18860-18863	for	_	
107-11	18864-18871	effects	_	
107-12	18872-18874	in	_	
107-13	18875-18878	the	_	
107-14	18879-18883	left	_	
107-15	18884-18887	STG	_	
107-16	18887-18888	.	_	

#Text=The association between changes in left STG activity and changes in PsyRats total scores was investigated using a regression model with a single contrast image (first > transfer run) from each subject and their corresponding change in PsyRats scores as a regressor.
#Text=a 3D SPM render of mean STG ROI based on localizer task (vocal stimuli > non-vocal stimuli). b 3D SPM render showing effect of rtfMRI-NF training in left STG ROI. c Plot showing effect of rtfMRI-NF training in left STG ROI (first/last run from visits 2, 3, and 4 plus transfer scan (visit 4)
#Text=In order to focus on signal change in voice-sensitive regions of the left STG, we conducted analyses within the mean left STG ROI created by the localizer task (contrast: vocal stimuli > non-vocal stimuli).
108-1	18889-18892	The	_	
108-2	18893-18904	association	_	
108-3	18905-18912	between	_	
108-4	18913-18920	changes	_	
108-5	18921-18923	in	_	
108-6	18924-18928	left	_	
108-7	18929-18932	STG	_	
108-8	18933-18941	activity	_	
108-9	18942-18945	and	_	
108-10	18946-18953	changes	_	
108-11	18954-18956	in	_	
108-12	18957-18964	PsyRats	_	
108-13	18965-18970	total	_	
108-14	18971-18977	scores	_	
108-15	18978-18981	was	_	
108-16	18982-18994	investigated	_	
108-17	18995-19000	using	_	
108-18	19001-19002	a	_	
108-19	19003-19013	regression	_	
108-20	19014-19019	model	_	
108-21	19020-19024	with	_	
108-22	19025-19026	a	_	
108-23	19027-19033	single	_	
108-24	19034-19042	contrast	_	
108-25	19043-19048	image	_	
108-26	19049-19050	(	_	
108-27	19050-19055	first	_	
108-28	19056-19057	>	_	
108-29	19058-19066	transfer	_	
108-30	19067-19070	run	_	
108-31	19070-19071	)	_	
108-32	19072-19076	from	_	
108-33	19077-19081	each	_	
108-34	19082-19089	subject	_	
108-35	19090-19093	and	_	
108-36	19094-19099	their	_	
108-37	19100-19113	corresponding	_	
108-38	19114-19120	change	_	
108-39	19121-19123	in	_	
108-40	19124-19131	PsyRats	_	
108-41	19132-19138	scores	_	
108-42	19139-19141	as	_	
108-43	19142-19143	a	_	
108-44	19144-19153	regressor	_	
108-45	19153-19154	.	_	
108-46	19155-19156	a	_	
108-47	19157-19159	3D	_	
108-48	19160-19163	SPM	_	
108-49	19164-19170	render	_	
108-50	19171-19173	of	_	
108-51	19174-19178	mean	_	
108-52	19179-19182	STG	_	
108-53	19183-19186	ROI	_	
108-54	19187-19192	based	_	
108-55	19193-19195	on	_	
108-56	19196-19205	localizer	_	
108-57	19206-19210	task	_	
108-58	19211-19212	(	_	
108-59	19212-19217	vocal	_	
108-60	19218-19225	stimuli	_	
108-61	19226-19227	>	_	
108-62	19228-19237	non-vocal	_	
108-63	19238-19245	stimuli	_	
108-64	19245-19246	)	_	
108-65	19246-19247	.	_	
108-66	19248-19249	b	_	
108-67	19250-19252	3D	_	
108-68	19253-19256	SPM	_	
108-69	19257-19263	render	_	
108-70	19264-19271	showing	_	
108-71	19272-19278	effect	_	
108-72	19279-19281	of	_	
108-73	19282-19291	rtfMRI-NF	_	
108-74	19292-19300	training	_	
108-75	19301-19303	in	_	
108-76	19304-19308	left	_	
108-77	19309-19312	STG	_	
108-78	19313-19316	ROI	_	
108-79	19316-19317	.	_	
108-80	19318-19319	c	_	
108-81	19320-19324	Plot	_	
108-82	19325-19332	showing	_	
108-83	19333-19339	effect	_	
108-84	19340-19342	of	_	
108-85	19343-19352	rtfMRI-NF	_	
108-86	19353-19361	training	_	
108-87	19362-19364	in	_	
108-88	19365-19369	left	_	
108-89	19370-19373	STG	_	
108-90	19374-19377	ROI	_	
108-91	19378-19379	(	_	
108-92	19379-19384	first	_	
108-93	19384-19385	/	_	
108-94	19385-19389	last	_	
108-95	19390-19393	run	_	
108-96	19394-19398	from	_	
108-97	19399-19405	visits	_	
108-98	19406-19407	2	_	
108-99	19407-19408	,	_	
108-100	19409-19410	3	_	
108-101	19410-19411	,	_	
108-102	19412-19415	and	_	
108-103	19416-19417	4	_	
108-104	19418-19422	plus	_	
108-105	19423-19431	transfer	_	
108-106	19432-19436	scan	_	
108-107	19437-19438	(	_	
108-108	19438-19443	visit	_	
108-109	19444-19445	4	_	
108-110	19445-19446	)	_	
108-111	19447-19449	In	_	
108-112	19450-19455	order	_	
108-113	19456-19458	to	_	
108-114	19459-19464	focus	_	
108-115	19465-19467	on	_	
108-116	19468-19474	signal	_	
108-117	19475-19481	change	_	
108-118	19482-19484	in	_	
108-119	19485-19500	voice-sensitive	_	
108-120	19501-19508	regions	_	
108-121	19509-19511	of	_	
108-122	19512-19515	the	_	
108-123	19516-19520	left	_	
108-124	19521-19524	STG	_	
108-125	19524-19525	,	_	
108-126	19526-19528	we	_	
108-127	19529-19538	conducted	_	
108-128	19539-19547	analyses	_	
108-129	19548-19554	within	_	
108-130	19555-19558	the	_	
108-131	19559-19563	mean	_	
108-132	19564-19568	left	_	
108-133	19569-19572	STG	_	
108-134	19573-19576	ROI	_	
108-135	19577-19584	created	_	
108-136	19585-19587	by	_	
108-137	19588-19591	the	_	
108-138	19592-19601	localizer	_	
108-139	19602-19606	task	_	
108-140	19607-19608	(	_	
108-141	19608-19616	contrast	_	
108-142	19616-19617	:	_	
108-143	19618-19623	vocal	_	
108-144	19624-19631	stimuli	_	
108-145	19632-19633	>	_	
108-146	19634-19643	non-vocal	_	
108-147	19644-19651	stimuli	_	
108-148	19651-19652	)	_	
108-149	19652-19653	.	_	

#Text=First, we adjusted obliqueness to match the individual T1-weighted structural image, removed the white matter control regions, and transformed the individual masks into MNI space, using parameters generated by unified segmentation of the T1 image.
109-1	19654-19659	First	_	
109-2	19659-19660	,	_	
109-3	19661-19663	we	_	
109-4	19664-19672	adjusted	_	
109-5	19673-19684	obliqueness	_	
109-6	19685-19687	to	_	
109-7	19688-19693	match	_	
109-8	19694-19697	the	_	
109-9	19698-19708	individual	_	
109-10	19709-19711	T1	_	
109-11	19711-19712	-	_	
109-12	19712-19720	weighted	_	
109-13	19721-19731	structural	_	
109-14	19732-19737	image	_	
109-15	19737-19738	,	_	
109-16	19739-19746	removed	_	
109-17	19747-19750	the	_	
109-18	19751-19756	white	_	
109-19	19757-19763	matter	_	
109-20	19764-19771	control	_	
109-21	19772-19779	regions	_	
109-22	19779-19780	,	_	
109-23	19781-19784	and	_	
109-24	19785-19796	transformed	_	
109-25	19797-19800	the	_	
109-26	19801-19811	individual	_	
109-27	19812-19817	masks	_	
109-28	19818-19822	into	_	
109-29	19823-19826	MNI	_	
109-30	19827-19832	space	_	
109-31	19832-19833	,	_	
109-32	19834-19839	using	_	
109-33	19840-19850	parameters	_	
109-34	19851-19860	generated	_	
109-35	19861-19863	by	_	
109-36	19864-19871	unified	_	
109-37	19872-19884	segmentation	_	
109-38	19885-19887	of	_	
109-39	19888-19891	the	_	
109-40	19892-19894	T1	_	
109-41	19895-19900	image	_	
109-42	19900-19901	.	_	

#Text=The mean mask was then computed using ImCalc in SPM12 based on the transformed individual functional localizer masks (Fig. 2a).
110-1	19902-19905	The	_	
110-2	19906-19910	mean	_	
110-3	19911-19915	mask	_	
110-4	19916-19919	was	_	
110-5	19920-19924	then	_	
110-6	19925-19933	computed	_	
110-7	19934-19939	using	_	
110-8	19940-19946	ImCalc	_	
110-9	19947-19949	in	_	
110-10	19950-19955	SPM12	_	
110-11	19956-19961	based	_	
110-12	19962-19964	on	_	
110-13	19965-19968	the	_	
110-14	19969-19980	transformed	_	
110-15	19981-19991	individual	_	
110-16	19992-20002	functional	_	
110-17	20003-20012	localizer	_	
110-18	20013-20018	masks	_	
110-19	20019-20020	(	_	
110-20	20020-20023	Fig	_	
110-21	20023-20024	.	_	
110-22	20025-20027	2a	_	
110-23	20027-20028	)	_	
110-24	20028-20029	.	_	

#Text=For all second-level analyses, significant ROI results are reported at a p value of ≤0.05 following family-wise error correction on the basis of response amplitude (i.e., peak-level family-wise error (FWE)).
111-1	20030-20033	For	_	
111-2	20034-20037	all	_	
111-3	20038-20050	second-level	_	
111-4	20051-20059	analyses	_	
111-5	20059-20060	,	_	
111-6	20061-20072	significant	_	
111-7	20073-20076	ROI	_	
111-8	20077-20084	results	_	
111-9	20085-20088	are	_	
111-10	20089-20097	reported	_	
111-11	20098-20100	at	_	
111-12	20101-20102	a	_	
111-13	20103-20104	p	_	
111-14	20105-20110	value	_	
111-15	20111-20113	of	_	
111-16	20114-20115	≤	_	
111-17	20115-20119	0.05	_	
111-18	20120-20129	following	_	
111-19	20130-20141	family-wise	_	
111-20	20142-20147	error	_	
111-21	20148-20158	correction	_	
111-22	20159-20161	on	_	
111-23	20162-20165	the	_	
111-24	20166-20171	basis	_	
111-25	20172-20174	of	_	
111-26	20175-20183	response	_	
111-27	20184-20193	amplitude	_	
111-28	20194-20195	(	_	
111-29	20195-20198	i.e	_	
111-30	20198-20199	.	_	
111-31	20199-20200	,	_	
111-32	20201-20211	peak-level	_	
111-33	20212-20223	family-wise	_	
111-34	20224-20229	error	_	
111-35	20230-20231	(	_	
111-36	20231-20234	FWE	_	
111-37	20234-20235	)	_	
111-38	20235-20236	)	_	
111-39	20236-20237	.	_	

#Text=Psychophysiological interactions
#Text=The effect of rtfMRI-NF training on functional connectivity was investigated by a PPI analysis with a left STG seed region derived from the group ANOVA analysis.
112-1	20238-20257	Psychophysiological	_	
112-2	20258-20270	interactions	_	
112-3	20271-20274	The	_	
112-4	20275-20281	effect	_	
112-5	20282-20284	of	_	
112-6	20285-20294	rtfMRI-NF	_	
112-7	20295-20303	training	_	
112-8	20304-20306	on	_	
112-9	20307-20317	functional	_	
112-10	20318-20330	connectivity	_	
112-11	20331-20334	was	_	
112-12	20335-20347	investigated	_	
112-13	20348-20350	by	_	
112-14	20351-20352	a	_	
112-15	20353-20356	PPI	_	
112-16	20357-20365	analysis	_	
112-17	20366-20370	with	_	
112-18	20371-20372	a	_	
112-19	20373-20377	left	_	
112-20	20378-20381	STG	_	
112-21	20382-20386	seed	_	
112-22	20387-20393	region	_	
112-23	20394-20401	derived	_	
112-24	20402-20406	from	_	
112-25	20407-20410	the	_	
112-26	20411-20416	group	_	
112-27	20417-20422	ANOVA	_	
112-28	20423-20431	analysis	_	
112-29	20431-20432	.	_	

#Text=First, the eigenvariate from the seed region extracted from the subject-specific models described above.
113-1	20433-20438	First	_	
113-2	20438-20439	,	_	
113-3	20440-20443	the	_	
113-4	20444-20456	eigenvariate	_	
113-5	20457-20461	from	_	
113-6	20462-20465	the	_	
113-7	20466-20470	seed	_	
113-8	20471-20477	region	_	
113-9	20478-20487	extracted	_	
113-10	20488-20492	from	_	
113-11	20493-20496	the	_	
113-12	20497-20513	subject-specific	_	
113-13	20514-20520	models	_	
113-14	20521-20530	described	_	
113-15	20531-20536	above	_	
113-16	20536-20537	.	_	

#Text=We used a 6 mm radius sphere, to pin the PPI analysis seed within the cluster size obtained in the repeated-measures ANOVA.
114-1	20538-20540	We	_	
114-2	20541-20545	used	_	
114-3	20546-20547	a	_	
114-4	20548-20549	6	_	
114-5	20550-20552	mm	_	
114-6	20553-20559	radius	_	
114-7	20560-20566	sphere	_	
114-8	20566-20567	,	_	
114-9	20568-20570	to	_	
114-10	20571-20574	pin	_	
114-11	20575-20578	the	_	
114-12	20579-20582	PPI	_	
114-13	20583-20591	analysis	_	
114-14	20592-20596	seed	_	
114-15	20597-20603	within	_	
114-16	20604-20607	the	_	
114-17	20608-20615	cluster	_	
114-18	20616-20620	size	_	
114-19	20621-20629	obtained	_	
114-20	20630-20632	in	_	
114-21	20633-20636	the	_	
114-22	20637-20654	repeated-measures	_	
114-23	20655-20660	ANOVA	_	
114-24	20660-20661	.	_	

#Text=Subject-specific response peak were required to be within the 6 mm of the group peak to be included in the PPI analysis.
115-1	20662-20678	Subject-specific	_	
115-2	20679-20687	response	_	
115-3	20688-20692	peak	_	
115-4	20693-20697	were	_	
115-5	20698-20706	required	_	
115-6	20707-20709	to	_	
115-7	20710-20712	be	_	
115-8	20713-20719	within	_	
115-9	20720-20723	the	_	
115-10	20724-20725	6	_	
115-11	20726-20728	mm	_	
115-12	20729-20731	of	_	
115-13	20732-20735	the	_	
115-14	20736-20741	group	_	
115-15	20742-20746	peak	_	
115-16	20747-20749	to	_	
115-17	20750-20752	be	_	
115-18	20753-20761	included	_	
115-19	20762-20764	in	_	
115-20	20765-20768	the	_	
115-21	20769-20772	PPI	_	
115-22	20773-20781	analysis	_	
115-23	20781-20782	.	_	

#Text=This was the case for all participants.
116-1	20783-20787	This	_	
116-2	20788-20791	was	_	
116-3	20792-20795	the	_	
116-4	20796-20800	case	_	
116-5	20801-20804	for	_	
116-6	20805-20808	all	_	
116-7	20809-20821	participants	_	
116-8	20821-20822	.	_	

#Text=Subsequently, two PPI regressors were created via deconvolution of the eigenvariate time series and by weighting of the resultant time series with the task contrast time series (the first and last rtfMRI-NF run).
117-1	20823-20835	Subsequently	_	
117-2	20835-20836	,	_	
117-3	20837-20840	two	_	
117-4	20841-20844	PPI	_	
117-5	20845-20855	regressors	_	
117-6	20856-20860	were	_	
117-7	20861-20868	created	_	
117-8	20869-20872	via	_	
117-9	20873-20886	deconvolution	_	
117-10	20887-20889	of	_	
117-11	20890-20893	the	_	
117-12	20894-20906	eigenvariate	_	
117-13	20907-20911	time	_	
117-14	20912-20918	series	_	
117-15	20919-20922	and	_	
117-16	20923-20925	by	_	
117-17	20926-20935	weighting	_	
117-18	20936-20938	of	_	
117-19	20939-20942	the	_	
117-20	20943-20952	resultant	_	
117-21	20953-20957	time	_	
117-22	20958-20964	series	_	
117-23	20965-20969	with	_	
117-24	20970-20973	the	_	
117-25	20974-20978	task	_	
117-26	20979-20987	contrast	_	
117-27	20988-20992	time	_	
117-28	20993-20999	series	_	
117-29	21000-21001	(	_	
117-30	21001-21004	the	_	
117-31	21005-21010	first	_	
117-32	21011-21014	and	_	
117-33	21015-21019	last	_	
117-34	21020-21029	rtfMRI-NF	_	
117-35	21030-21033	run	_	
117-36	21033-21034	)	_	
117-37	21034-21035	.	_	

#Text=The regressors were adjusted for the effect of interest, and reconvoled with the hemodynamic response function to provide the predicted temporal pattern of BOLD signal that would be expected in a region if its connectivity was changed when the seed is modulated by the rtfMRI-NF run (i.e., first vs. last).
118-1	21036-21039	The	_	
118-2	21040-21050	regressors	_	
118-3	21051-21055	were	_	
118-4	21056-21064	adjusted	_	
118-5	21065-21068	for	_	
118-6	21069-21072	the	_	
118-7	21073-21079	effect	_	
118-8	21080-21082	of	_	
118-9	21083-21091	interest	_	
118-10	21091-21092	,	_	
118-11	21093-21096	and	_	
118-12	21097-21107	reconvoled	_	
118-13	21108-21112	with	_	
118-14	21113-21116	the	_	
118-15	21117-21128	hemodynamic	_	
118-16	21129-21137	response	_	
118-17	21138-21146	function	_	
118-18	21147-21149	to	_	
118-19	21150-21157	provide	_	
118-20	21158-21161	the	_	
118-21	21162-21171	predicted	_	
118-22	21172-21180	temporal	_	
118-23	21181-21188	pattern	_	
118-24	21189-21191	of	_	
118-25	21192-21196	BOLD	_	
118-26	21197-21203	signal	_	
118-27	21204-21208	that	_	
118-28	21209-21214	would	_	
118-29	21215-21217	be	_	
118-30	21218-21226	expected	_	
118-31	21227-21229	in	_	
118-32	21230-21231	a	_	
118-33	21232-21238	region	_	
118-34	21239-21241	if	_	
118-35	21242-21245	its	_	
118-36	21246-21258	connectivity	_	
118-37	21259-21262	was	_	
118-38	21263-21270	changed	_	
118-39	21271-21275	when	_	
118-40	21276-21279	the	_	
118-41	21280-21284	seed	_	
118-42	21285-21287	is	_	
118-43	21288-21297	modulated	_	
118-44	21298-21300	by	_	
118-45	21301-21304	the	_	
118-46	21305-21314	rtfMRI-NF	_	
118-47	21315-21318	run	_	
118-48	21319-21320	(	_	
118-49	21320-21323	i.e	_	
118-50	21323-21324	.	_	
118-51	21324-21325	,	_	
118-52	21326-21331	first	_	
118-53	21332-21334	vs	_	
118-54	21334-21335	.	_	
118-55	21336-21340	last	_	
118-56	21340-21341	)	_	
118-57	21341-21342	.	_	

#Text=The resulting two contrasts (from the first and last rtfMRI-NF runs) were tested with a paired-sample t test at the second-level analysis.
119-1	21343-21346	The	_	
119-2	21347-21356	resulting	_	
119-3	21357-21360	two	_	
119-4	21361-21370	contrasts	_	
119-5	21371-21372	(	_	
119-6	21372-21376	from	_	
119-7	21377-21380	the	_	
119-8	21381-21386	first	_	
119-9	21387-21390	and	_	
119-10	21391-21395	last	_	
119-11	21396-21405	rtfMRI-NF	_	
119-12	21406-21410	runs	_	
119-13	21410-21411	)	_	
119-14	21412-21416	were	_	
119-15	21417-21423	tested	_	
119-16	21424-21428	with	_	
119-17	21429-21430	a	_	
119-18	21431-21444	paired-sample	_	
119-19	21445-21446	t	_	
119-20	21447-21451	test	_	
119-21	21452-21454	at	_	
119-22	21455-21458	the	_	
119-23	21459-21471	second-level	_	
119-24	21472-21480	analysis	_	
119-25	21480-21481	.	_	

#Text=Given our interest in functional connectivity changes in frontal and temporal speech and language regions activated during AVH, we studied changes in two ROIs taken from a meta-analysis of functional imaging studies in patients with AVH.
120-1	21482-21487	Given	_	
120-2	21488-21491	our	_	
120-3	21492-21500	interest	_	
120-4	21501-21503	in	_	
120-5	21504-21514	functional	_	
120-6	21515-21527	connectivity	_	
120-7	21528-21535	changes	_	
120-8	21536-21538	in	_	
120-9	21539-21546	frontal	_	
120-10	21547-21550	and	_	
120-11	21551-21559	temporal	_	
120-12	21560-21566	speech	_	
120-13	21567-21570	and	_	
120-14	21571-21579	language	_	
120-15	21580-21587	regions	_	
120-16	21588-21597	activated	_	
120-17	21598-21604	during	_	
120-18	21605-21608	AVH	_	
120-19	21608-21609	,	_	
120-20	21610-21612	we	_	
120-21	21613-21620	studied	_	
120-22	21621-21628	changes	_	
120-23	21629-21631	in	_	
120-24	21632-21635	two	_	
120-25	21636-21640	ROIs	_	
120-26	21641-21646	taken	_	
120-27	21647-21651	from	_	
120-28	21652-21653	a	_	
120-29	21654-21667	meta-analysis	_	
120-30	21668-21670	of	_	
120-31	21671-21681	functional	_	
120-32	21682-21689	imaging	_	
120-33	21690-21697	studies	_	
120-34	21698-21700	in	_	
120-35	21701-21709	patients	_	
120-36	21710-21714	with	_	
120-37	21715-21718	AVH	_	
120-38	21718-21719	.	_	

#Text=An IFG (Broca’s area) ROI was specified using MNI coordinates (−48, 10, 8) and an ROI in the supramarginal gyrus was specified using (−52, −20, 15).
121-1	21720-21722	An	_	
121-2	21723-21726	IFG	_	
121-3	21727-21728	(	_	
121-4	21728-21733	Broca	_	
121-5	21733-21734	’	_	
121-6	21734-21735	s	_	
121-7	21736-21740	area	_	
121-8	21740-21741	)	_	
121-9	21742-21745	ROI	_	
121-10	21746-21749	was	_	
121-11	21750-21759	specified	_	
121-12	21760-21765	using	_	
121-13	21766-21769	MNI	_	
121-14	21770-21781	coordinates	_	
121-15	21782-21783	(	_	
121-16	21783-21784	−	_	
121-17	21784-21786	48	_	
121-18	21786-21787	,	_	
121-19	21788-21790	10	_	
121-20	21790-21791	,	_	
121-21	21792-21793	8	_	
121-22	21793-21794	)	_	
121-23	21795-21798	and	_	
121-24	21799-21801	an	_	
121-25	21802-21805	ROI	_	
121-26	21806-21808	in	_	
121-27	21809-21812	the	_	
121-28	21813-21826	supramarginal	_	
121-29	21827-21832	gyrus	_	
121-30	21833-21836	was	_	
121-31	21837-21846	specified	_	
121-32	21847-21852	using	_	
121-33	21853-21854	(	_	
121-34	21854-21855	−	_	
121-35	21855-21857	52	_	
121-36	21857-21858	,	_	
121-37	21859-21860	−	_	
121-38	21860-21862	20	_	
121-39	21862-21863	,	_	
121-40	21864-21866	15	_	
121-41	21866-21867	)	_	
121-42	21867-21868	.	_	

#Text=Associations between left STG ROI functional connectivity and changes in PsyRats total scores were investigated using a regression model.
122-1	21869-21881	Associations	_	
122-2	21882-21889	between	_	
122-3	21890-21894	left	_	
122-4	21895-21898	STG	_	
122-5	21899-21902	ROI	_	
122-6	21903-21913	functional	_	
122-7	21914-21926	connectivity	_	
122-8	21927-21930	and	_	
122-9	21931-21938	changes	_	
122-10	21939-21941	in	_	
122-11	21942-21949	PsyRats	_	
122-12	21950-21955	total	_	
122-13	21956-21962	scores	_	
122-14	21963-21967	were	_	
122-15	21968-21980	investigated	_	
122-16	21981-21986	using	_	
122-17	21987-21988	a	_	
122-18	21989-21999	regression	_	
122-19	22000-22005	model	_	
122-20	22005-22006	.	_	

#Text=PPI results are reported at a p value of ≤0.025 following FWEpeak and correction for two ROIs.
123-1	22007-22010	PPI	_	
123-2	22011-22018	results	_	
123-3	22019-22022	are	_	
123-4	22023-22031	reported	_	
123-5	22032-22034	at	_	
123-6	22035-22036	a	_	
123-7	22037-22038	p	_	
123-8	22039-22044	value	_	
123-9	22045-22047	of	_	
123-10	22048-22049	≤	_	
123-11	22049-22054	0.025	_	
123-12	22055-22064	following	_	
123-13	22065-22072	FWEpeak	_	
123-14	22073-22076	and	_	
123-15	22077-22087	correction	_	
123-16	22088-22091	for	_	
123-17	22092-22095	two	_	
123-18	22096-22100	ROIs	_	
123-19	22100-22101	.	_	

#Text=Results
#Text=Patient characteristics and symptoms
#Text=Socio-demographic information of study participants
#Text=N = 11\tMean\tSD\t \tAge\t35.1\t8.1\t \tGender\t2 Females\t\t \tEducation (years)\t11.9\t1.5\t \tDuration of illness (years)\t10.8\t8.4\t \tAge at onset (years)\t24.3\t7\t \tMedication* mg\t607.5\t330\t \tWASI IQ\t98\t18.7\t \t
#Text=*Chlorpromazine equivalent; WASI Wechsler Abbreviated Scale of Intelligence
#Text=PANSS and PsyRats pre vs. post training; N = 11
#Text=Pre rtfMRI-NF\tMean\tSD\tPost rtfMRI-NF\tMean\tSD\tSig\tTest statistic\tEffect size\t \tPANSS Pos.\t20.4\t5.5\tPANSS Pos.\t21.3\t5.5\t0.32\tt = 1.05\t\t \tPANSS Neg.\t13.5\t4.9\tPANSS Neg.\t14.5\t5.3\t0.72\tt = 0.38\t\t \tPANSS Gen.\t35.2\t8.9\tPANSS Gen.\t34.6\t7.6\t0.4\tt = −0.89\t\t \tPsyRats Tot\t25.2\t4.4\tPsyRats Tot\t22.1\t8\t0.09\tt = 1.38\tCohen’s d = 0.45\t \tPsyRats BAO\t2.7\t1.1\tPsyRats BAO\t2\t1.2\t0.04\tt = 1.91\tCohen’s d = 0.65\t \tPsyRats IOD\t2.6\t1\tPsyRats IOD\t1.9\t1.1\t0.02\tt = 2.34\tCohen’s d = 0.66\t \t
#Text=PANSS Positive and Negative Syndrome Scale, Pos. positive subscale, Neg. negative, Gen. general psychopathology subscale, PsyRats Psychotic Symptom Rating Scale, Tot Total, BAO beliefs about origins, IOD intensity of distress, italics statistical significance
#Text=Patients’ clinical and socio-demographic information characteristics and IQ are reported in Table 1.
124-1	22102-22109	Results	_	
124-2	22110-22117	Patient	_	
124-3	22118-22133	characteristics	_	
124-4	22134-22137	and	_	
124-5	22138-22146	symptoms	_	
124-6	22147-22164	Socio-demographic	_	
124-7	22165-22176	information	_	
124-8	22177-22179	of	_	
124-9	22180-22185	study	_	
124-10	22186-22198	participants	_	
124-11	22199-22200	N	_	
124-12	22201-22202	=	_	
124-13	22203-22205	11	_	
124-14	22206-22210	Mean	_	
124-15	22211-22213	SD	_	
124-16	22216-22219	Age	_	
124-17	22220-22224	35.1	_	
124-18	22225-22228	8.1	_	
124-19	22231-22237	Gender	_	
124-20	22238-22239	2	_	
124-21	22240-22247	Females	_	
124-22	22251-22260	Education	_	
124-23	22261-22262	(	_	
124-24	22262-22267	years	_	
124-25	22267-22268	)	_	
124-26	22269-22273	11.9	_	
124-27	22274-22277	1.5	_	
124-28	22280-22288	Duration	_	
124-29	22289-22291	of	_	
124-30	22292-22299	illness	_	
124-31	22300-22301	(	_	
124-32	22301-22306	years	_	
124-33	22306-22307	)	_	
124-34	22308-22312	10.8	_	
124-35	22313-22316	8.4	_	
124-36	22319-22322	Age	_	
124-37	22323-22325	at	_	
124-38	22326-22331	onset	_	
124-39	22332-22333	(	_	
124-40	22333-22338	years	_	
124-41	22338-22339	)	_	
124-42	22340-22344	24.3	_	
124-43	22345-22346	7	_	
124-44	22349-22359	Medication	_	
124-45	22359-22360	*	_	
124-46	22361-22363	mg	_	
124-47	22364-22369	607.5	_	
124-48	22370-22373	330	_	
124-49	22376-22380	WASI	_	
124-50	22381-22383	IQ	_	
124-51	22384-22386	98	_	
124-52	22387-22391	18.7	_	
124-53	22395-22396	*	_	
124-54	22396-22410	Chlorpromazine	_	
124-55	22411-22421	equivalent	_	
124-56	22421-22422	;	_	
124-57	22423-22427	WASI	_	
124-58	22428-22436	Wechsler	_	
124-59	22437-22448	Abbreviated	_	
124-60	22449-22454	Scale	_	
124-61	22455-22457	of	_	
124-62	22458-22470	Intelligence	_	
124-63	22471-22476	PANSS	_	
124-64	22477-22480	and	_	
124-65	22481-22488	PsyRats	_	
124-66	22489-22492	pre	_	
124-67	22493-22495	vs	_	
124-68	22495-22496	.	_	
124-69	22497-22501	post	_	
124-70	22502-22510	training	_	
124-71	22510-22511	;	_	
124-72	22512-22513	N	_	
124-73	22514-22515	=	_	
124-74	22516-22518	11	_	
124-75	22519-22522	Pre	_	
124-76	22523-22532	rtfMRI-NF	_	
124-77	22533-22537	Mean	_	
124-78	22538-22540	SD	_	
124-79	22541-22545	Post	_	
124-80	22546-22555	rtfMRI-NF	_	
124-81	22556-22560	Mean	_	
124-82	22561-22563	SD	_	
124-83	22564-22567	Sig	_	
124-84	22568-22572	Test	_	
124-85	22573-22582	statistic	_	
124-86	22583-22589	Effect	_	
124-87	22590-22594	size	_	
124-88	22597-22602	PANSS	_	
124-89	22603-22606	Pos	_	
124-90	22606-22607	.	_	
124-91	22608-22612	20.4	_	
124-92	22613-22616	5.5	_	
124-93	22617-22622	PANSS	_	
124-94	22623-22626	Pos	_	
124-95	22626-22627	.	_	
124-96	22628-22632	21.3	_	
124-97	22633-22636	5.5	_	
124-98	22637-22641	0.32	_	
124-99	22642-22643	t	_	
124-100	22644-22645	=	_	
124-101	22646-22650	1.05	_	
124-102	22654-22659	PANSS	_	
124-103	22660-22663	Neg	_	
124-104	22663-22664	.	_	
124-105	22665-22669	13.5	_	
124-106	22670-22673	4.9	_	
124-107	22674-22679	PANSS	_	
124-108	22680-22683	Neg	_	
124-109	22683-22684	.	_	
124-110	22685-22689	14.5	_	
124-111	22690-22693	5.3	_	
124-112	22694-22698	0.72	_	
124-113	22699-22700	t	_	
124-114	22701-22702	=	_	
124-115	22703-22707	0.38	_	
124-116	22711-22716	PANSS	_	
124-117	22717-22720	Gen	_	
124-118	22720-22721	.	_	
124-119	22722-22726	35.2	_	
124-120	22727-22730	8.9	_	
124-121	22731-22736	PANSS	_	
124-122	22737-22740	Gen	_	
124-123	22740-22741	.	_	
124-124	22742-22746	34.6	_	
124-125	22747-22750	7.6	_	
124-126	22751-22754	0.4	_	
124-127	22755-22756	t	_	
124-128	22757-22758	=	_	
124-129	22759-22760	−	_	
124-130	22760-22764	0.89	_	
124-131	22768-22775	PsyRats	_	
124-132	22776-22779	Tot	_	
124-133	22780-22784	25.2	_	
124-134	22785-22788	4.4	_	
124-135	22789-22796	PsyRats	_	
124-136	22797-22800	Tot	_	
124-137	22801-22805	22.1	_	
124-138	22806-22807	8	_	
124-139	22808-22812	0.09	_	
124-140	22813-22814	t	_	
124-141	22815-22816	=	_	
124-142	22817-22821	1.38	_	
124-143	22822-22827	Cohen	_	
124-144	22827-22828	’	_	
124-145	22828-22829	s	_	
124-146	22830-22831	d	_	
124-147	22832-22833	=	_	
124-148	22834-22838	0.45	_	
124-149	22841-22848	PsyRats	_	
124-150	22849-22852	BAO	_	
124-151	22853-22856	2.7	_	
124-152	22857-22860	1.1	_	
124-153	22861-22868	PsyRats	_	
124-154	22869-22872	BAO	_	
124-155	22873-22874	2	_	
124-156	22875-22878	1.2	_	
124-157	22879-22883	0.04	_	
124-158	22884-22885	t	_	
124-159	22886-22887	=	_	
124-160	22888-22892	1.91	_	
124-161	22893-22898	Cohen	_	
124-162	22898-22899	’	_	
124-163	22899-22900	s	_	
124-164	22901-22902	d	_	
124-165	22903-22904	=	_	
124-166	22905-22909	0.65	_	
124-167	22912-22919	PsyRats	_	
124-168	22920-22923	IOD	_	
124-169	22924-22927	2.6	_	
124-170	22928-22929	1	_	
124-171	22930-22937	PsyRats	_	
124-172	22938-22941	IOD	_	
124-173	22942-22945	1.9	_	
124-174	22946-22949	1.1	_	
124-175	22950-22954	0.02	_	
124-176	22955-22956	t	_	
124-177	22957-22958	=	_	
124-178	22959-22963	2.34	_	
124-179	22964-22969	Cohen	_	
124-180	22969-22970	’	_	
124-181	22970-22971	s	_	
124-182	22972-22973	d	_	
124-183	22974-22975	=	_	
124-184	22976-22980	0.66	_	
124-185	22984-22989	PANSS	_	
124-186	22990-22998	Positive	_	
124-187	22999-23002	and	_	
124-188	23003-23011	Negative	_	
124-189	23012-23020	Syndrome	_	
124-190	23021-23026	Scale	_	
124-191	23026-23027	,	_	
124-192	23028-23031	Pos	_	
124-193	23031-23032	.	_	
124-194	23033-23041	positive	_	
124-195	23042-23050	subscale	_	
124-196	23050-23051	,	_	
124-197	23052-23055	Neg	_	
124-198	23055-23056	.	_	
124-199	23057-23065	negative	_	
124-200	23065-23066	,	_	
124-201	23067-23070	Gen	_	
124-202	23070-23071	.	_	
124-203	23072-23079	general	_	
124-204	23080-23095	psychopathology	_	
124-205	23096-23104	subscale	_	
124-206	23104-23105	,	_	
124-207	23106-23113	PsyRats	_	
124-208	23114-23123	Psychotic	_	
124-209	23124-23131	Symptom	_	
124-210	23132-23138	Rating	_	
124-211	23139-23144	Scale	_	
124-212	23144-23145	,	_	
124-213	23146-23149	Tot	_	
124-214	23150-23155	Total	_	
124-215	23155-23156	,	_	
124-216	23157-23160	BAO	_	
124-217	23161-23168	beliefs	_	
124-218	23169-23174	about	_	
124-219	23175-23182	origins	_	
124-220	23182-23183	,	_	
124-221	23184-23187	IOD	_	
124-222	23188-23197	intensity	_	
124-223	23198-23200	of	_	
124-224	23201-23209	distress	_	
124-225	23209-23210	,	_	
124-226	23211-23218	italics	_	
124-227	23219-23230	statistical	_	
124-228	23231-23243	significance	_	
124-229	23244-23252	Patients	_	
124-230	23252-23253	’	_	
124-231	23254-23262	clinical	_	
124-232	23263-23266	and	_	
124-233	23267-23284	socio-demographic	_	
124-234	23285-23296	information	_	
124-235	23297-23312	characteristics	_	
124-236	23313-23316	and	_	
124-237	23317-23319	IQ	_	
124-238	23320-23323	are	_	
124-239	23324-23332	reported	_	
124-240	23333-23335	in	_	
124-241	23336-23341	Table	_	
124-242	23342-23343	1	_	
124-243	23343-23344	.	_	

#Text=One participant’s data was excluded due to excessive movements during the fMRI acquisition.
125-1	23345-23348	One	_	
125-2	23349-23360	participant	_	
125-3	23360-23361	’	_	
125-4	23361-23362	s	_	
125-5	23363-23367	data	_	
125-6	23368-23371	was	_	
125-7	23372-23380	excluded	_	
125-8	23381-23384	due	_	
125-9	23385-23387	to	_	
125-10	23388-23397	excessive	_	
125-11	23398-23407	movements	_	
125-12	23408-23414	during	_	
125-13	23415-23418	the	_	
125-14	23419-23423	fMRI	_	
125-15	23424-23435	acquisition	_	
125-16	23435-23436	.	_	

#Text=Therefore, data in 11 participants were analyzed. rtfMRI-NF training did not worsen clinical symptoms as assessed by the PANSS scores (pre vs. post training scores) (Table 2.)
126-1	23437-23446	Therefore	_	
126-2	23446-23447	,	_	
126-3	23448-23452	data	_	
126-4	23453-23455	in	_	
126-5	23456-23458	11	_	
126-6	23459-23471	participants	_	
126-7	23472-23476	were	_	
126-8	23477-23485	analyzed	_	
126-9	23485-23486	.	_	
126-10	23487-23496	rtfMRI-NF	_	
126-11	23497-23505	training	_	
126-12	23506-23509	did	_	
126-13	23510-23513	not	_	
126-14	23514-23520	worsen	_	
126-15	23521-23529	clinical	_	
126-16	23530-23538	symptoms	_	
126-17	23539-23541	as	_	
126-18	23542-23550	assessed	_	
126-19	23551-23553	by	_	
126-20	23554-23557	the	_	
126-21	23558-23563	PANSS	_	
126-22	23564-23570	scores	_	
126-23	23571-23572	(	_	
126-24	23572-23575	pre	_	
126-25	23576-23578	vs	_	
126-26	23578-23579	.	_	
126-27	23580-23584	post	_	
126-28	23585-23593	training	_	
126-29	23594-23600	scores	_	
126-30	23600-23601	)	_	
126-31	23602-23603	(	_	
126-32	23603-23608	Table	_	
126-33	23609-23610	2	_	
126-34	23610-23611	.	_	
126-35	23611-23612	)	_	

#Text=There was a trend effect for reduced PsyRats Total scores pre vs. post rtfMRI-NF training (Table 2).
127-1	23613-23618	There	_	
127-2	23619-23622	was	_	
127-3	23623-23624	a	_	
127-4	23625-23630	trend	_	
127-5	23631-23637	effect	_	
127-6	23638-23641	for	_	
127-7	23642-23649	reduced	_	
127-8	23650-23657	PsyRats	_	
127-9	23658-23663	Total	_	
127-10	23664-23670	scores	_	
127-11	23671-23674	pre	_	
127-12	23675-23677	vs	_	
127-13	23677-23678	.	_	
127-14	23679-23683	post	_	
127-15	23684-23693	rtfMRI-NF	_	
127-16	23694-23702	training	_	
127-17	23703-23704	(	_	
127-18	23704-23709	Table	_	
127-19	23710-23711	2	_	
127-20	23711-23712	)	_	
127-21	23712-23713	.	_	

#Text=MLREM revealed a significant change in PsyRats Total scores over the rtfMRI-NF training period p = 0.015; (b = −0.76, 95% confidence interval: −1.38 to 0.15).
128-1	23714-23719	MLREM	_	
128-2	23720-23728	revealed	_	
128-3	23729-23730	a	_	
128-4	23731-23742	significant	_	
128-5	23743-23749	change	_	
128-6	23750-23752	in	_	
128-7	23753-23760	PsyRats	_	
128-8	23761-23766	Total	_	
128-9	23767-23773	scores	_	
128-10	23774-23778	over	_	
128-11	23779-23782	the	_	
128-12	23783-23792	rtfMRI-NF	_	
128-13	23793-23801	training	_	
128-14	23802-23808	period	_	
128-15	23809-23810	p	_	
128-16	23811-23812	=	_	
128-17	23813-23818	0.015	_	
128-18	23818-23819	;	_	
128-19	23820-23821	(	_	
128-20	23821-23822	b	_	
128-21	23823-23824	=	_	
128-22	23825-23826	−	_	
128-23	23826-23830	0.76	_	
128-24	23830-23831	,	_	
128-25	23832-23835	95%	_	
128-26	23836-23846	confidence	_	
128-27	23847-23855	interval	_	
128-28	23855-23856	:	_	
128-29	23857-23858	−	_	
128-30	23858-23862	1.38	_	
128-31	23863-23865	to	_	
128-32	23866-23870	0.15	_	
128-33	23870-23871	)	_	
128-34	23871-23872	.	_	

#Text=Exploratory analysis of PsyRats sub-items showed that there was a post training reduction in scores for PsyRats item 5 (beliefs regarding the origin of voices) (p = 0.05, t = 1.91) and PsyRats Item 9 (Intensity of distress) (p = 0.02, t = 2.34).
129-1	23873-23884	Exploratory	_	
129-2	23885-23893	analysis	_	
129-3	23894-23896	of	_	
129-4	23897-23904	PsyRats	_	
129-5	23905-23914	sub-items	_	
129-6	23915-23921	showed	_	
129-7	23922-23926	that	_	
129-8	23927-23932	there	_	
129-9	23933-23936	was	_	
129-10	23937-23938	a	_	
129-11	23939-23943	post	_	
129-12	23944-23952	training	_	
129-13	23953-23962	reduction	_	
129-14	23963-23965	in	_	
129-15	23966-23972	scores	_	
129-16	23973-23976	for	_	
129-17	23977-23984	PsyRats	_	
129-18	23985-23989	item	_	
129-19	23990-23991	5	_	
129-20	23992-23993	(	_	
129-21	23993-24000	beliefs	_	
129-22	24001-24010	regarding	_	
129-23	24011-24014	the	_	
129-24	24015-24021	origin	_	
129-25	24022-24024	of	_	
129-26	24025-24031	voices	_	
129-27	24031-24032	)	_	
129-28	24033-24034	(	_	
129-29	24034-24035	p	_	
129-30	24036-24037	=	_	
129-31	24038-24042	0.05	_	
129-32	24042-24043	,	_	
129-33	24044-24045	t	_	
129-34	24046-24047	=	_	
129-35	24048-24052	1.91	_	
129-36	24052-24053	)	_	
129-37	24054-24057	and	_	
129-38	24058-24065	PsyRats	_	
129-39	24066-24070	Item	_	
129-40	24071-24072	9	_	
129-41	24073-24074	(	_	
129-42	24074-24083	Intensity	_	
129-43	24084-24086	of	_	
129-44	24087-24095	distress	_	
129-45	24095-24096	)	_	
129-46	24097-24098	(	_	
129-47	24098-24099	p	_	
129-48	24100-24101	=	_	
129-49	24102-24106	0.02	_	
129-50	24106-24107	,	_	
129-51	24108-24109	t	_	
129-52	24110-24111	=	_	
129-53	24112-24116	2.34	_	
129-54	24116-24117	)	_	
129-55	24117-24118	.	_	

#Text=The post training effect for item 5 was maintained at a trend level (p = 0.055, t = 1.77) at 1-week follow-up.
130-1	24119-24122	The	_	
130-2	24123-24127	post	_	
130-3	24128-24136	training	_	
130-4	24137-24143	effect	_	
130-5	24144-24147	for	_	
130-6	24148-24152	item	_	
130-7	24153-24154	5	_	
130-8	24155-24158	was	_	
130-9	24159-24169	maintained	_	
130-10	24170-24172	at	_	
130-11	24173-24174	a	_	
130-12	24175-24180	trend	_	
130-13	24181-24186	level	_	
130-14	24187-24188	(	_	
130-15	24188-24189	p	_	
130-16	24190-24191	=	_	
130-17	24192-24197	0.055	_	
130-18	24197-24198	,	_	
130-19	24199-24200	t	_	
130-20	24201-24202	=	_	
130-21	24203-24207	1.77	_	
130-22	24207-24208	)	_	
130-23	24209-24211	at	_	
130-24	24212-24213	1	_	
130-25	24213-24214	-	_	
130-26	24214-24218	week	_	
130-27	24219-24228	follow-up	_	
130-28	24228-24229	.	_	

#Text=However, single PsyRats item effects did not survive correction for multiple testing.
131-1	24230-24237	However	_	
131-2	24237-24238	,	_	
131-3	24239-24245	single	_	
131-4	24246-24253	PsyRats	_	
131-5	24254-24258	item	_	
131-6	24259-24266	effects	_	
131-7	24267-24270	did	_	
131-8	24271-24274	not	_	
131-9	24275-24282	survive	_	
131-10	24283-24293	correction	_	
131-11	24294-24297	for	_	
131-12	24298-24306	multiple	_	
131-13	24307-24314	testing	_	
131-14	24314-24315	.	_	

#Text=Localizer scan
#Text=Across all participants the functional localizer task activated the left STG.
132-1	24316-24325	Localizer	_	
132-2	24326-24330	scan	_	
132-3	24331-24337	Across	_	
132-4	24338-24341	all	_	
132-5	24342-24354	participants	_	
132-6	24355-24358	the	_	
132-7	24359-24369	functional	_	
132-8	24370-24379	localizer	_	
132-9	24380-24384	task	_	
132-10	24385-24394	activated	_	
132-11	24395-24398	the	_	
132-12	24399-24403	left	_	
132-13	24404-24407	STG	_	
132-14	24407-24408	.	_	

#Text=Compared to non-vocal stimuli, vocal stimuli activated the voice-sensitive posterior left STG (x, y, z = −64, −14, 4); (t 1(10) = 3.16 [tpeak = 5.76] KE = 294, PFWE = 0.02, z-scorepeak = 3.74) with a sub-peak at (x, y, z = −64, −26, −4); ([tpeak = 5.59], PFWE = 0.02, z-scorepeak = 3.68) (Fig. 2a).
#Text=rtfMRI-NF training
#Text=There was a significant decrease in activity over rtfMRI-NF training runs in a cluster of KE = 405 in the left STG/superior temporal sulcus (x, y, z = −60, −30, 20); (t 1(60) = 2.39 [tpeak = 4.22], PFWE = 0.013, z-scorepeak = 3.93), extending to the supramarginal gyrus/IPG (x, y, z = −58, −36, 24); (t 1(60) = 2.39 [tpeak = 3.48], PFWE = 0.09, z-scorepeak = 3.31) (Fig. 2b, c).
133-1	24409-24417	Compared	_	
133-2	24418-24420	to	_	
133-3	24421-24430	non-vocal	_	
133-4	24431-24438	stimuli	_	
133-5	24438-24439	,	_	
133-6	24440-24445	vocal	_	
133-7	24446-24453	stimuli	_	
133-8	24454-24463	activated	_	
133-9	24464-24467	the	_	
133-10	24468-24483	voice-sensitive	_	
133-11	24484-24493	posterior	_	
133-12	24494-24498	left	_	
133-13	24499-24502	STG	_	
133-14	24503-24504	(	_	
133-15	24504-24505	x	_	
133-16	24505-24506	,	_	
133-17	24507-24508	y	_	
133-18	24508-24509	,	_	
133-19	24510-24511	z	_	
133-20	24512-24513	=	_	
133-21	24514-24515	−	_	
133-22	24515-24517	64	_	
133-23	24517-24518	,	_	
133-24	24519-24520	−	_	
133-25	24520-24522	14	_	
133-26	24522-24523	,	_	
133-27	24524-24525	4	_	
133-28	24525-24526	)	_	
133-29	24526-24527	;	_	
133-30	24528-24529	(	_	
133-31	24529-24530	t	_	
133-32	24531-24532	1	_	
133-33	24532-24533	(	_	
133-34	24533-24535	10	_	
133-35	24535-24536	)	_	
133-36	24537-24538	=	_	
133-37	24539-24543	3.16	_	
133-38	24544-24545	[	_	
133-39	24545-24550	tpeak	_	
133-40	24551-24552	=	_	
133-41	24553-24557	5.76	_	
133-42	24557-24558	]	_	
133-43	24559-24561	KE	_	
133-44	24562-24563	=	_	
133-45	24564-24567	294	_	
133-46	24567-24568	,	_	
133-47	24569-24573	PFWE	_	
133-48	24574-24575	=	_	
133-49	24576-24580	0.02	_	
133-50	24580-24581	,	_	
133-51	24582-24593	z-scorepeak	_	
133-52	24594-24595	=	_	
133-53	24596-24600	3.74	_	
133-54	24600-24601	)	_	
133-55	24602-24606	with	_	
133-56	24607-24608	a	_	
133-57	24609-24617	sub-peak	_	
133-58	24618-24620	at	_	
133-59	24621-24622	(	_	
133-60	24622-24623	x	_	
133-61	24623-24624	,	_	
133-62	24625-24626	y	_	
133-63	24626-24627	,	_	
133-64	24628-24629	z	_	
133-65	24630-24631	=	_	
133-66	24632-24633	−	_	
133-67	24633-24635	64	_	
133-68	24635-24636	,	_	
133-69	24637-24638	−	_	
133-70	24638-24640	26	_	
133-71	24640-24641	,	_	
133-72	24642-24643	−	_	
133-73	24643-24644	4	_	
133-74	24644-24645	)	_	
133-75	24645-24646	;	_	
133-76	24647-24648	(	_	
133-77	24648-24649	[	_	
133-78	24649-24654	tpeak	_	
133-79	24655-24656	=	_	
133-80	24657-24661	5.59	_	
133-81	24661-24662	]	_	
133-82	24662-24663	,	_	
133-83	24664-24668	PFWE	_	
133-84	24669-24670	=	_	
133-85	24671-24675	0.02	_	
133-86	24675-24676	,	_	
133-87	24677-24688	z-scorepeak	_	
133-88	24689-24690	=	_	
133-89	24691-24695	3.68	_	
133-90	24695-24696	)	_	
133-91	24697-24698	(	_	
133-92	24698-24701	Fig	_	
133-93	24701-24702	.	_	
133-94	24703-24705	2a	_	
133-95	24705-24706	)	_	
133-96	24706-24707	.	_	
133-97	24708-24717	rtfMRI-NF	_	
133-98	24718-24726	training	_	
133-99	24727-24732	There	_	
133-100	24733-24736	was	_	
133-101	24737-24738	a	_	
133-102	24739-24750	significant	_	
133-103	24751-24759	decrease	_	
133-104	24760-24762	in	_	
133-105	24763-24771	activity	_	
133-106	24772-24776	over	_	
133-107	24777-24786	rtfMRI-NF	_	
133-108	24787-24795	training	_	
133-109	24796-24800	runs	_	
133-110	24801-24803	in	_	
133-111	24804-24805	a	_	
133-112	24806-24813	cluster	_	
133-113	24814-24816	of	_	
133-114	24817-24819	KE	_	
133-115	24820-24821	=	_	
133-116	24822-24825	405	_	
133-117	24826-24828	in	_	
133-118	24829-24832	the	_	
133-119	24833-24837	left	_	
133-120	24838-24841	STG	_	
133-121	24841-24842	/	_	
133-122	24842-24850	superior	_	
133-123	24851-24859	temporal	_	
133-124	24860-24866	sulcus	_	
133-125	24867-24868	(	_	
133-126	24868-24869	x	_	
133-127	24869-24870	,	_	
133-128	24871-24872	y	_	
133-129	24872-24873	,	_	
133-130	24874-24875	z	_	
133-131	24876-24877	=	_	
133-132	24878-24879	−	_	
133-133	24879-24881	60	_	
133-134	24881-24882	,	_	
133-135	24883-24884	−	_	
133-136	24884-24886	30	_	
133-137	24886-24887	,	_	
133-138	24888-24890	20	_	
133-139	24890-24891	)	_	
133-140	24891-24892	;	_	
133-141	24893-24894	(	_	
133-142	24894-24895	t	_	
133-143	24896-24897	1	_	
133-144	24897-24898	(	_	
133-145	24898-24900	60	_	
133-146	24900-24901	)	_	
133-147	24902-24903	=	_	
133-148	24904-24908	2.39	_	
133-149	24909-24910	[	_	
133-150	24910-24915	tpeak	_	
133-151	24916-24917	=	_	
133-152	24918-24922	4.22	_	
133-153	24922-24923	]	_	
133-154	24923-24924	,	_	
133-155	24925-24929	PFWE	_	
133-156	24930-24931	=	_	
133-157	24932-24937	0.013	_	
133-158	24937-24938	,	_	
133-159	24939-24950	z-scorepeak	_	
133-160	24951-24952	=	_	
133-161	24953-24957	3.93	_	
133-162	24957-24958	)	_	
133-163	24958-24959	,	_	
133-164	24960-24969	extending	_	
133-165	24970-24972	to	_	
133-166	24973-24976	the	_	
133-167	24977-24990	supramarginal	_	
133-168	24991-24996	gyrus	_	
133-169	24996-24997	/	_	
133-170	24997-25000	IPG	_	
133-171	25001-25002	(	_	
133-172	25002-25003	x	_	
133-173	25003-25004	,	_	
133-174	25005-25006	y	_	
133-175	25006-25007	,	_	
133-176	25008-25009	z	_	
133-177	25010-25011	=	_	
133-178	25012-25013	−	_	
133-179	25013-25015	58	_	
133-180	25015-25016	,	_	
133-181	25017-25018	−	_	
133-182	25018-25020	36	_	
133-183	25020-25021	,	_	
133-184	25022-25024	24	_	
133-185	25024-25025	)	_	
133-186	25025-25026	;	_	
133-187	25027-25028	(	_	
133-188	25028-25029	t	_	
133-189	25030-25031	1	_	
133-190	25031-25032	(	_	
133-191	25032-25034	60	_	
133-192	25034-25035	)	_	
133-193	25036-25037	=	_	
133-194	25038-25042	2.39	_	
133-195	25043-25044	[	_	
133-196	25044-25049	tpeak	_	
133-197	25050-25051	=	_	
133-198	25052-25056	3.48	_	
133-199	25056-25057	]	_	
133-200	25057-25058	,	_	
133-201	25059-25063	PFWE	_	
133-202	25064-25065	=	_	
133-203	25066-25070	0.09	_	
133-204	25070-25071	,	_	
133-205	25072-25083	z-scorepeak	_	
133-206	25084-25085	=	_	
133-207	25086-25090	3.31	_	
133-208	25090-25091	)	_	
133-209	25092-25093	(	_	
133-210	25093-25096	Fig	_	
133-211	25096-25097	.	_	
133-212	25098-25100	2b	_	
133-213	25100-25101	,	_	
133-214	25102-25103	c	_	
133-215	25103-25104	)	_	
133-216	25104-25105	.	_	

#Text=There were no regions within the left STG ROI that showed increased activation over the course of the rtfMRI-NF.
134-1	25106-25111	There	_	
134-2	25112-25116	were	_	
134-3	25117-25119	no	_	
134-4	25120-25127	regions	_	
134-5	25128-25134	within	_	
134-6	25135-25138	the	_	
134-7	25139-25143	left	_	
134-8	25144-25147	STG	_	
134-9	25148-25151	ROI	_	
134-10	25152-25156	that	_	
134-11	25157-25163	showed	_	
134-12	25164-25173	increased	_	
134-13	25174-25184	activation	_	
134-14	25185-25189	over	_	
134-15	25190-25193	the	_	
134-16	25194-25200	course	_	
134-17	25201-25203	of	_	
134-18	25204-25207	the	_	
134-19	25208-25217	rtfMRI-NF	_	
134-20	25217-25218	.	_	

#Text=The down-regulation effect in the left STG ROI was significant across visits 2, 3, and 4 (x, y, z = −60, −28, 20); (t1(60) = 2.39[tpeak = 4.26], PFWE = 0.011, z-scorepeak = 3.96).
135-1	25219-25222	The	_	
135-2	25223-25238	down-regulation	_	
135-3	25239-25245	effect	_	
135-4	25246-25248	in	_	
135-5	25249-25252	the	_	
135-6	25253-25257	left	_	
135-7	25258-25261	STG	_	
135-8	25262-25265	ROI	_	
135-9	25266-25269	was	_	
135-10	25270-25281	significant	_	
135-11	25282-25288	across	_	
135-12	25289-25295	visits	_	
135-13	25296-25297	2	_	
135-14	25297-25298	,	_	
135-15	25299-25300	3	_	
135-16	25300-25301	,	_	
135-17	25302-25305	and	_	
135-18	25306-25307	4	_	
135-19	25308-25309	(	_	
135-20	25309-25310	x	_	
135-21	25310-25311	,	_	
135-22	25312-25313	y	_	
135-23	25313-25314	,	_	
135-24	25315-25316	z	_	
135-25	25317-25318	=	_	
135-26	25319-25320	−	_	
135-27	25320-25322	60	_	
135-28	25322-25323	,	_	
135-29	25324-25325	−	_	
135-30	25325-25327	28	_	
135-31	25327-25328	,	_	
135-32	25329-25331	20	_	
135-33	25331-25332	)	_	
135-34	25332-25333	;	_	
135-35	25334-25335	(	_	
135-36	25335-25337	t1	_	
135-37	25337-25338	(	_	
135-38	25338-25340	60	_	
135-39	25340-25341	)	_	
135-40	25342-25343	=	_	
135-41	25344-25348	2.39	_	
135-42	25348-25349	[	_	
135-43	25349-25354	tpeak	_	
135-44	25355-25356	=	_	
135-45	25357-25361	4.26	_	
135-46	25361-25362	]	_	
135-47	25362-25363	,	_	
135-48	25364-25368	PFWE	_	
135-49	25369-25370	=	_	
135-50	25371-25376	0.011	_	
135-51	25376-25377	,	_	
135-52	25378-25389	z-scorepeak	_	
135-53	25390-25391	=	_	
135-54	25392-25396	3.96	_	
135-55	25396-25397	)	_	
135-56	25397-25398	.	_	

#Text=Over the rtfMRI-NF training protocol, there was no suprathreshold effect during the baseline blocks, that is, STG ROI activity during baseline blocks remained stable across the training protocol.
136-1	25399-25403	Over	_	
136-2	25404-25407	the	_	
136-3	25408-25417	rtfMRI-NF	_	
136-4	25418-25426	training	_	
136-5	25427-25435	protocol	_	
136-6	25435-25436	,	_	
136-7	25437-25442	there	_	
136-8	25443-25446	was	_	
136-9	25447-25449	no	_	
136-10	25450-25464	suprathreshold	_	
136-11	25465-25471	effect	_	
136-12	25472-25478	during	_	
136-13	25479-25482	the	_	
136-14	25483-25491	baseline	_	
136-15	25492-25498	blocks	_	
136-16	25498-25499	,	_	
136-17	25500-25504	that	_	
136-18	25505-25507	is	_	
136-19	25507-25508	,	_	
136-20	25509-25512	STG	_	
136-21	25513-25516	ROI	_	
136-22	25517-25525	activity	_	
136-23	25526-25532	during	_	
136-24	25533-25541	baseline	_	
136-25	25542-25548	blocks	_	
136-26	25549-25557	remained	_	
136-27	25558-25564	stable	_	
136-28	25565-25571	across	_	
136-29	25572-25575	the	_	
136-30	25576-25584	training	_	
136-31	25585-25593	protocol	_	
136-32	25593-25594	.	_	

#Text=Transfer task
#Text=Relative to the first rtfMRI-NF training run, there was a significant reduction in activity in the left STG ROI during the transfer run x, y, z = (−60, −28, 16); (t 1(10) = 2.76[tpeak = 6.59]; KE = 156, PFWE = 0.03, z-scorepeak = 3.99).
137-1	25595-25603	Transfer	_	
137-2	25604-25608	task	_	
137-3	25609-25617	Relative	_	
137-4	25618-25620	to	_	
137-5	25621-25624	the	_	
137-6	25625-25630	first	_	
137-7	25631-25640	rtfMRI-NF	_	
137-8	25641-25649	training	_	
137-9	25650-25653	run	_	
137-10	25653-25654	,	_	
137-11	25655-25660	there	_	
137-12	25661-25664	was	_	
137-13	25665-25666	a	_	
137-14	25667-25678	significant	_	
137-15	25679-25688	reduction	_	
137-16	25689-25691	in	_	
137-17	25692-25700	activity	_	
137-18	25701-25703	in	_	
137-19	25704-25707	the	_	
137-20	25708-25712	left	_	
137-21	25713-25716	STG	_	
137-22	25717-25720	ROI	_	
137-23	25721-25727	during	_	
137-24	25728-25731	the	_	
137-25	25732-25740	transfer	_	
137-26	25741-25744	run	_	
137-27	25745-25746	x	_	
137-28	25746-25747	,	_	
137-29	25748-25749	y	_	
137-30	25749-25750	,	_	
137-31	25751-25752	z	_	
137-32	25753-25754	=	_	
137-33	25755-25756	(	_	
137-34	25756-25757	−	_	
137-35	25757-25759	60	_	
137-36	25759-25760	,	_	
137-37	25761-25762	−	_	
137-38	25762-25764	28	_	
137-39	25764-25765	,	_	
137-40	25766-25768	16	_	
137-41	25768-25769	)	_	
137-42	25769-25770	;	_	
137-43	25771-25772	(	_	
137-44	25772-25773	t	_	
137-45	25774-25775	1	_	
137-46	25775-25776	(	_	
137-47	25776-25778	10	_	
137-48	25778-25779	)	_	
137-49	25780-25781	=	_	
137-50	25782-25786	2.76	_	
137-51	25786-25787	[	_	
137-52	25787-25792	tpeak	_	
137-53	25793-25794	=	_	
137-54	25795-25799	6.59	_	
137-55	25799-25800	]	_	
137-56	25800-25801	;	_	
137-57	25802-25804	KE	_	
137-58	25805-25806	=	_	
137-59	25807-25810	156	_	
137-60	25810-25811	,	_	
137-61	25812-25816	PFWE	_	
137-62	25817-25818	=	_	
137-63	25819-25823	0.03	_	
137-64	25823-25824	,	_	
137-65	25825-25836	z-scorepeak	_	
137-66	25837-25838	=	_	
137-67	25839-25843	3.99	_	
137-68	25843-25844	)	_	
137-69	25844-25845	.	_	

#Text=PPI analysis
#Text=a SPM 3D render showing regions in left inferior frontal gyrus (IFG)/Insula and left inferior parietal gyrus (IPG)/supramarginal gyrus where functional connectivity was increased in the last rtfMRI-NF run compared to the first rtfMRI-NF (left hemisphere shown on left side of image) (p = 0.001 unc for purpose of figure). b Axial volumes showing left IFG and IPG regions. c Mean PPI parameter estimates in IPG/supramarginal gyrus for 1st vs. last rtfMRI-NF run and d mean PPI parameter estimates left insula/IFG for 1st vs. last rtfMRI-NF run
#Text=Using the seed region in the left posterior STG, PPI analysis revealed greater functional connectivity parameter estimates during the last rtfMRI-NF, relative to the first rtfMRI-NF run in a cluster covering the left insula extending to the left IFG (x, y, z = −48, 10, 2) (t1(10) = 6.66 [tpeak = 6.38]; KE = 34, PFWE = 0.002, z- scorepeak = 3.94) and in a cluster in the supramarginal gyrus/IPG (x, y, z, = −52, −20, 16), (t1(10) = 4.14 [tpeak = 5.11]; KE = 81, PFWE = 0.011, z-scorepeak = 3.51) (Fig. 3b).
138-1	25846-25849	PPI	_	
138-2	25850-25858	analysis	_	
138-3	25859-25860	a	_	
138-4	25861-25864	SPM	_	
138-5	25865-25867	3D	_	
138-6	25868-25874	render	_	
138-7	25875-25882	showing	_	
138-8	25883-25890	regions	_	
138-9	25891-25893	in	_	
138-10	25894-25898	left	_	
138-11	25899-25907	inferior	_	
138-12	25908-25915	frontal	_	
138-13	25916-25921	gyrus	_	
138-14	25922-25923	(	_	
138-15	25923-25926	IFG	_	
138-16	25926-25927	)	_	
138-17	25927-25928	/	_	
138-18	25928-25934	Insula	_	
138-19	25935-25938	and	_	
138-20	25939-25943	left	_	
138-21	25944-25952	inferior	_	
138-22	25953-25961	parietal	_	
138-23	25962-25967	gyrus	_	
138-24	25968-25969	(	_	
138-25	25969-25972	IPG	_	
138-26	25972-25973	)	_	
138-27	25973-25974	/	_	
138-28	25974-25987	supramarginal	_	
138-29	25988-25993	gyrus	_	
138-30	25994-25999	where	_	
138-31	26000-26010	functional	_	
138-32	26011-26023	connectivity	_	
138-33	26024-26027	was	_	
138-34	26028-26037	increased	_	
138-35	26038-26040	in	_	
138-36	26041-26044	the	_	
138-37	26045-26049	last	_	
138-38	26050-26059	rtfMRI-NF	_	
138-39	26060-26063	run	_	
138-40	26064-26072	compared	_	
138-41	26073-26075	to	_	
138-42	26076-26079	the	_	
138-43	26080-26085	first	_	
138-44	26086-26095	rtfMRI-NF	_	
138-45	26096-26097	(	_	
138-46	26097-26101	left	_	
138-47	26102-26112	hemisphere	_	
138-48	26113-26118	shown	_	
138-49	26119-26121	on	_	
138-50	26122-26126	left	_	
138-51	26127-26131	side	_	
138-52	26132-26134	of	_	
138-53	26135-26140	image	_	
138-54	26140-26141	)	_	
138-55	26142-26143	(	_	
138-56	26143-26144	p	_	
138-57	26145-26146	=	_	
138-58	26147-26152	0.001	_	
138-59	26153-26156	unc	_	
138-60	26157-26160	for	_	
138-61	26161-26168	purpose	_	
138-62	26169-26171	of	_	
138-63	26172-26178	figure	_	
138-64	26178-26179	)	_	
138-65	26179-26180	.	_	
138-66	26181-26182	b	_	
138-67	26183-26188	Axial	_	
138-68	26189-26196	volumes	_	
138-69	26197-26204	showing	_	
138-70	26205-26209	left	_	
138-71	26210-26213	IFG	_	
138-72	26214-26217	and	_	
138-73	26218-26221	IPG	_	
138-74	26222-26229	regions	_	
138-75	26229-26230	.	_	
138-76	26231-26232	c	_	
138-77	26233-26237	Mean	_	
138-78	26238-26241	PPI	_	
138-79	26242-26251	parameter	_	
138-80	26252-26261	estimates	_	
138-81	26262-26264	in	_	
138-82	26265-26268	IPG	_	
138-83	26268-26269	/	_	
138-84	26269-26282	supramarginal	_	
138-85	26283-26288	gyrus	_	
138-86	26289-26292	for	_	
138-87	26293-26296	1st	_	
138-88	26297-26299	vs	_	
138-89	26299-26300	.	_	
138-90	26301-26305	last	_	
138-91	26306-26315	rtfMRI-NF	_	
138-92	26316-26319	run	_	
138-93	26320-26323	and	_	
138-94	26324-26325	d	_	
138-95	26326-26330	mean	_	
138-96	26331-26334	PPI	_	
138-97	26335-26344	parameter	_	
138-98	26345-26354	estimates	_	
138-99	26355-26359	left	_	
138-100	26360-26366	insula	_	
138-101	26366-26367	/	_	
138-102	26367-26370	IFG	_	
138-103	26371-26374	for	_	
138-104	26375-26378	1st	_	
138-105	26379-26381	vs	_	
138-106	26381-26382	.	_	
138-107	26383-26387	last	_	
138-108	26388-26397	rtfMRI-NF	_	
138-109	26398-26401	run	_	
138-110	26402-26407	Using	_	
138-111	26408-26411	the	_	
138-112	26412-26416	seed	_	
138-113	26417-26423	region	_	
138-114	26424-26426	in	_	
138-115	26427-26430	the	_	
138-116	26431-26435	left	_	
138-117	26436-26445	posterior	_	
138-118	26446-26449	STG	_	
138-119	26449-26450	,	_	
138-120	26451-26454	PPI	_	
138-121	26455-26463	analysis	_	
138-122	26464-26472	revealed	_	
138-123	26473-26480	greater	_	
138-124	26481-26491	functional	_	
138-125	26492-26504	connectivity	_	
138-126	26505-26514	parameter	_	
138-127	26515-26524	estimates	_	
138-128	26525-26531	during	_	
138-129	26532-26535	the	_	
138-130	26536-26540	last	_	
138-131	26541-26550	rtfMRI-NF	_	
138-132	26550-26551	,	_	
138-133	26552-26560	relative	_	
138-134	26561-26563	to	_	
138-135	26564-26567	the	_	
138-136	26568-26573	first	_	
138-137	26574-26583	rtfMRI-NF	_	
138-138	26584-26587	run	_	
138-139	26588-26590	in	_	
138-140	26591-26592	a	_	
138-141	26593-26600	cluster	_	
138-142	26601-26609	covering	_	
138-143	26610-26613	the	_	
138-144	26614-26618	left	_	
138-145	26619-26625	insula	_	
138-146	26626-26635	extending	_	
138-147	26636-26638	to	_	
138-148	26639-26642	the	_	
138-149	26643-26647	left	_	
138-150	26648-26651	IFG	_	
138-151	26652-26653	(	_	
138-152	26653-26654	x	_	
138-153	26654-26655	,	_	
138-154	26656-26657	y	_	
138-155	26657-26658	,	_	
138-156	26659-26660	z	_	
138-157	26661-26662	=	_	
138-158	26663-26664	−	_	
138-159	26664-26666	48	_	
138-160	26666-26667	,	_	
138-161	26668-26670	10	_	
138-162	26670-26671	,	_	
138-163	26672-26673	2	_	
138-164	26673-26674	)	_	
138-165	26675-26676	(	_	
138-166	26676-26678	t1	_	
138-167	26678-26679	(	_	
138-168	26679-26681	10	_	
138-169	26681-26682	)	_	
138-170	26683-26684	=	_	
138-171	26685-26689	6.66	_	
138-172	26690-26691	[	_	
138-173	26691-26696	tpeak	_	
138-174	26697-26698	=	_	
138-175	26699-26703	6.38	_	
138-176	26703-26704	]	_	
138-177	26704-26705	;	_	
138-178	26706-26708	KE	_	
138-179	26709-26710	=	_	
138-180	26711-26713	34	_	
138-181	26713-26714	,	_	
138-182	26715-26719	PFWE	_	
138-183	26720-26721	=	_	
138-184	26722-26727	0.002	_	
138-185	26727-26728	,	_	
138-186	26729-26730	z	_	
138-187	26730-26731	-	_	
138-188	26732-26741	scorepeak	_	
138-189	26742-26743	=	_	
138-190	26744-26748	3.94	_	
138-191	26748-26749	)	_	
138-192	26750-26753	and	_	
138-193	26754-26756	in	_	
138-194	26757-26758	a	_	
138-195	26759-26766	cluster	_	
138-196	26767-26769	in	_	
138-197	26770-26773	the	_	
138-198	26774-26787	supramarginal	_	
138-199	26788-26793	gyrus	_	
138-200	26793-26794	/	_	
138-201	26794-26797	IPG	_	
138-202	26798-26799	(	_	
138-203	26799-26800	x	_	
138-204	26800-26801	,	_	
138-205	26802-26803	y	_	
138-206	26803-26804	,	_	
138-207	26805-26806	z	_	
138-208	26806-26807	,	_	
138-209	26808-26809	=	_	
138-210	26810-26811	−	_	
138-211	26811-26813	52	_	
138-212	26813-26814	,	_	
138-213	26815-26816	−	_	
138-214	26816-26818	20	_	
138-215	26818-26819	,	_	
138-216	26820-26822	16	_	
138-217	26822-26823	)	_	
138-218	26823-26824	,	_	
138-219	26825-26826	(	_	
138-220	26826-26828	t1	_	
138-221	26828-26829	(	_	
138-222	26829-26831	10	_	
138-223	26831-26832	)	_	
138-224	26833-26834	=	_	
138-225	26835-26839	4.14	_	
138-226	26840-26841	[	_	
138-227	26841-26846	tpeak	_	
138-228	26847-26848	=	_	
138-229	26849-26853	5.11	_	
138-230	26853-26854	]	_	
138-231	26854-26855	;	_	
138-232	26856-26858	KE	_	
138-233	26859-26860	=	_	
138-234	26861-26863	81	_	
138-235	26863-26864	,	_	
138-236	26865-26869	PFWE	_	
138-237	26870-26871	=	_	
138-238	26872-26877	0.011	_	
138-239	26877-26878	,	_	
138-240	26879-26890	z-scorepeak	_	
138-241	26891-26892	=	_	
138-242	26893-26897	3.51	_	
138-243	26897-26898	)	_	
138-244	26899-26900	(	_	
138-245	26900-26903	Fig	_	
138-246	26903-26904	.	_	
138-247	26905-26907	3b	_	
138-248	26907-26908	)	_	
138-249	26908-26909	.	_	

#Text=There were no areas where functional connectivity decreased after rtfMRI-NF training.
139-1	26910-26915	There	_	
139-2	26916-26920	were	_	
139-3	26921-26923	no	_	
139-4	26924-26929	areas	_	
139-5	26930-26935	where	_	
139-6	26936-26946	functional	_	
139-7	26947-26959	connectivity	_	
139-8	26960-26969	decreased	_	
139-9	26970-26975	after	_	
139-10	26976-26985	rtfMRI-NF	_	
139-11	26986-26994	training	_	
139-12	26994-26995	.	_	

#Text=PsyRat associations
#Text=A regression model testing the association between left STG down-regulation during the transfer run (1st run vs. transfer run) and changes in PsyRats Total scores was non-significant.
140-1	26996-27002	PsyRat	_	
140-2	27003-27015	associations	_	
140-3	27016-27017	A	_	
140-4	27018-27028	regression	_	
140-5	27029-27034	model	_	
140-6	27035-27042	testing	_	
140-7	27043-27046	the	_	
140-8	27047-27058	association	_	
140-9	27059-27066	between	_	
140-10	27067-27071	left	_	
140-11	27072-27075	STG	_	
140-12	27076-27091	down-regulation	_	
140-13	27092-27098	during	_	
140-14	27099-27102	the	_	
140-15	27103-27111	transfer	_	
140-16	27112-27115	run	_	
140-17	27116-27117	(	_	
140-18	27117-27120	1st	_	
140-19	27121-27124	run	_	
140-20	27125-27127	vs	_	
140-21	27127-27128	.	_	
140-22	27129-27137	transfer	_	
140-23	27138-27141	run	_	
140-24	27141-27142	)	_	
140-25	27143-27146	and	_	
140-26	27147-27154	changes	_	
140-27	27155-27157	in	_	
140-28	27158-27165	PsyRats	_	
140-29	27166-27171	Total	_	
140-30	27172-27178	scores	_	
140-31	27179-27182	was	_	
140-32	27183-27198	non-significant	_	
140-33	27198-27199	.	_	

#Text=There was, however, a significant positive association between change in PsyRat Total scores over the rtfMRI-NF training period (pre–post training scores) and functional connectivity between the left STG seed region and the left insula/IFG during the last rtfMRI-NF run (x, y, x = −48, 12, 4); (t1(09) = 1.83 [tpeak = 6.77]; KE = 233, PFWE = 0.01, z-scorepeak = 3.90).
141-1	27200-27205	There	_	
141-2	27206-27209	was	_	
141-3	27209-27210	,	_	
141-4	27211-27218	however	_	
141-5	27218-27219	,	_	
141-6	27220-27221	a	_	
141-7	27222-27233	significant	_	
141-8	27234-27242	positive	_	
141-9	27243-27254	association	_	
141-10	27255-27262	between	_	
141-11	27263-27269	change	_	
141-12	27270-27272	in	_	
141-13	27273-27279	PsyRat	_	
141-14	27280-27285	Total	_	
141-15	27286-27292	scores	_	
141-16	27293-27297	over	_	
141-17	27298-27301	the	_	
141-18	27302-27311	rtfMRI-NF	_	
141-19	27312-27320	training	_	
141-20	27321-27327	period	_	
141-21	27328-27329	(	_	
141-22	27329-27337	pre–post	_	
141-23	27338-27346	training	_	
141-24	27347-27353	scores	_	
141-25	27353-27354	)	_	
141-26	27355-27358	and	_	
141-27	27359-27369	functional	_	
141-28	27370-27382	connectivity	_	
141-29	27383-27390	between	_	
141-30	27391-27394	the	_	
141-31	27395-27399	left	_	
141-32	27400-27403	STG	_	
141-33	27404-27408	seed	_	
141-34	27409-27415	region	_	
141-35	27416-27419	and	_	
141-36	27420-27423	the	_	
141-37	27424-27428	left	_	
141-38	27429-27435	insula	_	
141-39	27435-27436	/	_	
141-40	27436-27439	IFG	_	
141-41	27440-27446	during	_	
141-42	27447-27450	the	_	
141-43	27451-27455	last	_	
141-44	27456-27465	rtfMRI-NF	_	
141-45	27466-27469	run	_	
141-46	27470-27471	(	_	
141-47	27471-27472	x	_	
141-48	27472-27473	,	_	
141-49	27474-27475	y	_	
141-50	27475-27476	,	_	
141-51	27477-27478	x	_	
141-52	27479-27480	=	_	
141-53	27481-27482	−	_	
141-54	27482-27484	48	_	
141-55	27484-27485	,	_	
141-56	27486-27488	12	_	
141-57	27488-27489	,	_	
141-58	27490-27491	4	_	
141-59	27491-27492	)	_	
141-60	27492-27493	;	_	
141-61	27494-27495	(	_	
141-62	27495-27497	t1	_	
141-63	27497-27498	(	_	
141-64	27498-27500	09	_	
141-65	27500-27501	)	_	
141-66	27502-27503	=	_	
141-67	27504-27508	1.83	_	
141-68	27509-27510	[	_	
141-69	27510-27515	tpeak	_	
141-70	27516-27517	=	_	
141-71	27518-27522	6.77	_	
141-72	27522-27523	]	_	
141-73	27523-27524	;	_	
141-74	27525-27527	KE	_	
141-75	27528-27529	=	_	
141-76	27530-27533	233	_	
141-77	27533-27534	,	_	
141-78	27535-27539	PFWE	_	
141-79	27540-27541	=	_	
141-80	27542-27546	0.01	_	
141-81	27546-27547	,	_	
141-82	27548-27559	z-scorepeak	_	
141-83	27560-27561	=	_	
141-84	27562-27566	3.90	_	
141-85	27566-27567	)	_	
141-86	27567-27568	.	_	

#Text=Discussion
#Text=We showed in this pioneering study that patients with SCZ and AVH could learn to down-regulate activity in speech-sensitive regions of their left STG with an average of 14 runs of 9 min NF training.
142-1	27569-27579	Discussion	_	
142-2	27580-27582	We	_	
142-3	27583-27589	showed	_	
142-4	27590-27592	in	_	
142-5	27593-27597	this	_	
142-6	27598-27608	pioneering	_	
142-7	27609-27614	study	_	
142-8	27615-27619	that	_	
142-9	27620-27628	patients	_	
142-10	27629-27633	with	_	
142-11	27634-27637	SCZ	_	
142-12	27638-27641	and	_	
142-13	27642-27645	AVH	_	
142-14	27646-27651	could	_	
142-15	27652-27657	learn	_	
142-16	27658-27660	to	_	
142-17	27661-27674	down-regulate	_	
142-18	27675-27683	activity	_	
142-19	27684-27686	in	_	
142-20	27687-27703	speech-sensitive	_	
142-21	27704-27711	regions	_	
142-22	27712-27714	of	_	
142-23	27715-27720	their	_	
142-24	27721-27725	left	_	
142-25	27726-27729	STG	_	
142-26	27730-27734	with	_	
142-27	27735-27737	an	_	
142-28	27738-27745	average	_	
142-29	27746-27748	of	_	
142-30	27749-27751	14	_	
142-31	27752-27756	runs	_	
142-32	27757-27759	of	_	
142-33	27760-27761	9	_	
142-34	27762-27765	min	_	
142-35	27766-27768	NF	_	
142-36	27769-27777	training	_	
142-37	27777-27778	.	_	

#Text=Left STG down-regulation was seen between scanner visits suggesting that this effect could not easily be attributed to within visit STG habituation over rtfMRI-training runs.
143-1	27779-27783	Left	_	
143-2	27784-27787	STG	_	
143-3	27788-27803	down-regulation	_	
143-4	27804-27807	was	_	
143-5	27808-27812	seen	_	
143-6	27813-27820	between	_	
143-7	27821-27828	scanner	_	
143-8	27829-27835	visits	_	
143-9	27836-27846	suggesting	_	
143-10	27847-27851	that	_	
143-11	27852-27856	this	_	
143-12	27857-27863	effect	_	
143-13	27864-27869	could	_	
143-14	27870-27873	not	_	
143-15	27874-27880	easily	_	
143-16	27881-27883	be	_	
143-17	27884-27894	attributed	_	
143-18	27895-27897	to	_	
143-19	27898-27904	within	_	
143-20	27905-27910	visit	_	
143-21	27911-27914	STG	_	
143-22	27915-27926	habituation	_	
143-23	27927-27931	over	_	
143-24	27932-27947	rtfMRI-training	_	
143-25	27948-27952	runs	_	
143-26	27952-27953	.	_	

#Text=Furthermore, rtfMRI-NF training resulted in increased functional connectivity between frontal and temporal language regions that was associated with changes in AVH symptom severity.
144-1	27954-27965	Furthermore	_	
144-2	27965-27966	,	_	
144-3	27967-27976	rtfMRI-NF	_	
144-4	27977-27985	training	_	
144-5	27986-27994	resulted	_	
144-6	27995-27997	in	_	
144-7	27998-28007	increased	_	
144-8	28008-28018	functional	_	
144-9	28019-28031	connectivity	_	
144-10	28032-28039	between	_	
144-11	28040-28047	frontal	_	
144-12	28048-28051	and	_	
144-13	28052-28060	temporal	_	
144-14	28061-28069	language	_	
144-15	28070-28077	regions	_	
144-16	28078-28082	that	_	
144-17	28083-28086	was	_	
144-18	28087-28097	associated	_	
144-19	28098-28102	with	_	
144-20	28103-28110	changes	_	
144-21	28111-28113	in	_	
144-22	28114-28117	AVH	_	
144-23	28118-28125	symptom	_	
144-24	28126-28134	severity	_	
144-25	28134-28135	.	_	

#Text=During the transfer scan, patients were able to reduce activity without visually presented feedback, suggesting that they had learnt strategies to reduce activity in the voice-sensitive region of the left STG.
145-1	28136-28142	During	_	
145-2	28143-28146	the	_	
145-3	28147-28155	transfer	_	
145-4	28156-28160	scan	_	
145-5	28160-28161	,	_	
145-6	28162-28170	patients	_	
145-7	28171-28175	were	_	
145-8	28176-28180	able	_	
145-9	28181-28183	to	_	
145-10	28184-28190	reduce	_	
145-11	28191-28199	activity	_	
145-12	28200-28207	without	_	
145-13	28208-28216	visually	_	
145-14	28217-28226	presented	_	
145-15	28227-28235	feedback	_	
145-16	28235-28236	,	_	
145-17	28237-28247	suggesting	_	
145-18	28248-28252	that	_	
145-19	28253-28257	they	_	
145-20	28258-28261	had	_	
145-21	28262-28268	learnt	_	
145-22	28269-28279	strategies	_	
145-23	28280-28282	to	_	
145-24	28283-28289	reduce	_	
145-25	28290-28298	activity	_	
145-26	28299-28301	in	_	
145-27	28302-28305	the	_	
145-28	28306-28321	voice-sensitive	_	
145-29	28322-28328	region	_	
145-30	28329-28331	of	_	
145-31	28332-28335	the	_	
145-32	28336-28340	left	_	
145-33	28341-28344	STG	_	
145-34	28344-28345	.	_	

#Text=It has been reported that AVH are associated with spontaneous brain activity, increase in blood flow, and increased resting state activity in the posterior STG.
146-1	28346-28348	It	_	
146-2	28349-28352	has	_	
146-3	28353-28357	been	_	
146-4	28358-28366	reported	_	
146-5	28367-28371	that	_	
146-6	28372-28375	AVH	_	
146-7	28376-28379	are	_	
146-8	28380-28390	associated	_	
146-9	28391-28395	with	_	
146-10	28396-28407	spontaneous	_	
146-11	28408-28413	brain	_	
146-12	28414-28422	activity	_	
146-13	28422-28423	,	_	
146-14	28424-28432	increase	_	
146-15	28433-28435	in	_	
146-16	28436-28441	blood	_	
146-17	28442-28446	flow	_	
146-18	28446-28447	,	_	
146-19	28448-28451	and	_	
146-20	28452-28461	increased	_	
146-21	28462-28469	resting	_	
146-22	28470-28475	state	_	
146-23	28476-28484	activity	_	
146-24	28485-28487	in	_	
146-25	28488-28491	the	_	
146-26	28492-28501	posterior	_	
146-27	28502-28505	STG	_	
146-28	28505-28506	.	_	

#Text=Reduced activity in the left STG brought about by rtfMRI-NF training demonstrates that participants can develop and apply an endogenous technique to regulate brain activity in this region, known to be involved in linguistic perception, and active when patients with SCZ are experiencing AVH.
147-1	28507-28514	Reduced	_	
147-2	28515-28523	activity	_	
147-3	28524-28526	in	_	
147-4	28527-28530	the	_	
147-5	28531-28535	left	_	
147-6	28536-28539	STG	_	
147-7	28540-28547	brought	_	
147-8	28548-28553	about	_	
147-9	28554-28556	by	_	
147-10	28557-28566	rtfMRI-NF	_	
147-11	28567-28575	training	_	
147-12	28576-28588	demonstrates	_	
147-13	28589-28593	that	_	
147-14	28594-28606	participants	_	
147-15	28607-28610	can	_	
147-16	28611-28618	develop	_	
147-17	28619-28622	and	_	
147-18	28623-28628	apply	_	
147-19	28629-28631	an	_	
147-20	28632-28642	endogenous	_	
147-21	28643-28652	technique	_	
147-22	28653-28655	to	_	
147-23	28656-28664	regulate	_	
147-24	28665-28670	brain	_	
147-25	28671-28679	activity	_	
147-26	28680-28682	in	_	
147-27	28683-28687	this	_	
147-28	28688-28694	region	_	
147-29	28694-28695	,	_	
147-30	28696-28701	known	_	
147-31	28702-28704	to	_	
147-32	28705-28707	be	_	
147-33	28708-28716	involved	_	
147-34	28717-28719	in	_	
147-35	28720-28730	linguistic	_	
147-36	28731-28741	perception	_	
147-37	28741-28742	,	_	
147-38	28743-28746	and	_	
147-39	28747-28753	active	_	
147-40	28754-28758	when	_	
147-41	28759-28767	patients	_	
147-42	28768-28772	with	_	
147-43	28773-28776	SCZ	_	
147-44	28777-28780	are	_	
147-45	28781-28793	experiencing	_	
147-46	28794-28797	AVH	_	
147-47	28797-28798	.	_	

#Text=However, although activity in the posterior STG region appears to be central to the perceptual experience, dysfunction in non-sensory regions is also likely to contribute to the phenomenological characteristics of AVH.
148-1	28799-28806	However	_	
148-2	28806-28807	,	_	
148-3	28808-28816	although	_	
148-4	28817-28825	activity	_	
148-5	28826-28828	in	_	
148-6	28829-28832	the	_	
148-7	28833-28842	posterior	_	
148-8	28843-28846	STG	_	
148-9	28847-28853	region	_	
148-10	28854-28861	appears	_	
148-11	28862-28864	to	_	
148-12	28865-28867	be	_	
148-13	28868-28875	central	_	
148-14	28876-28878	to	_	
148-15	28879-28882	the	_	
148-16	28883-28893	perceptual	_	
148-17	28894-28904	experience	_	
148-18	28904-28905	,	_	
148-19	28906-28917	dysfunction	_	
148-20	28918-28920	in	_	
148-21	28921-28932	non-sensory	_	
148-22	28933-28940	regions	_	
148-23	28941-28943	is	_	
148-24	28944-28948	also	_	
148-25	28949-28955	likely	_	
148-26	28956-28958	to	_	
148-27	28959-28969	contribute	_	
148-28	28970-28972	to	_	
148-29	28973-28976	the	_	
148-30	28977-28993	phenomenological	_	
148-31	28994-29009	characteristics	_	
148-32	29010-29012	of	_	
148-33	29013-29016	AVH	_	
148-34	29016-29017	.	_	

#Text=Several studies have reported altered functional and structural connectivity in fronto-temporal and perisylvian language networks.
149-1	29018-29025	Several	_	
149-2	29026-29033	studies	_	
149-3	29034-29038	have	_	
149-4	29039-29047	reported	_	
149-5	29048-29055	altered	_	
149-6	29056-29066	functional	_	
149-7	29067-29070	and	_	
149-8	29071-29081	structural	_	
149-9	29082-29094	connectivity	_	
149-10	29095-29097	in	_	
149-11	29098-29113	fronto-temporal	_	
149-12	29114-29117	and	_	
149-13	29118-29129	perisylvian	_	
149-14	29130-29138	language	_	
149-15	29139-29147	networks	_	
149-16	29147-29148	.	_	

#Text=In the present study, the enhanced coupling between the posterior STG seed region and the insula/IFG brought about by rtfMRI-NF training is of particular interest.
150-1	29149-29151	In	_	
150-2	29152-29155	the	_	
150-3	29156-29163	present	_	
150-4	29164-29169	study	_	
150-5	29169-29170	,	_	
150-6	29171-29174	the	_	
150-7	29175-29183	enhanced	_	
150-8	29184-29192	coupling	_	
150-9	29193-29200	between	_	
150-10	29201-29204	the	_	
150-11	29205-29214	posterior	_	
150-12	29215-29218	STG	_	
150-13	29219-29223	seed	_	
150-14	29224-29230	region	_	
150-15	29231-29234	and	_	
150-16	29235-29238	the	_	
150-17	29239-29245	insula	_	
150-18	29245-29246	/	_	
150-19	29246-29249	IFG	_	
150-20	29250-29257	brought	_	
150-21	29258-29263	about	_	
150-22	29264-29266	by	_	
150-23	29267-29276	rtfMRI-NF	_	
150-24	29277-29285	training	_	
150-25	29286-29288	is	_	
150-26	29289-29291	of	_	
150-27	29292-29302	particular	_	
150-28	29303-29311	interest	_	
150-29	29311-29312	.	_	

#Text=The IFG region contains the speech motor area (i.e., Broca’s area), also reported to be active during AVH.
151-1	29313-29316	The	_	
151-2	29317-29320	IFG	_	
151-3	29321-29327	region	_	
151-4	29328-29336	contains	_	
151-5	29337-29340	the	_	
151-6	29341-29347	speech	_	
151-7	29348-29353	motor	_	
151-8	29354-29358	area	_	
151-9	29359-29360	(	_	
151-10	29360-29363	i.e	_	
151-11	29363-29364	.	_	
151-12	29364-29365	,	_	
151-13	29366-29371	Broca	_	
151-14	29371-29372	’	_	
151-15	29372-29373	s	_	
151-16	29374-29378	area	_	
151-17	29378-29379	)	_	
151-18	29379-29380	,	_	
151-19	29381-29385	also	_	
151-20	29386-29394	reported	_	
151-21	29395-29397	to	_	
151-22	29398-29400	be	_	
151-23	29401-29407	active	_	
151-24	29408-29414	during	_	
151-25	29415-29418	AVH	_	
151-26	29418-29419	.	_	

#Text=Moreover, the subjective reality of AVH is associated with increased activity in the IFG, a region involved in both inner speech and in the imagination of others’ speech.
152-1	29420-29428	Moreover	_	
152-2	29428-29429	,	_	
152-3	29430-29433	the	_	
152-4	29434-29444	subjective	_	
152-5	29445-29452	reality	_	
152-6	29453-29455	of	_	
152-7	29456-29459	AVH	_	
152-8	29460-29462	is	_	
152-9	29463-29473	associated	_	
152-10	29474-29478	with	_	
152-11	29479-29488	increased	_	
152-12	29489-29497	activity	_	
152-13	29498-29500	in	_	
152-14	29501-29504	the	_	
152-15	29505-29508	IFG	_	
152-16	29508-29509	,	_	
152-17	29510-29511	a	_	
152-18	29512-29518	region	_	
152-19	29519-29527	involved	_	
152-20	29528-29530	in	_	
152-21	29531-29535	both	_	
152-22	29536-29541	inner	_	
152-23	29542-29548	speech	_	
152-24	29549-29552	and	_	
152-25	29553-29555	in	_	
152-26	29556-29559	the	_	
152-27	29560-29571	imagination	_	
152-28	29572-29574	of	_	
152-29	29575-29581	others	_	
152-30	29581-29582	’	_	
152-31	29583-29589	speech	_	
152-32	29589-29590	.	_	

#Text=Inner-speech models of AVH posit that increased activity in speech perception regions in the posterior STG is a consequence of reduced or defective signaling from speech motor areas; that is, speech motor regions fail to attenuate sensory activation in the STG.
153-1	29591-29603	Inner-speech	_	
153-2	29604-29610	models	_	
153-3	29611-29613	of	_	
153-4	29614-29617	AVH	_	
153-5	29618-29623	posit	_	
153-6	29624-29628	that	_	
153-7	29629-29638	increased	_	
153-8	29639-29647	activity	_	
153-9	29648-29650	in	_	
153-10	29651-29657	speech	_	
153-11	29658-29668	perception	_	
153-12	29669-29676	regions	_	
153-13	29677-29679	in	_	
153-14	29680-29683	the	_	
153-15	29684-29693	posterior	_	
153-16	29694-29697	STG	_	
153-17	29698-29700	is	_	
153-18	29701-29702	a	_	
153-19	29703-29714	consequence	_	
153-20	29715-29717	of	_	
153-21	29718-29725	reduced	_	
153-22	29726-29728	or	_	
153-23	29729-29738	defective	_	
153-24	29739-29748	signaling	_	
153-25	29749-29753	from	_	
153-26	29754-29760	speech	_	
153-27	29761-29766	motor	_	
153-28	29767-29772	areas	_	
153-29	29772-29773	;	_	
153-30	29774-29778	that	_	
153-31	29779-29781	is	_	
153-32	29781-29782	,	_	
153-33	29783-29789	speech	_	
153-34	29790-29795	motor	_	
153-35	29796-29803	regions	_	
153-36	29804-29808	fail	_	
153-37	29809-29811	to	_	
153-38	29812-29821	attenuate	_	
153-39	29822-29829	sensory	_	
153-40	29830-29840	activation	_	
153-41	29841-29843	in	_	
153-42	29844-29847	the	_	
153-43	29848-29851	STG	_	
153-44	29851-29852	.	_	

#Text=Consequently, this failure can produce confusion regarding the agency between one’s own actions/inner-speech and externally generated actions such as perceived voices and speech.
154-1	29853-29865	Consequently	_	
154-2	29865-29866	,	_	
154-3	29867-29871	this	_	
154-4	29872-29879	failure	_	
154-5	29880-29883	can	_	
154-6	29884-29891	produce	_	
154-7	29892-29901	confusion	_	
154-8	29902-29911	regarding	_	
154-9	29912-29915	the	_	
154-10	29916-29922	agency	_	
154-11	29923-29930	between	_	
154-12	29931-29934	one	_	
154-13	29934-29935	’	_	
154-14	29935-29936	s	_	
154-15	29937-29940	own	_	
154-16	29941-29948	actions	_	
154-17	29948-29949	/	_	
154-18	29949-29961	inner-speech	_	
154-19	29962-29965	and	_	
154-20	29966-29976	externally	_	
154-21	29977-29986	generated	_	
154-22	29987-29994	actions	_	
154-23	29995-29999	such	_	
154-24	30000-30002	as	_	
154-25	30003-30012	perceived	_	
154-26	30013-30019	voices	_	
154-27	30020-30023	and	_	
154-28	30024-30030	speech	_	
154-29	30030-30031	.	_	

#Text=The finding of increased coupling between the posterior STG region and the left insula (part of the same IFG cluster) is also of interest.
155-1	30032-30035	The	_	
155-2	30036-30043	finding	_	
155-3	30044-30046	of	_	
155-4	30047-30056	increased	_	
155-5	30057-30065	coupling	_	
155-6	30066-30073	between	_	
155-7	30074-30077	the	_	
155-8	30078-30087	posterior	_	
155-9	30088-30091	STG	_	
155-10	30092-30098	region	_	
155-11	30099-30102	and	_	
155-12	30103-30106	the	_	
155-13	30107-30111	left	_	
155-14	30112-30118	insula	_	
155-15	30119-30120	(	_	
155-16	30120-30124	part	_	
155-17	30125-30127	of	_	
155-18	30128-30131	the	_	
155-19	30132-30136	same	_	
155-20	30137-30140	IFG	_	
155-21	30141-30148	cluster	_	
155-22	30148-30149	)	_	
155-23	30150-30152	is	_	
155-24	30153-30157	also	_	
155-25	30158-30160	of	_	
155-26	30161-30169	interest	_	
155-27	30169-30170	.	_	

#Text=This region is thought to be an extension of Broca’s convolution important for verbal imagery and volumetric change in the insula has been shown to be correlated with the intensity of AVH.
156-1	30171-30175	This	_	
156-2	30176-30182	region	_	
156-3	30183-30185	is	_	
156-4	30186-30193	thought	_	
156-5	30194-30196	to	_	
156-6	30197-30199	be	_	
156-7	30200-30202	an	_	
156-8	30203-30212	extension	_	
156-9	30213-30215	of	_	
156-10	30216-30221	Broca	_	
156-11	30221-30222	’	_	
156-12	30222-30223	s	_	
156-13	30224-30235	convolution	_	
156-14	30236-30245	important	_	
156-15	30246-30249	for	_	
156-16	30250-30256	verbal	_	
156-17	30257-30264	imagery	_	
156-18	30265-30268	and	_	
156-19	30269-30279	volumetric	_	
156-20	30280-30286	change	_	
156-21	30287-30289	in	_	
156-22	30290-30293	the	_	
156-23	30294-30300	insula	_	
156-24	30301-30304	has	_	
156-25	30305-30309	been	_	
156-26	30310-30315	shown	_	
156-27	30316-30318	to	_	
156-28	30319-30321	be	_	
156-29	30322-30332	correlated	_	
156-30	30333-30337	with	_	
156-31	30338-30341	the	_	
156-32	30342-30351	intensity	_	
156-33	30352-30354	of	_	
156-34	30355-30358	AVH	_	
156-35	30358-30359	.	_	

#Text=Functional connectivity analysis also revealed increased coupling between the posterior STG seed region and a cluster just superior to the seed region in the left IPG/supramarginal gyrus, which is part of Wernicke’s area, and is known to be involved in speech processing.
157-1	30360-30370	Functional	_	
157-2	30371-30383	connectivity	_	
157-3	30384-30392	analysis	_	
157-4	30393-30397	also	_	
157-5	30398-30406	revealed	_	
157-6	30407-30416	increased	_	
157-7	30417-30425	coupling	_	
157-8	30426-30433	between	_	
157-9	30434-30437	the	_	
157-10	30438-30447	posterior	_	
157-11	30448-30451	STG	_	
157-12	30452-30456	seed	_	
157-13	30457-30463	region	_	
157-14	30464-30467	and	_	
157-15	30468-30469	a	_	
157-16	30470-30477	cluster	_	
157-17	30478-30482	just	_	
157-18	30483-30491	superior	_	
157-19	30492-30494	to	_	
157-20	30495-30498	the	_	
157-21	30499-30503	seed	_	
157-22	30504-30510	region	_	
157-23	30511-30513	in	_	
157-24	30514-30517	the	_	
157-25	30518-30522	left	_	
157-26	30523-30526	IPG	_	
157-27	30526-30527	/	_	
157-28	30527-30540	supramarginal	_	
157-29	30541-30546	gyrus	_	
157-30	30546-30547	,	_	
157-31	30548-30553	which	_	
157-32	30554-30556	is	_	
157-33	30557-30561	part	_	
157-34	30562-30564	of	_	
157-35	30565-30573	Wernicke	_	
157-36	30573-30574	’	_	
157-37	30574-30575	s	_	
157-38	30576-30580	area	_	
157-39	30580-30581	,	_	
157-40	30582-30585	and	_	
157-41	30586-30588	is	_	
157-42	30589-30594	known	_	
157-43	30595-30597	to	_	
157-44	30598-30600	be	_	
157-45	30601-30609	involved	_	
157-46	30610-30612	in	_	
157-47	30613-30619	speech	_	
157-48	30620-30630	processing	_	
157-49	30630-30631	.	_	

#Text=Reduced white matter integrity between left posterior STG and IPG has been reported previously in SCZ patients with AVH, suggesting reduced connectivity within speech and language perception areas, as well as with more distal speech motor regions in the IFG.
158-1	30632-30639	Reduced	_	
158-2	30640-30645	white	_	
158-3	30646-30652	matter	_	
158-4	30653-30662	integrity	_	
158-5	30663-30670	between	_	
158-6	30671-30675	left	_	
158-7	30676-30685	posterior	_	
158-8	30686-30689	STG	_	
158-9	30690-30693	and	_	
158-10	30694-30697	IPG	_	
158-11	30698-30701	has	_	
158-12	30702-30706	been	_	
158-13	30707-30715	reported	_	
158-14	30716-30726	previously	_	
158-15	30727-30729	in	_	
158-16	30730-30733	SCZ	_	
158-17	30734-30742	patients	_	
158-18	30743-30747	with	_	
158-19	30748-30751	AVH	_	
158-20	30751-30752	,	_	
158-21	30753-30763	suggesting	_	
158-22	30764-30771	reduced	_	
158-23	30772-30784	connectivity	_	
158-24	30785-30791	within	_	
158-25	30792-30798	speech	_	
158-26	30799-30802	and	_	
158-27	30803-30811	language	_	
158-28	30812-30822	perception	_	
158-29	30823-30828	areas	_	
158-30	30828-30829	,	_	
158-31	30830-30832	as	_	
158-32	30833-30837	well	_	
158-33	30838-30840	as	_	
158-34	30841-30845	with	_	
158-35	30846-30850	more	_	
158-36	30851-30857	distal	_	
158-37	30858-30864	speech	_	
158-38	30865-30870	motor	_	
158-39	30871-30878	regions	_	
158-40	30879-30881	in	_	
158-41	30882-30885	the	_	
158-42	30886-30889	IFG	_	
158-43	30889-30890	.	_	

#Text=A recent functional imaging study in SCZ patients with AVH, reports that patients displayed a deficit in prediction errors signaling in the posterior STG; the same region activated when patients experience AVH.
159-1	30891-30892	A	_	
159-2	30893-30899	recent	_	
159-3	30900-30910	functional	_	
159-4	30911-30918	imaging	_	
159-5	30919-30924	study	_	
159-6	30925-30927	in	_	
159-7	30928-30931	SCZ	_	
159-8	30932-30940	patients	_	
159-9	30941-30945	with	_	
159-10	30946-30949	AVH	_	
159-11	30949-30950	,	_	
159-12	30951-30958	reports	_	
159-13	30959-30963	that	_	
159-14	30964-30972	patients	_	
159-15	30973-30982	displayed	_	
159-16	30983-30984	a	_	
159-17	30985-30992	deficit	_	
159-18	30993-30995	in	_	
159-19	30996-31006	prediction	_	
159-20	31007-31013	errors	_	
159-21	31014-31023	signaling	_	
159-22	31024-31026	in	_	
159-23	31027-31030	the	_	
159-24	31031-31040	posterior	_	
159-25	31041-31044	STG	_	
159-26	31044-31045	;	_	
159-27	31046-31049	the	_	
159-28	31050-31054	same	_	
159-29	31055-31061	region	_	
159-30	31062-31071	activated	_	
159-31	31072-31076	when	_	
159-32	31077-31085	patients	_	
159-33	31086-31096	experience	_	
159-34	31097-31100	AVH	_	
159-35	31100-31101	.	_	

#Text=It is possible that sensory hyperactivity in speech perception regions may arise through sensory learning and predictive coding deficits within these regions, influencing prior beliefs on sensory input.
160-1	31102-31104	It	_	
160-2	31105-31107	is	_	
160-3	31108-31116	possible	_	
160-4	31117-31121	that	_	
160-5	31122-31129	sensory	_	
160-6	31130-31143	hyperactivity	_	
160-7	31144-31146	in	_	
160-8	31147-31153	speech	_	
160-9	31154-31164	perception	_	
160-10	31165-31172	regions	_	
160-11	31173-31176	may	_	
160-12	31177-31182	arise	_	
160-13	31183-31190	through	_	
160-14	31191-31198	sensory	_	
160-15	31199-31207	learning	_	
160-16	31208-31211	and	_	
160-17	31212-31222	predictive	_	
160-18	31223-31229	coding	_	
160-19	31230-31238	deficits	_	
160-20	31239-31245	within	_	
160-21	31246-31251	these	_	
160-22	31252-31259	regions	_	
160-23	31259-31260	,	_	
160-24	31261-31272	influencing	_	
160-25	31273-31278	prior	_	
160-26	31279-31286	beliefs	_	
160-27	31287-31289	on	_	
160-28	31290-31297	sensory	_	
160-29	31298-31303	input	_	
160-30	31303-31304	.	_	

#Text=Such a learning mechanism may rely on efficient coupling within speech and language regions.
161-1	31305-31309	Such	_	
161-2	31310-31311	a	_	
161-3	31312-31320	learning	_	
161-4	31321-31330	mechanism	_	
161-5	31331-31334	may	_	
161-6	31335-31339	rely	_	
161-7	31340-31342	on	_	
161-8	31343-31352	efficient	_	
161-9	31353-31361	coupling	_	
161-10	31362-31368	within	_	
161-11	31369-31375	speech	_	
161-12	31376-31379	and	_	
161-13	31380-31388	language	_	
161-14	31389-31396	regions	_	
161-15	31396-31397	.	_	

#Text=Overall, rtfMRI-NF training reduced activity in the posterior, speech-sensitive, STG, resulting in increased coupling between inferior frontal and posterior temporal speech and language regions.
162-1	31398-31405	Overall	_	
162-2	31405-31406	,	_	
162-3	31407-31416	rtfMRI-NF	_	
162-4	31417-31425	training	_	
162-5	31426-31433	reduced	_	
162-6	31434-31442	activity	_	
162-7	31443-31445	in	_	
162-8	31446-31449	the	_	
162-9	31450-31459	posterior	_	
162-10	31459-31460	,	_	
162-11	31461-31477	speech-sensitive	_	
162-12	31477-31478	,	_	
162-13	31479-31482	STG	_	
162-14	31482-31483	,	_	
162-15	31484-31493	resulting	_	
162-16	31494-31496	in	_	
162-17	31497-31506	increased	_	
162-18	31507-31515	coupling	_	
162-19	31516-31523	between	_	
162-20	31524-31532	inferior	_	
162-21	31533-31540	frontal	_	
162-22	31541-31544	and	_	
162-23	31545-31554	posterior	_	
162-24	31555-31563	temporal	_	
162-25	31564-31570	speech	_	
162-26	31571-31574	and	_	
162-27	31575-31583	language	_	
162-28	31584-31591	regions	_	
162-29	31591-31592	.	_	

#Text=These findings are broadly consistent with TMS studies that report a reduction in AVH symptomatology after low-frequency TMS is used to reduce cerebral perfusion in the STG, IFG (and cingulate cortex) measured with arterial spin labeling.
163-1	31593-31598	These	_	
163-2	31599-31607	findings	_	
163-3	31608-31611	are	_	
163-4	31612-31619	broadly	_	
163-5	31620-31630	consistent	_	
163-6	31631-31635	with	_	
163-7	31636-31639	TMS	_	
163-8	31640-31647	studies	_	
163-9	31648-31652	that	_	
163-10	31653-31659	report	_	
163-11	31660-31661	a	_	
163-12	31662-31671	reduction	_	
163-13	31672-31674	in	_	
163-14	31675-31678	AVH	_	
163-15	31679-31693	symptomatology	_	
163-16	31694-31699	after	_	
163-17	31700-31713	low-frequency	_	
163-18	31714-31717	TMS	_	
163-19	31718-31720	is	_	
163-20	31721-31725	used	_	
163-21	31726-31728	to	_	
163-22	31729-31735	reduce	_	
163-23	31736-31744	cerebral	_	
163-24	31745-31754	perfusion	_	
163-25	31755-31757	in	_	
163-26	31758-31761	the	_	
163-27	31762-31765	STG	_	
163-28	31765-31766	,	_	
163-29	31767-31770	IFG	_	
163-30	31771-31772	(	_	
163-31	31772-31775	and	_	
163-32	31776-31785	cingulate	_	
163-33	31786-31792	cortex	_	
163-34	31792-31793	)	_	
163-35	31794-31802	measured	_	
163-36	31803-31807	with	_	
163-37	31808-31816	arterial	_	
163-38	31817-31821	spin	_	
163-39	31822-31830	labeling	_	
163-40	31830-31831	.	_	

#Text=However, compared to rTMS, rtfMRI-NF protocols can be more targeted, helping to establish causality of associations between functional and clinical phenotypes.
164-1	31832-31839	However	_	
164-2	31839-31840	,	_	
164-3	31841-31849	compared	_	
164-4	31850-31852	to	_	
164-5	31853-31857	rTMS	_	
164-6	31857-31858	,	_	
164-7	31859-31868	rtfMRI-NF	_	
164-8	31869-31878	protocols	_	
164-9	31879-31882	can	_	
164-10	31883-31885	be	_	
164-11	31886-31890	more	_	
164-12	31891-31899	targeted	_	
164-13	31899-31900	,	_	
164-14	31901-31908	helping	_	
164-15	31909-31911	to	_	
164-16	31912-31921	establish	_	
164-17	31922-31931	causality	_	
164-18	31932-31934	of	_	
164-19	31935-31947	associations	_	
164-20	31948-31955	between	_	
164-21	31956-31966	functional	_	
164-22	31967-31970	and	_	
164-23	31971-31979	clinical	_	
164-24	31980-31990	phenotypes	_	
164-25	31990-31991	.	_	

#Text=The study has some limitations that should be discussed.
165-1	31992-31995	The	_	
165-2	31996-32001	study	_	
165-3	32002-32005	has	_	
165-4	32006-32010	some	_	
165-5	32011-32022	limitations	_	
165-6	32023-32027	that	_	
165-7	32028-32034	should	_	
165-8	32035-32037	be	_	
165-9	32038-32047	discussed	_	
165-10	32047-32048	.	_	

#Text=We did not combine our functional localizer with an anatomical mask, which would help to define the left STG.
166-1	32049-32051	We	_	
166-2	32052-32055	did	_	
166-3	32056-32059	not	_	
166-4	32060-32067	combine	_	
166-5	32068-32071	our	_	
166-6	32072-32082	functional	_	
166-7	32083-32092	localizer	_	
166-8	32093-32097	with	_	
166-9	32098-32100	an	_	
166-10	32101-32111	anatomical	_	
166-11	32112-32116	mask	_	
166-12	32116-32117	,	_	
166-13	32118-32123	which	_	
166-14	32124-32129	would	_	
166-15	32130-32134	help	_	
166-16	32135-32137	to	_	
166-17	32138-32144	define	_	
166-18	32145-32148	the	_	
166-19	32149-32153	left	_	
166-20	32154-32157	STG	_	
166-21	32157-32158	.	_	

#Text=However, as can been seen Fig. 2a, our task isolated the left STG and contiguous inferior parietal cortex, that is, brain regions associated with the speech-sensitive cortex and regions that are associated with AVH.
167-1	32159-32166	However	_	
167-2	32166-32167	,	_	
167-3	32168-32170	as	_	
167-4	32171-32174	can	_	
167-5	32175-32179	been	_	
167-6	32180-32184	seen	_	
167-7	32185-32188	Fig	_	
167-8	32188-32189	.	_	
167-9	32190-32192	2a	_	
167-10	32192-32193	,	_	
167-11	32194-32197	our	_	
167-12	32198-32202	task	_	
167-13	32203-32211	isolated	_	
167-14	32212-32215	the	_	
167-15	32216-32220	left	_	
167-16	32221-32224	STG	_	
167-17	32225-32228	and	_	
167-18	32229-32239	contiguous	_	
167-19	32240-32248	inferior	_	
167-20	32249-32257	parietal	_	
167-21	32258-32264	cortex	_	
167-22	32264-32265	,	_	
167-23	32266-32270	that	_	
167-24	32271-32273	is	_	
167-25	32273-32274	,	_	
167-26	32275-32280	brain	_	
167-27	32281-32288	regions	_	
167-28	32289-32299	associated	_	
167-29	32300-32304	with	_	
167-30	32305-32308	the	_	
167-31	32309-32325	speech-sensitive	_	
167-32	32326-32332	cortex	_	
167-33	32333-32336	and	_	
167-34	32337-32344	regions	_	
167-35	32345-32349	that	_	
167-36	32350-32353	are	_	
167-37	32354-32364	associated	_	
167-38	32365-32369	with	_	
167-39	32370-32373	AVH	_	
167-40	32373-32374	.	_	

#Text=Further, the sample size was small and we did not compare our experimental group to a control condition (e.g., a sham rtfMRI-NF condition).
168-1	32375-32382	Further	_	
168-2	32382-32383	,	_	
168-3	32384-32387	the	_	
168-4	32388-32394	sample	_	
168-5	32395-32399	size	_	
168-6	32400-32403	was	_	
168-7	32404-32409	small	_	
168-8	32410-32413	and	_	
168-9	32414-32416	we	_	
168-10	32417-32420	did	_	
168-11	32421-32424	not	_	
168-12	32425-32432	compare	_	
168-13	32433-32436	our	_	
168-14	32437-32449	experimental	_	
168-15	32450-32455	group	_	
168-16	32456-32458	to	_	
168-17	32459-32460	a	_	
168-18	32461-32468	control	_	
168-19	32469-32478	condition	_	
168-20	32479-32480	(	_	
168-21	32480-32483	e.g	_	
168-22	32483-32484	.	_	
168-23	32484-32485	,	_	
168-24	32486-32487	a	_	
168-25	32488-32492	sham	_	
168-26	32493-32502	rtfMRI-NF	_	
168-27	32503-32512	condition	_	
168-28	32512-32513	)	_	
168-29	32513-32514	.	_	

#Text=Thus, it cannot be ruled out that the reduced left STG activity observed over the training period was a placebo effect of some kind.
169-1	32515-32519	Thus	_	
169-2	32519-32520	,	_	
169-3	32521-32523	it	_	
169-4	32524-32530	cannot	_	
169-5	32531-32533	be	_	
169-6	32534-32539	ruled	_	
169-7	32540-32543	out	_	
169-8	32544-32548	that	_	
169-9	32549-32552	the	_	
169-10	32553-32560	reduced	_	
169-11	32561-32565	left	_	
169-12	32566-32569	STG	_	
169-13	32570-32578	activity	_	
169-14	32579-32587	observed	_	
169-15	32588-32592	over	_	
169-16	32593-32596	the	_	
169-17	32597-32605	training	_	
169-18	32606-32612	period	_	
169-19	32613-32616	was	_	
169-20	32617-32618	a	_	
169-21	32619-32626	placebo	_	
169-22	32627-32633	effect	_	
169-23	32634-32636	of	_	
169-24	32637-32641	some	_	
169-25	32642-32646	kind	_	
169-26	32646-32647	.	_	

#Text=We will now need to conduct a larger randomized control trial to exclude this possibility and to test if rtfMRI-NF training can be used as a novel therapeutic intervention in people with SCZ and AVH.
170-1	32648-32650	We	_	
170-2	32651-32655	will	_	
170-3	32656-32659	now	_	
170-4	32660-32664	need	_	
170-5	32665-32667	to	_	
170-6	32668-32675	conduct	_	
170-7	32676-32677	a	_	
170-8	32678-32684	larger	_	
170-9	32685-32695	randomized	_	
170-10	32696-32703	control	_	
170-11	32704-32709	trial	_	
170-12	32710-32712	to	_	
170-13	32713-32720	exclude	_	
170-14	32721-32725	this	_	
170-15	32726-32737	possibility	_	
170-16	32738-32741	and	_	
170-17	32742-32744	to	_	
170-18	32745-32749	test	_	
170-19	32750-32752	if	_	
170-20	32753-32762	rtfMRI-NF	_	
170-21	32763-32771	training	_	
170-22	32772-32775	can	_	
170-23	32776-32778	be	_	
170-24	32779-32783	used	_	
170-25	32784-32786	as	_	
170-26	32787-32788	a	_	
170-27	32789-32794	novel	_	
170-28	32795-32806	therapeutic	_	
170-29	32807-32819	intervention	_	
170-30	32820-32822	in	_	
170-31	32823-32829	people	_	
170-32	32830-32834	with	_	
170-33	32835-32838	SCZ	_	
170-34	32839-32842	and	_	
170-35	32843-32846	AVH	_	
170-36	32846-32847	.	_	

#Text=It does seem, however, that patients with SCZ and AVH do have the ability to regulate activity (neural plasticity, i.e., alter the functional organization of the brain) in speech sensory–motor regions, in contrast to suggestions that patients have a general deficit in cortical plasticity.
171-1	32848-32850	It	_	
171-2	32851-32855	does	_	
171-3	32856-32860	seem	_	
171-4	32860-32861	,	_	
171-5	32862-32869	however	_	
171-6	32869-32870	,	_	
171-7	32871-32875	that	_	
171-8	32876-32884	patients	_	
171-9	32885-32889	with	_	
171-10	32890-32893	SCZ	_	
171-11	32894-32897	and	_	
171-12	32898-32901	AVH	_	
171-13	32902-32904	do	_	
171-14	32905-32909	have	_	
171-15	32910-32913	the	_	
171-16	32914-32921	ability	_	
171-17	32922-32924	to	_	
171-18	32925-32933	regulate	_	
171-19	32934-32942	activity	_	
171-20	32943-32944	(	_	
171-21	32944-32950	neural	_	
171-22	32951-32961	plasticity	_	
171-23	32961-32962	,	_	
171-24	32963-32966	i.e	_	
171-25	32966-32967	.	_	
171-26	32967-32968	,	_	
171-27	32969-32974	alter	_	
171-28	32975-32978	the	_	
171-29	32979-32989	functional	_	
171-30	32990-33002	organization	_	
171-31	33003-33005	of	_	
171-32	33006-33009	the	_	
171-33	33010-33015	brain	_	
171-34	33015-33016	)	_	
171-35	33017-33019	in	_	
171-36	33020-33026	speech	_	
171-37	33027-33040	sensory–motor	_	
171-38	33041-33048	regions	_	
171-39	33048-33049	,	_	
171-40	33050-33052	in	_	
171-41	33053-33061	contrast	_	
171-42	33062-33064	to	_	
171-43	33065-33076	suggestions	_	
171-44	33077-33081	that	_	
171-45	33082-33090	patients	_	
171-46	33091-33095	have	_	
171-47	33096-33097	a	_	
171-48	33098-33105	general	_	
171-49	33106-33113	deficit	_	
171-50	33114-33116	in	_	
171-51	33117-33125	cortical	_	
171-52	33126-33136	plasticity	_	
171-53	33136-33137	.	_	

#Text=This may open the way for wider investigations using neurotherapies, such as rtfMRI-NF, in people with SCZ.
172-1	33138-33142	This	_	
172-2	33143-33146	may	_	
172-3	33147-33151	open	_	
172-4	33152-33155	the	_	
172-5	33156-33159	way	_	
172-6	33160-33163	for	_	
172-7	33164-33169	wider	_	
172-8	33170-33184	investigations	_	
172-9	33185-33190	using	_	
172-10	33191-33205	neurotherapies	_	
172-11	33205-33206	,	_	
172-12	33207-33211	such	_	
172-13	33212-33214	as	_	
172-14	33215-33224	rtfMRI-NF	_	
172-15	33224-33225	,	_	
172-16	33226-33228	in	_	
172-17	33229-33235	people	_	
172-18	33236-33240	with	_	
172-19	33241-33244	SCZ	_	
172-20	33244-33245	.	_	

#Text=Electronic supplementary material
#Text=Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
173-1	33246-33256	Electronic	_	
173-2	33257-33270	supplementary	_	
173-3	33271-33279	material	_	
173-4	33280-33291	Publisher's	_	
173-5	33292-33296	note	_	
173-6	33296-33297	:	_	
173-7	33298-33306	Springer	_	
173-8	33307-33313	Nature	_	
173-9	33314-33321	remains	_	
173-10	33322-33329	neutral	_	
173-11	33330-33334	with	_	
173-12	33335-33341	regard	_	
173-13	33342-33344	to	_	
173-14	33345-33359	jurisdictional	_	
173-15	33360-33366	claims	_	
173-16	33367-33369	in	_	
173-17	33370-33379	published	_	
173-18	33380-33384	maps	_	
173-19	33385-33388	and	_	
173-20	33389-33402	institutional	_	
173-21	33403-33415	affiliations	_	
173-22	33415-33416	.	_	

#Text=Electronic supplementary material
#Text=Supplementary Information accompanies this paper at 10.1038/s41398-017-0067-5.
174-1	33417-33427	Electronic	_	
174-2	33428-33441	supplementary	_	
174-3	33442-33450	material	_	
174-4	33451-33464	Supplementary	_	
174-5	33465-33476	Information	_	
174-6	33477-33488	accompanies	_	
174-7	33489-33493	this	_	
174-8	33494-33499	paper	_	
174-9	33500-33502	at	_	
174-10	33503-33510	10.1038	_	
174-11	33510-33511	/	_	
174-12	33511-33517	s41398	_	
174-13	33517-33518	-	_	
174-14	33518-33521	017	_	
174-15	33521-33522	-	_	
174-16	33522-33526	0067	_	
174-17	33526-33527	-	_	
174-18	33527-33528	5	_	
174-19	33528-33529	.	_	

#Text=Conflict of interest
#Text=N.O., V.G., O.O., L.S.
175-1	33530-33538	Conflict	_	
175-2	33539-33541	of	_	
175-3	33542-33550	interest	_	
175-4	33551-33554	N.O	_	
175-5	33554-33555	.	_	
175-6	33555-33556	,	_	
175-7	33557-33560	V.G	_	
175-8	33560-33561	.	_	
175-9	33561-33562	,	_	
175-10	33563-33566	O.O	_	
175-11	33566-33567	.	_	
175-12	33567-33568	,	_	
175-13	33569-33572	L.S	_	
175-14	33572-33573	.	_	

#Text=-L., and P.A. report no biomedical financial interest or potential conflicts of interest.
176-1	33573-33574	-	_	
176-2	33574-33575	L	_	
176-3	33575-33576	.	_	
176-4	33576-33577	,	_	
176-5	33578-33581	and	_	
176-6	33582-33585	P.A	_	
176-7	33585-33586	.	_	
176-8	33587-33593	report	_	
176-9	33594-33596	no	_	
176-10	33597-33607	biomedical	_	
176-11	33608-33617	financial	_	
176-12	33618-33626	interest	_	
176-13	33627-33629	or	_	
176-14	33630-33639	potential	_	
176-15	33640-33649	conflicts	_	
176-16	33650-33652	of	_	
176-17	33653-33661	interest	_	
176-18	33661-33662	.	_	

#Text=The other authors declare that they have no conflict of interest.
177-1	33663-33666	The	_	
177-2	33667-33672	other	_	
177-3	33673-33680	authors	_	
177-4	33681-33688	declare	_	
177-5	33689-33693	that	_	
177-6	33694-33698	they	_	
177-7	33699-33703	have	_	
177-8	33704-33706	no	_	
177-9	33707-33715	conflict	_	
177-10	33716-33718	of	_	
177-11	33719-33727	interest	_	
177-12	33727-33728	.	_	

#Text=References
#Text=The auditory hallucination: a phenomenological survey
#Text=Auditory hallucinations: a review of psychological treatments
#Text=Non‐adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies
#Text=The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations
#Text=Neuroimaging auditory hallucinations in schizophrenia: from neuroanatomy to neurochemistry and beyond
#Text=Neuroanatomy of auditory verbal hallucinations in schizophrenia: a quantitative meta-analysis of voxel-based morphometry studies
#Text=Quantitative meta-analysis on state and trait aspects of auditory verbal hallucinations in schizophrenia
#Text=Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis
#Text=Voice-selective areas in human auditory cortex
#Text=Neural activity in speech-sensitive auditory cortex during silence
#Text=Aberrant resting-state connectivity in non-psychotic individuals with auditory hallucinations
#Text=Repeated measurements of cerebral blood flow in the left superior temporal gyrus reveal tonic hyperactivity in patients with auditory verbal hallucinations: a possible trait marker
#Text=Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations
#Text=Electrophysiological evidence of corollary discharge dysfunction in schizophrenia during talking and thinking
#Text=Curcic-Blake B. et al.
178-1	33729-33739	References	_	
178-2	33740-33743	The	_	
178-3	33744-33752	auditory	_	
178-4	33753-33766	hallucination	_	
178-5	33766-33767	:	_	
178-6	33768-33769	a	_	
178-7	33770-33786	phenomenological	_	
178-8	33787-33793	survey	_	
178-9	33794-33802	Auditory	_	
178-10	33803-33817	hallucinations	_	
178-11	33817-33818	:	_	
178-12	33819-33820	a	_	
178-13	33821-33827	review	_	
178-14	33828-33830	of	_	
178-15	33831-33844	psychological	_	
178-16	33845-33855	treatments	_	
178-17	33856-33869	Non‐adherence	_	
178-18	33870-33872	to	_	
178-19	33873-33883	medication	_	
178-20	33884-33886	in	_	
178-21	33887-33895	patients	_	
178-22	33896-33900	with	_	
178-23	33901-33910	psychotic	_	
178-24	33911-33920	disorders	_	
178-25	33920-33921	:	_	
178-26	33922-33934	epidemiology	_	
178-27	33934-33935	,	_	
178-28	33936-33948	contributing	_	
178-29	33949-33956	factors	_	
178-30	33957-33960	and	_	
178-31	33961-33971	management	_	
178-32	33972-33982	strategies	_	
178-33	33983-33986	The	_	
178-34	33987-34000	hallucinating	_	
178-35	34001-34006	brain	_	
178-36	34006-34007	:	_	
178-37	34008-34009	a	_	
178-38	34010-34016	review	_	
178-39	34017-34019	of	_	
178-40	34020-34030	structural	_	
178-41	34031-34034	and	_	
178-42	34035-34045	functional	_	
178-43	34046-34058	neuroimaging	_	
178-44	34059-34066	studies	_	
178-45	34067-34069	of	_	
178-46	34070-34084	hallucinations	_	
178-47	34085-34097	Neuroimaging	_	
178-48	34098-34106	auditory	_	
178-49	34107-34121	hallucinations	_	
178-50	34122-34124	in	_	
178-51	34125-34138	schizophrenia	_	
178-52	34138-34139	:	_	
178-53	34140-34144	from	_	
178-54	34145-34157	neuroanatomy	_	
178-55	34158-34160	to	_	
178-56	34161-34175	neurochemistry	_	
178-57	34176-34179	and	_	
178-58	34180-34186	beyond	_	
178-59	34187-34199	Neuroanatomy	_	
178-60	34200-34202	of	_	
178-61	34203-34211	auditory	_	
178-62	34212-34218	verbal	_	
178-63	34219-34233	hallucinations	_	
178-64	34234-34236	in	_	
178-65	34237-34250	schizophrenia	_	
178-66	34250-34251	:	_	
178-67	34252-34253	a	_	
178-68	34254-34266	quantitative	_	
178-69	34267-34280	meta-analysis	_	
178-70	34281-34283	of	_	
178-71	34284-34295	voxel-based	_	
178-72	34296-34307	morphometry	_	
178-73	34308-34315	studies	_	
178-74	34316-34328	Quantitative	_	
178-75	34329-34342	meta-analysis	_	
178-76	34343-34345	on	_	
178-77	34346-34351	state	_	
178-78	34352-34355	and	_	
178-79	34356-34361	trait	_	
178-80	34362-34369	aspects	_	
178-81	34370-34372	of	_	
178-82	34373-34381	auditory	_	
178-83	34382-34388	verbal	_	
178-84	34389-34403	hallucinations	_	
178-85	34404-34406	in	_	
178-86	34407-34420	schizophrenia	_	
178-87	34421-34429	Cortical	_	
178-88	34430-34441	activations	_	
178-89	34442-34448	during	_	
178-90	34449-34457	auditory	_	
178-91	34458-34464	verbal	_	
178-92	34465-34479	hallucinations	_	
178-93	34480-34482	in	_	
178-94	34483-34496	schizophrenia	_	
178-95	34496-34497	:	_	
178-96	34498-34499	a	_	
178-97	34500-34516	coordinate-based	_	
178-98	34517-34530	meta-analysis	_	
178-99	34531-34546	Voice-selective	_	
178-100	34547-34552	areas	_	
178-101	34553-34555	in	_	
178-102	34556-34561	human	_	
178-103	34562-34570	auditory	_	
178-104	34571-34577	cortex	_	
178-105	34578-34584	Neural	_	
178-106	34585-34593	activity	_	
178-107	34594-34596	in	_	
178-108	34597-34613	speech-sensitive	_	
178-109	34614-34622	auditory	_	
178-110	34623-34629	cortex	_	
178-111	34630-34636	during	_	
178-112	34637-34644	silence	_	
178-113	34645-34653	Aberrant	_	
178-114	34654-34667	resting-state	_	
178-115	34668-34680	connectivity	_	
178-116	34681-34683	in	_	
178-117	34684-34697	non-psychotic	_	
178-118	34698-34709	individuals	_	
178-119	34710-34714	with	_	
178-120	34715-34723	auditory	_	
178-121	34724-34738	hallucinations	_	
178-122	34739-34747	Repeated	_	
178-123	34748-34760	measurements	_	
178-124	34761-34763	of	_	
178-125	34764-34772	cerebral	_	
178-126	34773-34778	blood	_	
178-127	34779-34783	flow	_	
178-128	34784-34786	in	_	
178-129	34787-34790	the	_	
178-130	34791-34795	left	_	
178-131	34796-34804	superior	_	
178-132	34805-34813	temporal	_	
178-133	34814-34819	gyrus	_	
178-134	34820-34826	reveal	_	
178-135	34827-34832	tonic	_	
178-136	34833-34846	hyperactivity	_	
178-137	34847-34849	in	_	
178-138	34850-34858	patients	_	
178-139	34859-34863	with	_	
178-140	34864-34872	auditory	_	
178-141	34873-34879	verbal	_	
178-142	34880-34894	hallucinations	_	
178-143	34894-34895	:	_	
178-144	34896-34897	a	_	
178-145	34898-34906	possible	_	
178-146	34907-34912	trait	_	
178-147	34913-34919	marker	_	
178-148	34920-34927	Reduced	_	
178-149	34928-34942	frontotemporal	_	
178-150	34943-34953	functional	_	
178-151	34954-34966	connectivity	_	
178-152	34967-34969	in	_	
178-153	34970-34983	schizophrenia	_	
178-154	34984-34994	associated	_	
178-155	34995-34999	with	_	
178-156	35000-35008	auditory	_	
178-157	35009-35023	hallucinations	_	
178-158	35024-35044	Electrophysiological	_	
178-159	35045-35053	evidence	_	
178-160	35054-35056	of	_	
178-161	35057-35066	corollary	_	
178-162	35067-35076	discharge	_	
178-163	35077-35088	dysfunction	_	
178-164	35089-35091	in	_	
178-165	35092-35105	schizophrenia	_	
178-166	35106-35112	during	_	
178-167	35113-35120	talking	_	
178-168	35121-35124	and	_	
178-169	35125-35133	thinking	_	
178-170	35134-35146	Curcic-Blake	_	
178-171	35147-35148	B	_	
178-172	35148-35149	.	_	
178-173	35150-35152	et	_	
178-174	35153-35155	al	_	
178-175	35155-35156	.	_	

#Text=When Broca goes uninformed: reduced information flow to Broca’s area in schizophrenia patients with auditory hallucinations.
179-1	35157-35161	When	_	
179-2	35162-35167	Broca	_	
179-3	35168-35172	goes	_	
179-4	35173-35183	uninformed	_	
179-5	35183-35184	:	_	
179-6	35185-35192	reduced	_	
179-7	35193-35204	information	_	
179-8	35205-35209	flow	_	
179-9	35210-35212	to	_	
179-10	35213-35218	Broca	_	
179-11	35218-35219	’	_	
179-12	35219-35220	s	_	
179-13	35221-35225	area	_	
179-14	35226-35228	in	_	
179-15	35229-35242	schizophrenia	_	
179-16	35243-35251	patients	_	
179-17	35252-35256	with	_	
179-18	35257-35265	auditory	_	
179-19	35266-35280	hallucinations	_	
179-20	35280-35281	.	_	

#Text=Schizophr.
180-1	35282-35291	Schizophr	_	
180-2	35291-35292	.	_	

#Text=Bull.39: 1087–1095 (2013).
181-1	35293-35297	Bull	_	
181-2	35297-35300	.39	_	
181-3	35300-35301	:	_	
181-4	35302-35306	1087	_	
181-5	35306-35307	–	_	
181-6	35307-35311	1095	_	
181-7	35312-35313	(	_	
181-8	35313-35317	2013	_	
181-9	35317-35318	)	_	
181-10	35318-35319	.	_	

#Text=Elevated functional connectivity along a corticostriatal loop and the mechanism of auditory/verbal hallucinations in patients with schizophrenia
#Text=Abnormal monitoring of inner speech: a physiological basis for auditory hallucinations
#Text=Increased superior temporal activation associated with external misattributions of self-generated speech in schizophrenia
#Text=Probing the pathophysiology of auditory/verbal hallucinations by combining functional magnetic resonance imaging and transcranial magnetic stimulation
#Text=Neurobiology of psychiatric symptomatology: From origin to treatment of auditory verbal hallucinations
#Text=Translating neurocognitive models of auditory-verbal hallucinations into therapy: using real-time fMRI-neurofeedback to treat voices
#Text=Taking back the brain: could neurofeedback training be effective for relieving distressing auditory verbal hallucinations in patients with schizophrenia?
182-1	35320-35328	Elevated	_	
182-2	35329-35339	functional	_	
182-3	35340-35352	connectivity	_	
182-4	35353-35358	along	_	
182-5	35359-35360	a	_	
182-6	35361-35376	corticostriatal	_	
182-7	35377-35381	loop	_	
182-8	35382-35385	and	_	
182-9	35386-35389	the	_	
182-10	35390-35399	mechanism	_	
182-11	35400-35402	of	_	
182-12	35403-35411	auditory	_	
182-13	35411-35412	/	_	
182-14	35412-35418	verbal	_	
182-15	35419-35433	hallucinations	_	
182-16	35434-35436	in	_	
182-17	35437-35445	patients	_	
182-18	35446-35450	with	_	
182-19	35451-35464	schizophrenia	_	
182-20	35465-35473	Abnormal	_	
182-21	35474-35484	monitoring	_	
182-22	35485-35487	of	_	
182-23	35488-35493	inner	_	
182-24	35494-35500	speech	_	
182-25	35500-35501	:	_	
182-26	35502-35503	a	_	
182-27	35504-35517	physiological	_	
182-28	35518-35523	basis	_	
182-29	35524-35527	for	_	
182-30	35528-35536	auditory	_	
182-31	35537-35551	hallucinations	_	
182-32	35552-35561	Increased	_	
182-33	35562-35570	superior	_	
182-34	35571-35579	temporal	_	
182-35	35580-35590	activation	_	
182-36	35591-35601	associated	_	
182-37	35602-35606	with	_	
182-38	35607-35615	external	_	
182-39	35616-35631	misattributions	_	
182-40	35632-35634	of	_	
182-41	35635-35649	self-generated	_	
182-42	35650-35656	speech	_	
182-43	35657-35659	in	_	
182-44	35660-35673	schizophrenia	_	
182-45	35674-35681	Probing	_	
182-46	35682-35685	the	_	
182-47	35686-35701	pathophysiology	_	
182-48	35702-35704	of	_	
182-49	35705-35713	auditory	_	
182-50	35713-35714	/	_	
182-51	35714-35720	verbal	_	
182-52	35721-35735	hallucinations	_	
182-53	35736-35738	by	_	
182-54	35739-35748	combining	_	
182-55	35749-35759	functional	_	
182-56	35760-35768	magnetic	_	
182-57	35769-35778	resonance	_	
182-58	35779-35786	imaging	_	
182-59	35787-35790	and	_	
182-60	35791-35803	transcranial	_	
182-61	35804-35812	magnetic	_	
182-62	35813-35824	stimulation	_	
182-63	35825-35837	Neurobiology	_	
182-64	35838-35840	of	_	
182-65	35841-35852	psychiatric	_	
182-66	35853-35867	symptomatology	_	
182-67	35867-35868	:	_	
182-68	35869-35873	From	_	
182-69	35874-35880	origin	_	
182-70	35881-35883	to	_	
182-71	35884-35893	treatment	_	
182-72	35894-35896	of	_	
182-73	35897-35905	auditory	_	
182-74	35906-35912	verbal	_	
182-75	35913-35927	hallucinations	_	
182-76	35928-35939	Translating	_	
182-77	35940-35954	neurocognitive	_	
182-78	35955-35961	models	_	
182-79	35962-35964	of	_	
182-80	35965-35980	auditory-verbal	_	
182-81	35981-35995	hallucinations	_	
182-82	35996-36000	into	_	
182-83	36001-36008	therapy	_	
182-84	36008-36009	:	_	
182-85	36010-36015	using	_	
182-86	36016-36025	real-time	_	
182-87	36026-36044	fMRI-neurofeedback	_	
182-88	36045-36047	to	_	
182-89	36048-36053	treat	_	
182-90	36054-36060	voices	_	
182-91	36061-36067	Taking	_	
182-92	36068-36072	back	_	
182-93	36073-36076	the	_	
182-94	36077-36082	brain	_	
182-95	36082-36083	:	_	
182-96	36084-36089	could	_	
182-97	36090-36103	neurofeedback	_	
182-98	36104-36112	training	_	
182-99	36113-36115	be	_	
182-100	36116-36125	effective	_	
182-101	36126-36129	for	_	
182-102	36130-36139	relieving	_	
182-103	36140-36151	distressing	_	
182-104	36152-36160	auditory	_	
182-105	36161-36167	verbal	_	
182-106	36168-36182	hallucinations	_	
182-107	36183-36185	in	_	
182-108	36186-36194	patients	_	
182-109	36195-36199	with	_	
182-110	36200-36213	schizophrenia	_	
182-111	36213-36214	?	_	

#Text=Targeting treatment-resistant auditory verbal hallucinations in schizophrenia with fMRI-based neurofeedback—exploring different cases of schizophrenia
#Text=Recovery of the default mode network after demanding neurofeedback training occurs in spatio-temporally segregated subnetworks
#Text=Dynamic reconfiguration of human brain functional networks through neurofeedback
#Text=Association AP.
183-1	36215-36224	Targeting	_	
183-2	36225-36244	treatment-resistant	_	
183-3	36245-36253	auditory	_	
183-4	36254-36260	verbal	_	
183-5	36261-36275	hallucinations	_	
183-6	36276-36278	in	_	
183-7	36279-36292	schizophrenia	_	
183-8	36293-36297	with	_	
183-9	36298-36308	fMRI-based	_	
183-10	36309-36332	neurofeedback—exploring	_	
183-11	36333-36342	different	_	
183-12	36343-36348	cases	_	
183-13	36349-36351	of	_	
183-14	36352-36365	schizophrenia	_	
183-15	36366-36374	Recovery	_	
183-16	36375-36377	of	_	
183-17	36378-36381	the	_	
183-18	36382-36389	default	_	
183-19	36390-36394	mode	_	
183-20	36395-36402	network	_	
183-21	36403-36408	after	_	
183-22	36409-36418	demanding	_	
183-23	36419-36432	neurofeedback	_	
183-24	36433-36441	training	_	
183-25	36442-36448	occurs	_	
183-26	36449-36451	in	_	
183-27	36452-36469	spatio-temporally	_	
183-28	36470-36480	segregated	_	
183-29	36481-36492	subnetworks	_	
183-30	36493-36500	Dynamic	_	
183-31	36501-36516	reconfiguration	_	
183-32	36517-36519	of	_	
183-33	36520-36525	human	_	
183-34	36526-36531	brain	_	
183-35	36532-36542	functional	_	
183-36	36543-36551	networks	_	
183-37	36552-36559	through	_	
183-38	36560-36573	neurofeedback	_	
183-39	36574-36585	Association	_	
183-40	36586-36588	AP	_	
183-41	36588-36589	.	_	

#Text=Diagnostic and statistical manual of mental disorders (DSM-5®).
184-1	36590-36600	Diagnostic	_	
184-2	36601-36604	and	_	
184-3	36605-36616	statistical	_	
184-4	36617-36623	manual	_	
184-5	36624-36626	of	_	
184-6	36627-36633	mental	_	
184-7	36634-36643	disorders	_	
184-8	36644-36645	(	_	
184-9	36645-36648	DSM	_	
184-10	36648-36649	-	_	
184-11	36649-36650	5	_	
184-12	36650-36651	®	_	
184-13	36651-36652	)	_	
184-14	36652-36653	.	_	

#Text=(American Psychiatric Pub, Arlington, VA; 2013).
185-1	36654-36655	(	_	
185-2	36655-36663	American	_	
185-3	36664-36675	Psychiatric	_	
185-4	36676-36679	Pub	_	
185-5	36679-36680	,	_	
185-6	36681-36690	Arlington	_	
185-7	36690-36691	,	_	
185-8	36692-36694	VA	_	
185-9	36694-36695	;	_	
185-10	36696-36700	2013	_	
185-11	36700-36701	)	_	
185-12	36701-36702	.	_	

#Text=The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation
#Text=The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
#Text=Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS)
#Text=Wechsler D.
186-1	36703-36706	The	_	
186-2	36707-36715	Positive	_	
186-3	36716-36719	and	_	
186-4	36720-36728	Negative	_	
186-5	36729-36737	Syndrome	_	
186-6	36738-36743	Scale	_	
186-7	36744-36745	(	_	
186-8	36745-36750	PANSS	_	
186-9	36750-36751	)	_	
186-10	36751-36752	:	_	
186-11	36753-36762	rationale	_	
186-12	36763-36766	and	_	
186-13	36767-36782	standardisation	_	
186-14	36783-36786	The	_	
186-15	36787-36795	Positive	_	
186-16	36796-36799	and	_	
186-17	36800-36808	Negative	_	
186-18	36809-36817	Syndrome	_	
186-19	36818-36823	Scale	_	
186-20	36824-36825	(	_	
186-21	36825-36830	PANSS	_	
186-22	36830-36831	)	_	
186-23	36832-36835	for	_	
186-24	36836-36849	schizophrenia	_	
186-25	36850-36856	Scales	_	
186-26	36857-36859	to	_	
186-27	36860-36867	measure	_	
186-28	36868-36878	dimensions	_	
186-29	36879-36881	of	_	
186-30	36882-36896	hallucinations	_	
186-31	36897-36900	and	_	
186-32	36901-36910	delusions	_	
186-33	36910-36911	:	_	
186-34	36912-36915	the	_	
186-35	36916-36925	psychotic	_	
186-36	36926-36933	symptom	_	
186-37	36934-36940	rating	_	
186-38	36941-36947	scales	_	
186-39	36948-36949	(	_	
186-40	36949-36956	PSYRATS	_	
186-41	36956-36957	)	_	
186-42	36958-36966	Wechsler	_	
186-43	36967-36968	D	_	
186-44	36968-36969	.	_	

#Text=Wechsler Abbreviated Scale of Intelligence (WASI).
187-1	36970-36978	Wechsler	_	
187-2	36979-36990	Abbreviated	_	
187-3	36991-36996	Scale	_	
187-4	36997-36999	of	_	
187-5	37000-37012	Intelligence	_	
187-6	37013-37014	(	_	
187-7	37014-37018	WASI	_	
187-8	37018-37019	)	_	
187-9	37019-37020	.	_	

#Text=(The Psychological Corporation, San Antonio, TX, 1999).
188-1	37021-37022	(	_	
188-2	37022-37025	The	_	
188-3	37026-37039	Psychological	_	
188-4	37040-37051	Corporation	_	
188-5	37051-37052	,	_	
188-6	37053-37056	San	_	
188-7	37057-37064	Antonio	_	
188-8	37064-37065	,	_	
188-9	37066-37068	TX	_	
188-10	37068-37069	,	_	
188-11	37070-37074	1999	_	
188-12	37074-37075	)	_	
188-13	37075-37076	.	_	

#Text=Bodurka, J. & Bandettini, P.
189-1	37077-37084	Bodurka	_	
189-2	37084-37085	,	_	
189-3	37086-37087	J	_	
189-4	37087-37088	.	_	
189-5	37089-37090	&	_	
189-6	37091-37101	Bandettini	_	
189-7	37101-37102	,	_	
189-8	37103-37104	P	_	
189-9	37104-37105	.	_	

#Text=A.
190-1	37106-37107	A	_	
190-2	37107-37108	.	_	

#Text=Real-time software for monitoring MRI scanner opertaions.
191-1	37109-37118	Real-time	_	
191-2	37119-37127	software	_	
191-3	37128-37131	for	_	
191-4	37132-37142	monitoring	_	
191-5	37143-37146	MRI	_	
191-6	37147-37154	scanner	_	
191-7	37155-37165	opertaions	_	
191-8	37165-37166	.	_	

#Text=In Proceedings of Human Brain Mapping, S85 (Neuroimage: Melbourne, 2008).
192-1	37167-37169	In	_	
192-2	37170-37181	Proceedings	_	
192-3	37182-37184	of	_	
192-4	37185-37190	Human	_	
192-5	37191-37196	Brain	_	
192-6	37197-37204	Mapping	_	
192-7	37204-37205	,	_	
192-8	37206-37209	S85	_	
192-9	37210-37211	(	_	
192-10	37211-37221	Neuroimage	_	
192-11	37221-37222	:	_	
192-12	37223-37232	Melbourne	_	
192-13	37232-37233	,	_	
192-14	37234-37238	2008	_	
192-15	37238-37239	)	_	
192-16	37239-37240	.	_	

#Text=AFNI: software for analysis and visualization of functional magnetic resonance neuroimages
#Text=Real-time fMRI neurofeedback in adolescents with attention deficit hyperactivity disorder
#Text=Acquired self-control of insula cortex modulates emotion recognition and brain network connectivity in schizophrenia
#Text=Regulation of anterior insular cortex activity using real-time fMRI
#Text=Singer J.
193-1	37241-37245	AFNI	_	
193-2	37245-37246	:	_	
193-3	37247-37255	software	_	
193-4	37256-37259	for	_	
193-5	37260-37268	analysis	_	
193-6	37269-37272	and	_	
193-7	37273-37286	visualization	_	
193-8	37287-37289	of	_	
193-9	37290-37300	functional	_	
193-10	37301-37309	magnetic	_	
193-11	37310-37319	resonance	_	
193-12	37320-37331	neuroimages	_	
193-13	37332-37341	Real-time	_	
193-14	37342-37346	fMRI	_	
193-15	37347-37360	neurofeedback	_	
193-16	37361-37363	in	_	
193-17	37364-37375	adolescents	_	
193-18	37376-37380	with	_	
193-19	37381-37390	attention	_	
193-20	37391-37398	deficit	_	
193-21	37399-37412	hyperactivity	_	
193-22	37413-37421	disorder	_	
193-23	37422-37430	Acquired	_	
193-24	37431-37443	self-control	_	
193-25	37444-37446	of	_	
193-26	37447-37453	insula	_	
193-27	37454-37460	cortex	_	
193-28	37461-37470	modulates	_	
193-29	37471-37478	emotion	_	
193-30	37479-37490	recognition	_	
193-31	37491-37494	and	_	
193-32	37495-37500	brain	_	
193-33	37501-37508	network	_	
193-34	37509-37521	connectivity	_	
193-35	37522-37524	in	_	
193-36	37525-37538	schizophrenia	_	
193-37	37539-37549	Regulation	_	
193-38	37550-37552	of	_	
193-39	37553-37561	anterior	_	
193-40	37562-37569	insular	_	
193-41	37570-37576	cortex	_	
193-42	37577-37585	activity	_	
193-43	37586-37591	using	_	
193-44	37592-37601	real-time	_	
193-45	37602-37606	fMRI	_	
193-46	37607-37613	Singer	_	
193-47	37614-37615	J	_	
193-48	37615-37616	.	_	

#Text=D. & Willett J.
194-1	37617-37618	D	_	
194-2	37618-37619	.	_	
194-3	37620-37621	&	_	
194-4	37622-37629	Willett	_	
194-5	37630-37631	J	_	
194-6	37631-37632	.	_	

#Text=B.
195-1	37633-37634	B	_	
195-2	37634-37635	.	_	

#Text=Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence (Oxford University Press, 2003).
196-1	37636-37643	Applied	_	
196-2	37644-37656	Longitudinal	_	
196-3	37657-37661	Data	_	
196-4	37662-37670	Analysis	_	
196-5	37670-37671	:	_	
196-6	37672-37680	Modeling	_	
196-7	37681-37687	Change	_	
196-8	37688-37691	and	_	
196-9	37692-37697	Event	_	
196-10	37698-37708	Occurrence	_	
196-11	37709-37710	(	_	
196-12	37710-37716	Oxford	_	
196-13	37717-37727	University	_	
196-14	37728-37733	Press	_	
196-15	37733-37734	,	_	
196-16	37735-37739	2003	_	
196-17	37739-37740	)	_	
196-18	37740-37741	.	_	

#Text=Evans, A.
197-1	37742-37747	Evans	_	
197-2	37747-37748	,	_	
197-3	37749-37750	A	_	
197-4	37750-37751	.	_	

#Text=C. et al.
198-1	37752-37753	C	_	
198-2	37753-37754	.	_	
198-3	37755-37757	et	_	
198-4	37758-37760	al	_	
198-5	37760-37761	.	_	

#Text=(eds). 3D statistical neuroanatomical models from 305 MRI volumes.
199-1	37762-37763	(	_	
199-2	37763-37766	eds	_	
199-3	37766-37767	)	_	
199-4	37767-37768	.	_	
199-5	37769-37771	3D	_	
199-6	37772-37783	statistical	_	
199-7	37784-37799	neuroanatomical	_	
199-8	37800-37806	models	_	
199-9	37807-37811	from	_	
199-10	37812-37815	305	_	
199-11	37816-37819	MRI	_	
199-12	37820-37827	volumes	_	
199-13	37827-37828	.	_	

#Text=In Nuclear Science Symposium and Medical Imaging Conference,1993 IEEE Conference Record (IEEE, 1993).
200-1	37829-37831	In	_	
200-2	37832-37839	Nuclear	_	
200-3	37840-37847	Science	_	
200-4	37848-37857	Symposium	_	
200-5	37858-37861	and	_	
200-6	37862-37869	Medical	_	
200-7	37870-37877	Imaging	_	
200-8	37878-37888	Conference	_	
200-9	37888-37889	,	_	
200-10	37889-37893	1993	_	
200-11	37894-37898	IEEE	_	
200-12	37899-37909	Conference	_	
200-13	37910-37916	Record	_	
200-14	37917-37918	(	_	
200-15	37918-37922	IEEE	_	
200-16	37922-37923	,	_	
200-17	37924-37928	1993	_	
200-18	37928-37929	)	_	
200-19	37929-37930	.	_	

#Text=Interaction of language, auditory and memory brain networks in auditory verbal hallucinations
#Text=Auditory verbal hallucinations and brain dysconnectivity in the perisylvian language network: a multimodal investigation
#Text=Altered integrity of perisylvian language pathways in schizophrenia: relationship to auditory hallucinations
#Text=Reality of auditory verbal hallucinations
#Text=Functional anatomy of inner speech and auditory verbal imagery
#Text=On the relation of speech to language
#Text=Broca’s region: from action to language
#Text=Towards a neuropsychology of schizophrenia
#Text=Functional magnetic resonance imaging of inner speech in schizophrenia
#Text=Inner speech models of auditory verbal hallucinations: evidence from behavioural and neuroimaging studies
#Text=A functional study of auditory verbal imagery
#Text=Structural correlates of auditory hallucinations in schizophrenia: a meta-analysis
#Text=Human brain language areas identified by functional magnetic resonance imaging
#Text=Deficits in predictive coding underlie hallucinations in schizophrenia
#Text=Reduced neuronal activity in language-related regions after transcranial magnetic stimulation therapy for auditory verbal hallucinations
#Text=Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
201-1	37931-37942	Interaction	_	
201-2	37943-37945	of	_	
201-3	37946-37954	language	_	
201-4	37954-37955	,	_	
201-5	37956-37964	auditory	_	
201-6	37965-37968	and	_	
201-7	37969-37975	memory	_	
201-8	37976-37981	brain	_	
201-9	37982-37990	networks	_	
201-10	37991-37993	in	_	
201-11	37994-38002	auditory	_	
201-12	38003-38009	verbal	_	
201-13	38010-38024	hallucinations	_	
201-14	38025-38033	Auditory	_	
201-15	38034-38040	verbal	_	
201-16	38041-38055	hallucinations	_	
201-17	38056-38059	and	_	
201-18	38060-38065	brain	_	
201-19	38066-38081	dysconnectivity	_	
201-20	38082-38084	in	_	
201-21	38085-38088	the	_	
201-22	38089-38100	perisylvian	_	
201-23	38101-38109	language	_	
201-24	38110-38117	network	_	
201-25	38117-38118	:	_	
201-26	38119-38120	a	_	
201-27	38121-38131	multimodal	_	
201-28	38132-38145	investigation	_	
201-29	38146-38153	Altered	_	
201-30	38154-38163	integrity	_	
201-31	38164-38166	of	_	
201-32	38167-38178	perisylvian	_	
201-33	38179-38187	language	_	
201-34	38188-38196	pathways	_	
201-35	38197-38199	in	_	
201-36	38200-38213	schizophrenia	_	
201-37	38213-38214	:	_	
201-38	38215-38227	relationship	_	
201-39	38228-38230	to	_	
201-40	38231-38239	auditory	_	
201-41	38240-38254	hallucinations	_	
201-42	38255-38262	Reality	_	
201-43	38263-38265	of	_	
201-44	38266-38274	auditory	_	
201-45	38275-38281	verbal	_	
201-46	38282-38296	hallucinations	_	
201-47	38297-38307	Functional	_	
201-48	38308-38315	anatomy	_	
201-49	38316-38318	of	_	
201-50	38319-38324	inner	_	
201-51	38325-38331	speech	_	
201-52	38332-38335	and	_	
201-53	38336-38344	auditory	_	
201-54	38345-38351	verbal	_	
201-55	38352-38359	imagery	_	
201-56	38360-38362	On	_	
201-57	38363-38366	the	_	
201-58	38367-38375	relation	_	
201-59	38376-38378	of	_	
201-60	38379-38385	speech	_	
201-61	38386-38388	to	_	
201-62	38389-38397	language	_	
201-63	38398-38403	Broca	_	
201-64	38403-38404	’	_	
201-65	38404-38405	s	_	
201-66	38406-38412	region	_	
201-67	38412-38413	:	_	
201-68	38414-38418	from	_	
201-69	38419-38425	action	_	
201-70	38426-38428	to	_	
201-71	38429-38437	language	_	
201-72	38438-38445	Towards	_	
201-73	38446-38447	a	_	
201-74	38448-38463	neuropsychology	_	
201-75	38464-38466	of	_	
201-76	38467-38480	schizophrenia	_	
201-77	38481-38491	Functional	_	
201-78	38492-38500	magnetic	_	
201-79	38501-38510	resonance	_	
201-80	38511-38518	imaging	_	
201-81	38519-38521	of	_	
201-82	38522-38527	inner	_	
201-83	38528-38534	speech	_	
201-84	38535-38537	in	_	
201-85	38538-38551	schizophrenia	_	
201-86	38552-38557	Inner	_	
201-87	38558-38564	speech	_	
201-88	38565-38571	models	_	
201-89	38572-38574	of	_	
201-90	38575-38583	auditory	_	
201-91	38584-38590	verbal	_	
201-92	38591-38605	hallucinations	_	
201-93	38605-38606	:	_	
201-94	38607-38615	evidence	_	
201-95	38616-38620	from	_	
201-96	38621-38632	behavioural	_	
201-97	38633-38636	and	_	
201-98	38637-38649	neuroimaging	_	
201-99	38650-38657	studies	_	
201-100	38658-38659	A	_	
201-101	38660-38670	functional	_	
201-102	38671-38676	study	_	
201-103	38677-38679	of	_	
201-104	38680-38688	auditory	_	
201-105	38689-38695	verbal	_	
201-106	38696-38703	imagery	_	
201-107	38704-38714	Structural	_	
201-108	38715-38725	correlates	_	
201-109	38726-38728	of	_	
201-110	38729-38737	auditory	_	
201-111	38738-38752	hallucinations	_	
201-112	38753-38755	in	_	
201-113	38756-38769	schizophrenia	_	
201-114	38769-38770	:	_	
201-115	38771-38772	a	_	
201-116	38773-38786	meta-analysis	_	
201-117	38787-38792	Human	_	
201-118	38793-38798	brain	_	
201-119	38799-38807	language	_	
201-120	38808-38813	areas	_	
201-121	38814-38824	identified	_	
201-122	38825-38827	by	_	
201-123	38828-38838	functional	_	
201-124	38839-38847	magnetic	_	
201-125	38848-38857	resonance	_	
201-126	38858-38865	imaging	_	
201-127	38866-38874	Deficits	_	
201-128	38875-38877	in	_	
201-129	38878-38888	predictive	_	
201-130	38889-38895	coding	_	
201-131	38896-38904	underlie	_	
201-132	38905-38919	hallucinations	_	
201-133	38920-38922	in	_	
201-134	38923-38936	schizophrenia	_	
201-135	38937-38944	Reduced	_	
201-136	38945-38953	neuronal	_	
201-137	38954-38962	activity	_	
201-138	38963-38965	in	_	
201-139	38966-38982	language-related	_	
201-140	38983-38990	regions	_	
201-141	38991-38996	after	_	
201-142	38997-39009	transcranial	_	
201-143	39010-39018	magnetic	_	
201-144	39019-39030	stimulation	_	
201-145	39031-39038	therapy	_	
201-146	39039-39042	for	_	
201-147	39043-39051	auditory	_	
201-148	39052-39058	verbal	_	
201-149	39059-39073	hallucinations	_	
201-150	39074-39087	Dysconnection	_	
201-151	39088-39090	in	_	
201-152	39091-39104	schizophrenia	_	
201-153	39104-39105	:	_	
201-154	39106-39110	from	_	
201-155	39111-39119	abnormal	_	
201-156	39120-39128	synaptic	_	
201-157	39129-39139	plasticity	_	
201-158	39140-39142	to	_	
201-159	39143-39151	failures	_	
201-160	39152-39154	of	_	
201-161	39155-39170	self-monitoring	_	
